<DOCUMENT>
<TYPE>EX-2.1
<SEQUENCE>2
<FILENAME>v57052exv2w1.htm
<DESCRIPTION>EX-2.1
<TEXT>
<HTML>
<HEAD>
<TITLE>exv2w1</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->


<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="right" style="font-size: 10pt; margin-top: 12pt">Exhibit 2.1
</DIV>


<DIV align="right" style="font-size: 10pt; margin-top: 6pt"><B>EXECUTION VERSION</b>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 100pt">&nbsp;
</DIV>
<DIV align="center" style="font-size: 10pt; margin-top: 80pt"><B>AGREEMENT AND PLAN OF MERGER</B>
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>AMONG</B>
</DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>IVY HOLDINGS INC.,</B>
</DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>IVY MERGER SUB CORP.</B>
</DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>AND</B>
</DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>PROSPECT MEDICAL HOLDINGS, INC.</B>
</DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>Dated as of August&nbsp;16, 2010</B>
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><U><B>TABLE CONTENTS</B></U>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt; text-align: justify" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="88%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" colspan="2"><B>Page</B></TD>

</TR>

<TR><TD>&nbsp;</TD></TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">ARTICLE I The Merger</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">2</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">1.1&nbsp;&nbsp;&nbsp;&nbsp; The Merger</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">2</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">1.2&nbsp;&nbsp;&nbsp;&nbsp; Effective Time</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">2</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">1.3&nbsp;&nbsp;&nbsp;&nbsp; Closing</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">3</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">1.4&nbsp;&nbsp;&nbsp;&nbsp; Directors and Officers of the Surviving Corporation</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">3</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">1.5&nbsp;&nbsp;&nbsp;&nbsp; Subsequent Actions</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">3</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">ARTICLE II Merger Consideration; Conversion of Stock</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">3</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">2.1&nbsp;&nbsp;&nbsp;&nbsp; Conversion of Stock</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">3</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">2.2&nbsp;&nbsp;&nbsp;&nbsp; Disposition of Certificates and Book-Entry Shares</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">5</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">2.3&nbsp;&nbsp;&nbsp;&nbsp; Withholding Rights</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">8</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">2.4&nbsp;&nbsp;&nbsp;&nbsp; Appraisal Rights</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">8</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">2.5&nbsp;&nbsp;&nbsp;&nbsp; Adjustments to Prevent Dilution</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">8</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">ARTICLE III Representations and Warranties of the Company</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">9</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">3.1&nbsp;&nbsp;&nbsp;&nbsp; Existence; Good Standing; Authority; Compliance with Law</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">9</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">3.2&nbsp;&nbsp;&nbsp;&nbsp; Authorization, Takeover Laws, Validity and Effect of Agreements</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">10</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">3.3&nbsp;&nbsp;&nbsp;&nbsp; Capitalization</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">11</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">3.4&nbsp;&nbsp;&nbsp;&nbsp; Subsidiaries</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">13</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">3.5&nbsp;&nbsp;&nbsp;&nbsp; Other Interests</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">13</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">3.6&nbsp;&nbsp;&nbsp;&nbsp; Consents and Approvals; No Violations</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">13</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">3.7&nbsp;&nbsp;&nbsp;&nbsp; SEC Reports; Undisclosed Liabilities; Sarbanes-Oxley</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">14</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">3.8&nbsp;&nbsp;&nbsp;&nbsp; Litigation</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">16</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">3.9&nbsp;&nbsp;&nbsp;&nbsp; Absence of Certain Changes</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">16</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">3.10&nbsp;&nbsp; Taxes</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">16</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">3.11&nbsp;&nbsp; Properties</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">18</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">3.12&nbsp;&nbsp; Environmental Matters</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">19</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">3.13&nbsp;&nbsp; Employee Benefit Plans</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">20</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">3.14&nbsp;&nbsp; Labor and Employment Matters</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">23</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">3.15&nbsp;&nbsp; No Brokers</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">24</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">3.16&nbsp;&nbsp; Opinion of Financial Advisor</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">24</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">3.17&nbsp;&nbsp; Vote Required</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">24</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">3.18&nbsp;&nbsp; Material Contracts</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">24</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">3.19&nbsp;&nbsp; Insurance</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">25</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">3.20&nbsp;&nbsp; Proxy Statement and Schedule&nbsp;13E-3</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">25</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">3.21&nbsp;&nbsp; No Payments to Employees, Officers, Directors or Consultants</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">26</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">3.22&nbsp;&nbsp; Intellectual Property</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">26</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">3.23&nbsp;&nbsp; Affiliate Transactions</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">27</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">3.24&nbsp;&nbsp; Questionable Payments</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">27</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">3.25&nbsp;&nbsp; Internal Controls</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">27</TD>
    <TD>&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->i<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="center">
<TABLE style="font-size: 10pt; text-align: justify" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="88%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">3.26&nbsp;&nbsp; Regulatory Matters</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">28</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">ARTICLE IV Representations and Warranties of Parent and Merger Sub</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">31</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">4.1&nbsp;&nbsp;&nbsp;&nbsp; Corporate Organization</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">31</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">4.2&nbsp;&nbsp;&nbsp;&nbsp; Authority Relative to this Agreement</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">32</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">4.3&nbsp;&nbsp;&nbsp;&nbsp; Consents and Approvals; No Violations</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">32</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">4.4&nbsp;&nbsp;&nbsp;&nbsp; Ownership and Operations of Parent and Merger Sub</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">33</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">4.5&nbsp;&nbsp;&nbsp;&nbsp; Litigation</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">33</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">4.6&nbsp;&nbsp;&nbsp;&nbsp; Sufficient Funds</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">33</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">4.7&nbsp;&nbsp;&nbsp;&nbsp; Information in the Proxy Statement and Schedule&nbsp;13E-3</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">33</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">4.8&nbsp;&nbsp;&nbsp;&nbsp; Fund Guarantee</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">34</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">4.9&nbsp;&nbsp;&nbsp;&nbsp; Brokers</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">34</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">4.10&nbsp;&nbsp; Investigation and Agreement by Parent and Merger Sub; No Other
Representations or Warranties</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">34</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">4.11&nbsp;&nbsp; Ownership of Company Common Stock</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">35</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">4.12&nbsp;&nbsp; Financial Condition of Merger Sub</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">35</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">ARTICLE V Conduct of Business Pending the Merger</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">35</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">5.1&nbsp;&nbsp;&nbsp;&nbsp; Conduct of Business by the Company</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">35</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">ARTICLE VI Covenants</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">38</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">6.1&nbsp;&nbsp;&nbsp;&nbsp; Proxy Statement and Schedule&nbsp;13E-3; Stockholders Meeting</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">38</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">6.2&nbsp;&nbsp;&nbsp;&nbsp; Other Filings</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">39</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">6.3&nbsp;&nbsp;&nbsp;&nbsp; Reasonable Best Efforts</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">40</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">6.4&nbsp;&nbsp;&nbsp;&nbsp; Solicitation; Change in Recommendation</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">40</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">6.5&nbsp;&nbsp;&nbsp;&nbsp; Officers&#146; and Directors&#146; Indemnification</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">46</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">6.6&nbsp;&nbsp;&nbsp;&nbsp; Access to Information; Confidentiality</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">49</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">6.7&nbsp;&nbsp;&nbsp;&nbsp; Public Announcements</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">49</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">6.8&nbsp;&nbsp;&nbsp;&nbsp; Revolver Financing</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">50</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">6.9&nbsp;&nbsp;&nbsp;&nbsp; Adoption by Parent</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">50</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">6.10&nbsp;&nbsp; Notification of Certain Matters</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">50</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">6.11&nbsp;&nbsp; Change in Control Offer</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">51</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">6.12&nbsp;&nbsp; Backstop Commitment Letter</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">51</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">6.13&nbsp;&nbsp; Stock Option Agreements</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">51</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">6.14&nbsp;&nbsp; Warrant Amendments</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">51</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">6.15&nbsp;&nbsp; Note Indenture</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">51</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">6.16&nbsp;&nbsp; Employee Benefits Matters</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">51</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">6.17&nbsp;&nbsp; Rule&nbsp;16b-3</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">52</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">ARTICLE VII Conditions to the Merger</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">52</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">7.1&nbsp;&nbsp;&nbsp;&nbsp; Conditions to the Obligations of Each Party to Effect the Merger</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">52</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">7.2&nbsp;&nbsp;&nbsp;&nbsp; Conditions to Obligations of Parent and Merger Sub</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">53</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">7.3&nbsp;&nbsp;&nbsp;&nbsp; Conditions to Obligations of the Company</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">54</TD>
    <TD>&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->ii<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="center">
<TABLE style="font-size: 10pt; text-align: justify" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="88%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">ARTICLE VIII Termination, Amendment and Waiver</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">55</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">8.1&nbsp;&nbsp;&nbsp; Termination</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">55</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">8.2&nbsp;&nbsp;&nbsp; Effect of Termination</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">56</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">8.3&nbsp;&nbsp;&nbsp; Fees and Expenses</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">57</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">8.4&nbsp;&nbsp;&nbsp; Amendment</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">58</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">8.5&nbsp;&nbsp;&nbsp; Extension; Waiver</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">58</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">ARTICLE IX General Provisions</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">59</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">9.1&nbsp;&nbsp;&nbsp; Notices</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">59</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">9.2&nbsp;&nbsp;&nbsp; Certain Definitions</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">60</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">9.3&nbsp;&nbsp;&nbsp; Terms Defined Elsewhere</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">66</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">9.4&nbsp;&nbsp;&nbsp; Interpretation</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">69</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">9.5&nbsp;&nbsp;&nbsp; Non-Survival of Representations, Warranties, Covenants and Agreements</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">69</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">9.6&nbsp;&nbsp;&nbsp; Entire Agreement; Specific Performance</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">69</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">9.7&nbsp;&nbsp;&nbsp; Assignment; Benefit</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">70</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">9.8&nbsp;&nbsp;&nbsp; Severability</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">70</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">9.9&nbsp;&nbsp;&nbsp; Choice of Law; Consent to Jurisdiction</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">70</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">9.10&nbsp;&nbsp;Expenses</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">71</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">9.11&nbsp;&nbsp;Counterparts</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">71</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">

<TD><DIV style="margin-left:30px; text-indent:-15px">9.12&nbsp;&nbsp;No Personal Liability of Directors, Officers, Owners, Etc.</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">71</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">9.13&nbsp;&nbsp;Company Disclosure Schedule</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">72</TD>
    <TD>&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>EXHIBITS</B>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="91%">&nbsp;</TD>
</TR>
<TR></TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD nowrap colspan="3" valign="top" align="center">Exhibit&nbsp; A</TD>
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">Form of Second Amended and Restated Certificate of Incorporation</DIV></TD>
</TR>
<TR valign="bottom">
    <TD nowrap colspan="3" valign="top" align="center">Exhibit&nbsp; B</TD>
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">Form of Third Amended and Restated Bylaws</DIV></TD>
</TR>
<TR valign="bottom">
    <TD nowrap colspan="3" valign="top" align="center">Exhibit&nbsp; C</TD>
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">Fund Guarantee</DIV></TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>



<P align="center" style="font-size: 10pt"><!-- Folio -->iii<!-- /Folio -->
</DIV>



<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><U><B>AGREEMENT AND PLAN OF MERGER</B></U>
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This AGREEMENT AND PLAN OF MERGER (hereinafter referred to as this &#147;<U>Agreement</U>&#148;), dated
August&nbsp;16, 2010 is by and among IVY HOLDINGS INC., a Delaware corporation (&#147;<U>Parent</U>&#148;), IVY
MERGER SUB CORP., a Delaware corporation and an indirect wholly-owned subsidiary of Parent
(&#147;<U>Merger Sub</U>&#148;), and PROSPECT MEDICAL HOLDINGS, INC., a Delaware corporation (the
&#147;<U>Company</U>&#148;).
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;WHEREAS, it is proposed that pursuant to this Agreement, and upon the terms and subject to the
conditions set forth herein, Merger Sub will be merged with and into the Company with the Company
continuing as the Surviving Corporation (the &#147;<U>Merger</U>,&#148; and together with the other
transactions contemplated by this Agreement, the &#147;<U>Transaction</U>&#148;), in accordance with the
General Corporation Law of the State of Delaware (the &#147;<U>DGCL</U>&#148;), whereby each issued and
outstanding share of common stock of the Company, par value $.01 per share (the &#147;<U>Company Common
Stock</U>&#148;), not owned directly or indirectly by Parent, Merger Sub or the Company and other than
Dissenting Shares, will be converted into the right to receive $8.50 in cash, without interest (the
&#147;<U>Per Share Merger Consideration</U>&#148;) subject to any withholding of Taxes required by
applicable Law;
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;WHEREAS, the Board of Directors of the Company (the &#147;<U>Company Board</U>&#148;) has formed a
special committee of the Company Board (the &#147;<U>Special Committee</U>&#148;) for the purpose of, among
other things, evaluating and making a recommendation to the Company Board with respect to what
action should be taken regarding any business combination, including with respect to this Agreement
and the Transaction;
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;WHEREAS, the Company Board has, acting upon the unanimous recommendation of the Special
Committee, and on the terms and subject to the conditions set forth herein, (i)&nbsp;approved this
Agreement and the Transaction, including the Merger, (ii)&nbsp;determined that the Transaction,
including the Merger, is fair to and in the best interests of the Company and its stockholders,
(iii)&nbsp;approved and declared advisable this Agreement and the Transaction, including the Merger, and
(iv)&nbsp;resolved to recommend that the Company&#146;s stockholders adopt this Agreement;
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;WHEREAS, the Boards of Directors of Parent and Merger Sub have, on the terms and subject to
the conditions set forth herein, unanimously approved and declared advisable this Agreement and the
Transaction, including the Merger;
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;WHEREAS, concurrently with the execution and delivery of this Agreement, and as a condition
and inducement to the willingness of Parent and Merger Sub to enter into this Agreement, Parent and
certain stockholders of the Company (the &#147;<U>Contributing Stockholders</U>&#148;) are entering into a
Contribution and Subscription Agreement dated as of the date of this Agreement (the
&#147;<U>Contribution Agreement</U>&#148;), pursuant to which, among other things, the Contributing
Stockholders have agreed to contribute, immediately prior to the consummation of the Merger, a
portion of their shares of Company Common Stock to Parent (as set forth in the Contribution
Agreement) in exchange for shares of common stock of Parent; and
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;WHEREAS, concurrently with the execution and delivery of this Agreement, and as a condition
and inducement to the willingness of Parent and Merger Sub to enter into this
</DIV>




<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="justify" style="font-size: 10pt; margin-top: 6pt">Agreement, Parent and the Contributing Stockholders have entered into a Company Stockholder
Voting Agreement, dated as of the date of this Agreement (the &#147;<U>Company Stockholder
Agreement</U>&#148;), pursuant to which such stockholders have, among other things, agreed (subject to
certain exceptions) to vote all of the shares of Company Common Stock that such stockholders own in
favor of the adoption of this Agreement.
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;NOW, THEREFORE, in consideration of the mutual covenants and premises contained in this
Agreement and for other good and valuable consideration, the receipt and adequacy of which are
hereby acknowledged, the parties to this Agreement agree as follows:
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt">ARTICLE I
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><U>The Merger</U>
</DIV>

<DIV align="justify" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.1 <U>The Merger</U>.
</DIV>



<DIV align="justify" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) Subject to the terms and conditions of this Agreement, and in accordance with the
DGCL, at the Effective Time, the Company and Merger Sub shall consummate the Merger pursuant
to which (i)&nbsp;Merger Sub shall be merged with and into the Company and the separate corporate
existence of Merger Sub shall thereupon cease, (ii)&nbsp;the Company shall be the surviving
corporation in the Merger and shall continue to be governed by the DGCL and (iii)&nbsp;the
separate corporate existence of the Company with all its rights, privileges, immunities,
powers and franchises shall continue unaffected by the Merger. The corporation surviving
the Merger is sometimes hereinafter referred to as the &#147;<U>Surviving Corporation</U>.&#148; The
Merger shall have the effects set forth herein and in Section&nbsp;259 of the DGCL.
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) At the Effective Time, the certificate of incorporation of the Company shall be
amended so as to read in the form of <U>Exhibit&nbsp;A</U> hereto and as so amended shall, from
and after the Effective Time, be the certificate of incorporation of the Surviving
Corporation until thereafter changed or amended as provided therein or by applicable Law.
At the Effective Time, the bylaws of the Company shall be amended so as to read in the form
of <U>Exhibit&nbsp;B</U> hereto and as so amended shall, from and after the Effective Time, be
the bylaws of the Surviving Corporation until thereafter changed or amended in accordance
with the Certificate of Incorporation of the Surviving Corporation or by applicable Law.
</DIV>

<DIV align="justify" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.2 <U>Effective Time</U>. The Company shall cause an appropriate certificate of merger or
other appropriate document (the &#147;<U>Certificate of Merger&#148;</U>) to be duly executed and filed in
accordance with the DGCL on the Closing Date (or on such other date as Parent and the Company may
agree) with the Secretary of State of the State of Delaware in accordance with the relevant
provisions of the DGCL. The Merger shall become effective at the time such Certificate of Merger
shall have been duly filed with, and accepted by, the Secretary of State of the State of Delaware
or such later date and time as is agreed upon by the parties and specified in the Certificate of
Merger, such date and time hereinafter referred to as the &#147;<U>Effective Time</U>.&#148;
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->2<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV align="justify" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.3 <U>Closing</U>. The closing of the Merger (the &#147;<U>Closing</U>&#148;) will take place at
10:00&nbsp;a.m., New York time, on a date to be specified by the parties, such date to be no later than
the third Business Day after satisfaction or waiver of all of the conditions set forth in Article
VII (other than those conditions that by their nature are to be satisfied at the Closing, and
subject to the satisfaction or waiver of such conditions) (the &#147;<U>Closing Date</U>&#148;), at the
offices of Latham &#038; Watkins LLP, 885 Third Avenue, New York, NY 10022, unless another time, date or
place is agreed to in writing by the parties hereto.
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.4 <U>Directors and Officers of the Surviving Corporation</U>. The directors of Merger Sub
immediately prior to the Effective Time shall, from and after the Effective Time, be the directors
of the Surviving Corporation, and the officers of the Company immediately prior to the Effective
Time, from and after the Effective Time, shall continue as the officers of the Surviving
Corporation, in each case until their respective successors shall have been duly elected or
appointed and qualified, or until their earlier death, resignation or removal in accordance with
the Surviving Corporation&#146;s certificate of incorporation and bylaws.
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.5 <U>Subsequent Actions</U>. If at any time after the Effective Time the Surviving
Corporation shall determine, in its sole discretion, or shall be advised, that any deeds, bills of
sale, instruments of conveyance, assignments, assurances or any other actions or things are
necessary or desirable to vest, perfect or confirm of record or otherwise in the Surviving
Corporation its right, title or interest in, to or under any of the rights, properties or assets of
either of the Company or Merger Sub acquired or to be acquired by the Surviving Corporation as a
result of, or in connection with, the Merger or otherwise to carry out this Agreement, then the
officers and directors of the Surviving Corporation shall be authorized to execute and deliver, in
the name and on behalf of either the Company or Merger Sub, all such deeds, bills of sale,
instruments of conveyance, assignments and assurances and to take and do, in the name and on behalf
of each of such corporation or otherwise, all such other actions and things as may be necessary or
desirable to vest, perfect or confirm any and all right, title or interest in, to and under such
rights, properties or assets in the Surviving Corporation or otherwise to carry out this Agreement.
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt">ARTICLE II
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><U>Merger Consideration; Conversion of Stock</U>
</DIV>

<DIV align="justify" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.1 <U>Conversion of Stock</U>. At the Effective Time, by virtue of the Merger and without
any action on the part of the Company, Parent, Merger Sub or any holder of Company Common Stock:
</DIV>



<DIV align="justify" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) <U>Capital Stock of Merger Sub</U>. Each share of common stock of Merger Sub, par
value $.01 per share, issued and outstanding immediately prior to the Effective Time shall
be converted into and become one (1)&nbsp;validly issued, fully paid and nonassessable share of
common stock of the Surviving Corporation, par value $.01 per share.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->3<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="justify" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) <U>Cancellation of Company Common Stock Owned Directly or Indirectly by the
Company, Parent or Merger Sub</U>. Each outstanding or issued share of Company Common Stock
that is owned by the Company as treasury stock or by any wholly owned direct or indirect
Subsidiary of the Company and any shares of Company Common Stock owned by Parent, Merger
Sub, or by any wholly-owned direct or indirect Subsidiary of Parent (collectively, the
&#147;<U>Excluded Shares</U>&#148;) shall, immediately prior to the Effective Time, automatically be
canceled and shall cease to exist, and no cash, stock or other consideration shall be
delivered or deliverable in exchange therefor.
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) <U>Conversion of Company Common Stock</U>. Each share of Company Common Stock
issued and outstanding immediately prior to the Effective Time (other than Excluded Shares
and Dissenting Shares) shall automatically be converted into the right to receive cash in an
amount equal to the Per Share Merger Consideration. As of the Effective Time, all shares of
Company Common Stock issued and outstanding immediately prior to the Effective Time shall no
longer be outstanding and shall automatically be canceled and shall cease to exist, and each
holder of a certificate (a &#147;<U>Certificate</U>&#148;) or book-entry shares (&#147;<U>Book-Entry
Shares</U>&#148;) representing any such shares of Company Common Stock shall cease to have any
rights with respect to such shares, except, in all cases, the right to receive (other than
with respect to Excluded Shares and Dissenting Shares) the Per Share Merger Consideration,
without interest, upon surrender of such Certificate or Book-Entry Shares in accordance with
Section&nbsp;2.2. The right of any holder of any share of Company Common Stock to receive the
Per Share Merger Consideration shall be subject to and reduced by the amount of any
withholding that is required under applicable Tax Law.
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) <U>Treatment of Company Stock Awards</U>.
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i)
(x) Except as set forth in clause (y) below, at the Effective Time, each Company Stock Option under
any Company Equity Incentive Plan, including any and all
Company Stock Options under the Prospect Medical Holdings Inc., 2008 Omnibus Equity Incentive Plan, shall be
canceled and (y) the Company shall use commercially reasonable best efforts to obtain all agreements or
consents necessary for each Company Stock Option under the 1998 Plan to be canceled at the Effective Time.
In consideration of each such
cancellation set forth in clauses (x) and (y) of the previous sentence, the holder thereof shall be entitled to
receive a cash payment equal to the product of (A)&nbsp;the number of shares of Company Common
Stock subject to such Company Stock Option that are then vested and exercisable immediately
prior to the Effective Time (after giving effect to any determination by the Compensation
Committee of the Company Board, in its sole discretion, to accelerate the vesting of all or
a portion of the number of shares of Company Common Stock subject to such Company Stock
Option) and (B)&nbsp;the excess, if any, of the Per Share Merger Consideration over the exercise
price per share of such Company Stock Option, less any applicable withholding Taxes. If the exercise price per share of any Company Stock Option is equal to or
greater than the Per Share Merger Consideration, then such Company Stock Option shall be
canceled at the Effective Time without any cash payment being made in respect thereof, and
if any shares of Company Common Stock subject to such a Company Stock Option are unvested
and unexercisable immediately prior to the Effective Time, then such Company Stock Option
shall be cancelled at the Effective Time to the extent shares of
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->4<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="justify" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">Company Common Stock are unvested and unexercisable without any cash payment being made in respect thereof. The
amount payable pursuant to this Section&nbsp;2.1(d)(i) is referred to herein as the &#147;<U>Option
Merger Consideration</U>&#148;.
</DIV>



<DIV align="justify" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii) At the Effective Time, restrictions on each outstanding share of restricted stock
issued under any Company Equity Incentive Plans (the &#147;<U>Company Restricted Shares</U>&#148;),
will lapse as of such Effective Time and such Company Restricted Shares shall be treated in
the same manner as other shares of Company Common Stock pursuant to Section&nbsp;2.1(c).
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii) From and after the Effective Time, the Company Equity Incentive Plans shall
terminate and all rights under any provision of any other plan, program or arrangement
providing for the issuance or grant of any other interest in respect of the Company Common
Stock or the capital stock of any Subsidiary shall be cancelled. The Company shall ensure
that, after the Effective Time, no Person shall have any right to acquire any capital stock
of the Company or the Surviving Corporation or any other Equity Interest therein (including
&#147;phantom&#148; stock or stock appreciation rights), except as set forth herein. The Company
Board (or if appropriate, any committee thereof administering the Company Equity Incentive
Plans) shall adopt such resolutions or take such other actions as may be required, to effect
the foregoing.
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e)
<U>Treatment of Company Warrants</U>. The Company shall use
commercially reasonable best efforts to obtain all amendments and
modifications necessary for each Company Warrant
that is outstanding immediately prior to the Effective Time to cease to represent a right
to acquire shares of Company Common Stock at the Effective Time and
for each Company Warrant to automatically convert at the Effective Time into the right to receive cash, without interest, equal to
the product of (x)&nbsp;the excess, if any, of the Per Share Merger Consideration over the per
share exercise price of such Company Warrant, multiplied by (y)&nbsp;the number of shares of
Company Common Stock issuable upon exercise of such Company Warrant; <U>provided</U> that
if the exercise price per share of any such Company Warrant is equal to or greater than the
Per Share Merger Consideration, such Company Warrant shall be canceled at the Effective Time
without any cash payment being made in respect thereof. The amount payable pursuant to this
Section&nbsp;2.1(e) is referred to herein as the &#147;<U>Warrant Merger Consideration</U>.&#148;
</DIV>

<DIV align="justify" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.2 <U>Disposition of Certificates and Book-Entry Shares</U>.
</DIV>



<DIV align="justify" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) <U>Paying Agent</U>. Prior to the mailing of the Proxy Statement, the Parent
shall appoint, subject to the Company&#146;s prior approval (such approval not to be unreasonably
withheld or delayed), a bank or trust company to act as Paying Agent (the &#147;<U>Paying Agent</U>&#148;) for the payment of the Per Share Merger Consideration, the
Option Merger Consideration and the Warrant Merger Consideration (collectively, the
&#147;<U>Merger Consideration&#148;</U>). Parent will enter into a paying agent agreement with the
Paying Agent (the &#147;<U>Paying Agent Agreement</U>&#148;) on customary terms, which terms shall be
in form and substance reasonably acceptable to the Company, prior to the Effective Time. At
the Effective Time, Parent shall deposit, or cause to be deposited (including by causing the
Company and the Company Subsidiaries to deposit) with the Paying Agent, for the benefit of
the holders of shares of Company Common Stock (including shares of
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->5<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="justify" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">Company Common Stock issuable upon exercise of Company Stock Options and the Company Warrants at or prior to the
Effective Time), holders of Company Stock Options and holders of Company Warrants, for
payment in accordance with Section&nbsp;2.1, the aggregate Merger Consideration (such total
deposited cash being hereinafter referred to as the &#147;<U>Payment Fund</U>&#148;). The Paying
Agent shall make payments of the Merger Consideration out of the Payment Fund in accordance
with this Agreement and the Paying Agent Agreement. The Payment Fund shall not be used for
any other purpose. Any and all interest earned on the Payment Fund shall be paid to Parent.
</DIV>



<DIV align="justify" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) <U>Stock Transfer Books</U>. At the Effective Time, the common stock transfer
books of the Company shall be closed and thereafter there shall be no further registration
of transfers of shares of Company Common Stock outstanding immediately prior to the
Effective Time on the records of the Company. From and after the Effective Time, the
holders of Certificates and Book-Entry Shares representing ownership of the Company Common
Stock outstanding immediately prior to the Effective Time shall cease to have rights with
respect to such Company Common Stock, except as otherwise provided for herein. On or after
the Effective Time, any Certificates or Book-Entry Shares presented to the Paying Agent or
Parent for any reason (other than Certificates or Book-Entry Shares representing Excluded
Shares or Dissenting Shares) shall be converted into the right to receive the Per Share
Merger Consideration. On and after the Effective Time, a holder of a Company Stock Option
outstanding immediately prior to the Effective Time shall have only the right to receive the
Option Merger Consideration. On or after the Effective Time, a holder of a Company Warrant
outstanding immediately prior to the Effective Time shall only have the right to receive the
Warrant Merger Consideration.
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) <U>Payment Procedures</U>.
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) As soon as possible after the Effective Time (but in any event within five (5)
Business Days), Parent and the Surviving Corporation shall cause the Paying Agent to mail to
each holder of record of a Certificate or Book-Entry Shares that immediately prior to the
Effective Time represented outstanding shares of Company Common Stock (other than Excluded
Shares) (A)&nbsp;a letter of transmittal (which shall specify that delivery shall be effected,
and risk of loss shall pass to the Paying Agent, only upon proper delivery of the
Certificates or Book-Entry Shares to the Paying Agent, and which letter shall be in such
form and have such other provisions as Parent may reasonably specify) and (B)&nbsp;instructions
for use in effecting the surrender of the Certificates or Book-Entry Shares in exchange for
the Per Share Merger Consideration. Upon the proper surrender of a Certificate or
Book-Entry Shares for cancellation to the Paying Agent or to such other agent or agents
reasonably satisfactory to the Company as may be appointed by Parent, together with such letter of transmittal, duly executed and completed in accordance
with the instructions thereto, and such other documents as may reasonably be required by the
Paying Agent, the holder of such Certificate or Book-Entry Shares shall be entitled to
receive in exchange therefor the amount of cash payable in respect of the shares of Company
Common Stock previously represented by such Certificate or Book-Entry Shares pursuant to the
provisions of this Article&nbsp;II, and the Certificate or Book-Entry Shares so surrendered shall
forthwith be canceled. In the event of a transfer of ownership of Company Common Stock that
is not registered in the transfer records of the Company,
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->6<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="justify" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">payment may be made to a Person other than the Person in whose name the Certificate so surrendered is registered, if such
Certificate shall be properly endorsed or otherwise be in proper form for transfer and the
Person requesting such payment shall pay any transfer or other Taxes required by reason of
the payment to a Person other than the registered holder of such Certificate or establish to
the satisfaction of Parent that such Tax has been paid or is not applicable.
</DIV>



<DIV align="justify" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) <U>Termination of Payment Fund</U>. Any portion of the Payment Fund which remains
undistributed for one (1)&nbsp;year after the Effective Time shall be delivered to the Surviving
Corporation (including any interest received with respect thereto), and any holders of
 shares of Company Common Stock, Company Restricted Shares, Company Warrants or Company Stock
Options prior to the Effective Time who have not theretofore complied with this Article&nbsp;II
shall thereafter look only to the Surviving Company and only as general creditors thereof
for payment of the Per Share Merger Consideration, the Option Merger Consideration or the
Warrant Merger Consideration, as applicable.
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e) <U>No Liability</U>. None of Parent, Merger Sub, the Surviving Corporation, the
Company or the Paying Agent, or any employee, officer, director, agent or Affiliate thereof,
shall be liable to any Person in respect of any Merger Consideration properly paid to a
public official pursuant to any applicable abandoned property, escheat or similar Law.
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f) <U>Investment of Payment Fund</U>. The Paying Agent shall invest the Payment Fund
as directed by Parent or the Surviving Corporation; <U>provided</U>, <U>however</U>, that
the Payment Fund shall not be invested in any manner that would preclude, limit or delay the
Paying Agent from timely making all payments contemplated by this Article&nbsp;II; and
<U>provided</U>, <U>further</U>, that, if invested, such investments shall be in
short-term obligations of, or short-term obligations guaranteed by, the United States of
America. Any net profit resulting from, or interest or income produced by, such investments
shall be payable to Parent. To the extent that there are losses with respect to such
investments, or the Payment Fund diminishes for other reasons below the level required for
the Paying Agent to make prompt payments of the Merger Consideration as contemplated hereby,
Parent or the Surviving Corporation shall promptly replace or restore the portion of the
Payment Fund lost through investments or other events so as to ensure that the Payment Fund
is, at all times, maintained at a level sufficient to make such payments.
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(g) <U>Lost Certificates</U>. If any Certificate shall have been lost, stolen or
destroyed, upon the making of an affidavit of that fact by the Person claiming such
Certificate to be lost, stolen or destroyed and, if required by the Paying Agent or
Parent, the posting by such Person of a bond in customary amount and upon such terms as may
be required by Paying Agent or Parent as indemnity against any claim that may be made
against Paying Agent or Parent with regard to such Certificate, the Paying Agent will issue
in exchange for such lost, stolen or destroyed Certificate the Per Share Merger
Consideration payable in respect thereof, pursuant to this Agreement.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->7<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="justify" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.3 <U>Withholding Rights</U>. Each of Parent, any Affiliate of Parent, the Surviving
Corporation and the Paying Agent shall be entitled to deduct and withhold, or cause the Paying
Agent to deduct and withhold, as applicable, from the consideration otherwise payable pursuant to
this Agreement to any Person such amounts as it is required to deduct and withhold with respect to
the making of such payment under the Internal Revenue Code of 1986, as amended (the
&#147;<U>Code</U>&#148;), and the rules and regulations promulgated thereunder, or any provision of state,
local or other Tax Law. To the extent that amounts are so withheld by Parent, any Affiliate of
Parent, the Surviving Corporation or the Paying Agent, such withheld amounts shall be treated for
all purposes of this Agreement as having been paid to the Person in respect of which such deduction
and withholding was made by Parent, any Affiliate of Parent, the Surviving Corporation or the
Paying Agent.
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.4 <U>Appraisal Rights</U>. Notwithstanding anything in this Agreement to the contrary, all
shares of Company Common Stock outstanding immediately prior to the Effective Time and held by a
holder who is entitled to demand and properly demands appraisal of such shares (&#147;<U>Dissenting
Shares</U>&#148;) pursuant to, and who complies in all respects with, Section&nbsp;262 of the DGCL (the
&#147;<U>Appraisal Rights</U>&#148;) shall not be converted into, or represent the right to receive the Per
Share Merger Consideration. Such holders of Dissenting Shares shall instead be entitled to payment
of the fair value of such Dissenting Shares in accordance with the Appraisal Rights;
<U>provided</U>, <U>however</U>, that if any such holder shall fail to perfect or otherwise shall
waive, withdraw or lose the right to appraisal under the Appraisal Rights, then the right of such
holder to be paid the fair value of such holder&#146;s Dissenting Shares shall cease and such Dissenting
Shares shall be deemed to have been converted as of the Effective Time into, and to have become
exchangeable solely for the right to receive, the Per Share Merger Consideration, without interest.
The Company shall give Parent (i)&nbsp;prompt notice of any written demands for appraisal, attempted
withdrawals of such demands, and any other instruments served pursuant to applicable Law that are
received by the Company relating to Company stockholders&#146; rights of appraisal and (ii)&nbsp;the
opportunity to direct all negotiations and proceedings with respect to demands for appraisal by
Company stockholders under the DGCL; <U>provided</U> that Parent shall not be permitted to take
any action in connection therewith that would require the Company to incur material costs or to pay
any amount prior to the Closing or to take or refrain from taking any action that would reasonably
be expected to be adverse to the Company if the Closing does not occur. The Company shall not,
prior to the Effective Time, except with the prior written consent of Parent, voluntarily (x)&nbsp;make
any payment with respect to any demands for appraisal or any offer to settle or (y)&nbsp;settle any such
demands.
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.5 <U>Adjustments to Prevent Dilution</U>. In the event that, between the date of this Agreement and the Effective Time, the Company
changes the number of shares of Company Common Stock issued and outstanding as a result of a
reclassification, stock split (including a reverse stock split), stock dividend or distribution,
recapitalization or other similar transaction, the Merger Consideration shall be correspondingly
adjusted to reflect such change and to provide the holders of Company Common Stock, Company Stock
Options, Company Restricted Shares and Company Warrants, in the aggregate, the same economic effect
as contemplated by this Agreement prior to such action, and as so adjusted shall, from and after
the date of such event, be the Merger Consideration.
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->8<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV align="center" style="font-size: 10pt; margin-top: 18pt">ARTICLE III
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><U>Representations and Warranties of the Company</U>
</DIV>
<DIV align="justify" style="font-size: 10pt; margin-top: 6pt">The Company represents and warrants to Parent and Merger Sub that, except as disclosed (i)&nbsp;in the
disclosure schedule dated as of the date of this Agreement and delivered by the Company to the
Parent and Merger Sub prior to the execution hereof (the &#147;<U>Company Disclosure Schedule</U>&#148;) or
(ii)&nbsp;other than with respect to the representations and warranties in Section&nbsp;3.2 or Section&nbsp;3.3,
in the Company SEC Reports filed with the SEC on or after September&nbsp;30, 2008 and on or prior to the date
hereof (&#147;<U>Filed SEC Documents</U>&#148;), the following statements are true and correct (it being
understood and agreed that any disclosure in the Filed SEC Documents shall be deemed disclosed with
respect to any Section of this Article&nbsp;III only to the extent that such disclosure is in sufficient
detail to put a reasonable person on notice of the relevance of the facts or circumstances so
disclosed). The term &#147;Filed SEC Documents&#148; shall not be deemed to include (x)&nbsp;the exhibits and
schedules thereto or any documents incorporated by reference therein or (y)&nbsp;disclosures in such
Filed SEC Documents referred to in the &#147;Risk Factors&#148; and &#147;Forward Looking Statements&#148; sections
thereof or any other disclosures in the Filed SEC Documents which are forward-looking in nature.
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.1 <U>Existence; Good Standing; Authority; Compliance with Law</U>.
</DIV>



<DIV align="justify" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) The Company is a corporation duly organized, validly existing and in good standing
under the laws of the State of Delaware.
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) The Company is duly qualified or licensed to do business as a foreign corporation
and is in good standing under the laws of any other jurisdiction in which the character of
the properties owned, leased or operated by it therein or in which the transaction of its
business makes such qualification or licensing necessary, except where the failure to be so
qualified or licensed has not had, and would not reasonably be expected to have,
individually or in the aggregate, a Company Material Adverse Effect. The Company has all
requisite corporate power and authority to own, operate, lease and encumber its properties
and carry on its business as now conducted, except where the failure to have such power or
authority has not had, and would not reasonably be expected to have, individually or in the
aggregate, a Company Material Adverse Effect.
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) Each of the entities listed in Section&nbsp;3.1(c) of the Company Disclosure Schedule
(the &#147;<U>Company Subsidiaries</U>&#148;) is a corporation, professional medical corporation,
joint venture, limited partnership or limited liability company duly incorporated or
organized, validly existing and in good standing under the laws of its jurisdiction of
incorporation or organization. Each Company Subsidiary is duly qualified or licensed to do
business and is in good standing in each jurisdiction in which the ownership of its property
or the conduct of its business requires such qualification or licensing, except for
jurisdictions in which such failure to be so qualified, licensed or to be in good standing
has not had, and would not reasonably be expected to have, individually or in the aggregate,
a Company Material Adverse Effect. Each Company Subsidiary has all requisite power and
authority to own, operate, lease and encumber its
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->9<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="justify" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">properties and carry on its business as now conducted. The Company has no Subsidiaries other than the Company Subsidiaries.
</DIV>



<DIV align="justify" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) Since September&nbsp;30, 2009, neither the Company nor any of the Company Subsidiaries
has been in violation of any Law or any order of any court, governmental authority or
arbitration board or tribunal, or has received any written notice that the Company or any of
the Company Subsidiaries is in violation of any Law to which the Company or any Company
Subsidiary or any of their respective properties or assets is subject, except where such
violation, alone or together with all other violations, has not had or would be reasonably
expected not to have a Company Material Adverse Effect.
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e) The Company has previously provided or made available to Parent true and complete
copies of the certificate of incorporation and bylaws and the other charter documents,
articles of incorporation, bylaws, organizational documents and partnership, limited
liability company and joint venture agreements (and in each such case, all amendments
thereto) of the Company and each of the Company Subsidiaries (other than inactive Company
Subsidiaries) as in effect on the date of this Agreement.
</DIV>

<DIV align="justify" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.2 <U>Authorization, Takeover Laws, Validity and Effect of Agreements</U>.
</DIV>



<DIV align="justify" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) The Company has all requisite corporate power and authority to execute and deliver
this Agreement and to consummate the transactions contemplated hereby and perform its
obligations hereunder. The execution, delivery and performance by the Company of this
Agreement and the consummation of the transactions contemplated hereby have been duly
authorized by all necessary corporate action on behalf of the Company, and no other
corporate action on the part of the Company is necessary to authorize the execution,
delivery and performance by the Company of the Agreement and the consummation by it of the
Transaction, other than with respect to completion of the Merger, which requires obtaining
the Company Stockholder Approval. In connection with the foregoing, the Company Board has
taken such actions and votes as are necessary to render the provisions of any &#147;fair price,&#148;
&#147;moratorium,&#148; &#147;control share acquisition&#148; or any other anti-takeover statute or similar
federal or state statute (&#147;<U>Takeover Laws</U>&#148;) inapplicable to the execution, delivery
or performance of this Agreement or the Transaction, including the Contribution Agreement.
This Agreement, assuming due and valid authorization, execution and delivery hereof by Parent and Merger Sub,
constitutes a valid and legally binding obligation of the Company, enforceable against the
Company in accordance with its terms, subject to applicable bankruptcy, insolvency,
moratorium or other similar Laws relating to or affecting creditors&#146; rights and general
principles of equity.
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) As of the date hereof, each of the Special Committee and the Company Board has
unanimously (i)&nbsp;determined the Merger is fair to, and in the best interests of, the Company
and its stockholders and (ii)&nbsp;declared advisable this Agreement and the Merger and the
Transaction. As of the date hereof, the Company Board has unanimously approved this
Agreement, the Merger and the Transaction and resolved, subject to Section&nbsp;6.4, to recommend
adoption of this Agreement to the holders of Company
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->10<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="justify" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">Common Stock. The Company Board has directed that this Agreement be submitted to the holders of Company Common Stock for their
adoption, subject to Section&nbsp;6.4.
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.3 <U>Capitalization</U>.
</DIV>



<DIV align="justify" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) The authorized capital stock of the Company consists of 40,000,000 shares of
Company Common Stock and 5,000,000 shares of Preferred Stock, par value $0.01 per share
(&#147;<U>Company Preferred Stock</U>&#148;). As of the date of this Agreement, (i)&nbsp;21,189,413
shares of Company Common Stock were issued and outstanding, (ii)&nbsp;no shares of Company
Preferred Stock were issued and outstanding, (iii)&nbsp;4,510,554 shares of Company Common Stock
(subject to adjustment on the terms set forth in the Company Equity Incentive Plans) were
authorized and reserved for issuance upon exercise of Company Stock Options under the
Company Equity Incentive Plans, 3,507,216 shares of which were vested, (iv)&nbsp;33,334 unvested
 shares of Company Restricted Shares were issued and outstanding under the Company Equity
Incentive Plans, (v)&nbsp;453,081 shares of the Company Common Stock are subject to issuance
pursuant to the Company Warrants and (vi)&nbsp;805,250 additional shares of Company Common Stock
were authorized and reserved for issuance pursuant to the Company Equity Incentive Plans.
As of the date of this Agreement, the Company had no shares of Company Common Stock issued
or reserved for issuance other than as described above. Since September&nbsp;30, 2009, the
Company has not issued any shares of Company Common Stock or other Equity Interests other
than pursuant to the exercise of Company Stock Options under a Company Equity Incentive
Plan. All such issued and outstanding shares of capital stock of the Company are duly
authorized, validly issued, fully paid, nonassessable and free of preemptive rights. As of
the date hereof, neither the Company nor any Company Subsidiary is a party to any
stockholder rights agreement, &#147;poison pill&#148; or similar anti takeover arrangement or plan.
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) Neither the Company nor any Company Subsidiary has issued any &#147;phantom&#148; stock or
stock appreciation rights.
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) Except for the Company Stock Options (all of which have been issued under the
Company Equity Incentive Plans) and the Company Warrants, as of the date of this Agreement, there are not any existing options, warrants, calls, subscriptions,
convertible securities, or other rights, agreements or commitments which obligate the
Company or any Company Subsidiary to issue, transfer or sell any shares of capital stock of
the Company. To the extent required by applicable Law, each of the Company Equity Incentive
Plans (including all amendments requiring such approval) have been duly approved by the
Company&#146;s stockholders. With respect to the Company Stock Options, (i)&nbsp;each grant of a
Company Stock Option was duly authorized no later than the date on which the grant of such
Company Stock Option was by its terms to be effective (the &#147;<U>Grant Date</U>&#148;) by all
necessary corporate action, including, as applicable, approval by the Company Board, or a
committee thereof, or a duly authorized delegate thereof, and any required approval by the
stockholders of the Company by the necessary number of votes or written consents, and the
award agreement governing such grant, if any, was duly executed and delivered by each party
thereto, (ii)&nbsp;each such grant was made in accordance with the terms of the applicable
Company Equity Incentive Plan, the
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->11<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="justify" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">Exchange Act and all other applicable Laws, including the rules of Nasdaq<B>, </B>(iii)&nbsp;the per share exercise price of each Company Stock Option was not
less than the fair market value of a share of Company Common Stock on the applicable Grant
Date, (iv)&nbsp;each such grant was properly accounted for in all material respects in accordance
with GAAP in the financial statements (including the related notes) of the Company and
disclosed in the Company SEC Reports in accordance with the Exchange Act and all other
applicable Laws, and (v)&nbsp;no modifications have been made to any such grants after the Grant
Date except as permitted by applicable Laws.
</DIV>



<DIV align="justify" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) The Company has no outstanding bonds, debentures or notes the holders of which have
the right to vote (or which are convertible into or exercisable for securities having the
right to vote) with the stockholders of the Company on any matter.
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e) Section&nbsp;3.3(e) of the Company Disclosure Schedule sets forth a true, complete and
correct list of Company Stock Options, including the name of the Person to whom such Company
Stock Options have been granted, the number of shares subject to each Company Stock Option,
the per share exercise price for each Company Stock Option and the portion of each Company
Stock Option that is currently exercisable.
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f) Section&nbsp;3.3(f) of the Company Disclosure Schedule sets forth a true, complete and
correct list of the Company Warrants, including the name of the Person to whom such Company
Warrant has been granted, the number of shares subject to each such Company Warrant, the per
share exercise price for each Company Warrant and the portion of each Company Warrant that
is currently exercisable.
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(g) Section&nbsp;3.3(g) of the Company Disclosure Schedule sets forth a true, complete and
correct list of the unvested Company Restricted Shares outstanding under the Company Equity
Incentive Plans, including the name of the Person to whom such Company Restricted Shares
have been granted, the Company Equity Incentive Plan under which such Company Restricted
Shares were issued, the issue date, the applicable vesting and acceleration provisions, any
performance targets or market conditions related to vesting, the number of Company
Restricted Shares granted and the repurchase price relating to each grant of Company
Restricted Shares.
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(h) Except for the Company Stockholder Agreement, there are no agreements or
understandings to which the Company or any Company Subsidiary is a party (i)&nbsp;with respect to
the voting rights of, (ii)&nbsp;requiring the registration for sale of, (iii)&nbsp;granting any
preemptive or anti dilution rights with respect to or (iv)&nbsp;which restrict the transfer of
any shares of capital stock of the Company (other than agreements restricting the transfer
of unvested shares of restricted Company Common Stock issued and outstanding under the
Company Equity Incentive Plans), and, to the Company&#146;s Knowledge there are no third party
agreements or understandings with respect to the voting of any such shares or which restrict
the transfer of any such shares.
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) There are no outstanding obligations of the Company to repurchase, redeem or
otherwise acquire any shares of capital stock, partnership interests or any other securities
of the Company (other than in satisfaction of withholding tax obligations
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->12<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="justify" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">pursuant to certain awards outstanding under the Company Equity Incentive Plans in the event the
grantees fail to satisfy withholding tax obligations).
</DIV>



<DIV align="justify" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(j) Except as set forth in the Filed SEC Documents, the Company has no material
Indebtedness outstanding. As of the date hereof, there are no unconsolidated Company
Subsidiaries or any off-balance sheet arrangements of any type (including any off-balance
sheet arrangements required to be disclosed pursuant to Item&nbsp;303(a)(4) of Regulation&nbsp;S-K
promulgated under the Securities Act) that have not been described in the Filed SEC
Documents nor any obligations to enter into any such arrangements.
</DIV>

<DIV align="justify" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.4 <U>Subsidiaries</U>.
</DIV>



<DIV align="justify" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) Section&nbsp;3.1(c) of the Company Disclosure Schedule sets forth the name and
jurisdiction of incorporation or organization of each Company Subsidiary. All issued and
outstanding shares or other Equity Interests of each corporate Company Subsidiary are duly
authorized, validly issued, fully paid and nonassessable. Except as set forth in Section
3.4(a) of the Company Disclosure Schedule, all issued and outstanding shares or other Equity
Interests of each Company Subsidiary are owned directly or indirectly by the Company free
and clear of all liens, pledges, security interests, claims, or other encumbrances on title
(&#147;<U>Encumbrances</U>&#148;).
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) There are no outstanding obligations of any Company Subsidiary to repurchase,
redeem or otherwise acquire any shares of capital stock, partnership interests or any other
securities of any Company Subsidiary.
</DIV>

<DIV align="justify" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.5 <U>Other Interests</U>. Section&nbsp;3.5 of the Company Disclosure Schedule sets forth all
interests and investments (whether equity or debt) in any Person owned directly or indirectly by
the Company other than investments in short-term investment securities, Equity Interests in Company
Subsidiaries and intercompany receivables owing by and to wholly owned Company Subsidiaries or by
wholly owned Company Subsidiaries to the Company.
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.6 <U>Consents and Approvals; No Violations</U>.
</DIV>



<DIV align="justify" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) Assuming the Company Stockholder Approval has been obtained, and except for (a)
filings, permits, authorizations, consents and approvals required under (i)&nbsp;the Exchange
Act, the Securities Act and state securities or state &#147;blue sky&#148; laws and (ii)&nbsp;the HSR Act
and (b)&nbsp;the filing of the Certificate of Merger, and as set forth in Section&nbsp;3.6 of the
Company Disclosure Schedule, none of the execution, delivery or performance of this
Agreement by the Company, the consummation by the Company of the Transaction or compliance
by the Company with any of the provisions herein do or will (i)&nbsp;violate, conflict with or
result in any breach of any provision of the organizational documents of the Company or any
Company Subsidiary, (ii)&nbsp;require any filing by the Company with, notice to, or permit,
authorization, consent or approval of, any state or federal government or governmental
authority or by any United States or state court of competent jurisdiction or of any other
country, territory or governmental body (a &#147;<U>Governmental Entity</U>&#148;), (iii)&nbsp;conflict
with or result in a violation or breach by the Company of, or constitute (with or without
due notice or lapse of time or both) a default
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->13<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="justify" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">(or result in the termination or cancellation of or the loss of material benefit under or accelerate the performance required by, or give
rise to any right of termination, cancellation, modification or acceleration) under, any of
the terms, conditions or provisions of any Material Contract to which the Company or any
Company Subsidiary is a party or by which the Company or any Company Subsidiary or any of
their respective properties or assets may be bound, or (iv)&nbsp;violate or conflict with any
applicable Laws, excluding from the foregoing clauses (ii), (iii)&nbsp;and (iv)&nbsp;such filings,
notices, permits, authorizations, consents, approvals, violations, breaches, defaults,
terminations, cancellations, losses and accelerations which have not and would not
reasonably be expected to, individually or in the aggregate, (A)&nbsp;prevent or materially delay
consummation of the Merger, (B)&nbsp;otherwise prevent or materially delay performance by the
Company of its obligations under this Agreement or (C)&nbsp;have a material adverse effect on the
ability of the Company and the Company Subsidiaries taken as a whole to conduct their
businesses in the ordinary course consistent with past practice.
</DIV>



<DIV align="justify" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) None of the execution, delivery or performance of this Agreement by the Company, or
the consummation by the Company of the Transaction, do or will violate, conflict with or
result in any material breach of any provision of any Indebtedness of the Company or any
Company Subsidiary. No &#147;Default&#148; (as defined in the Note Indenture) or &#147;Event of Default&#148;
(as defined in the Note Indenture) has occurred and is existing under the Note Indenture.
None of the execution, delivery or performance of this Agreement by the Company, or the
consummation by the Company of the Transaction, do or will violate, conflict with or result
in a violation or breach by the Company of, or constitute a &#147;Default&#148; (as defined in the
Note Indenture) or an &#147;Event of Default&#148; (as defined in the Note Indenture) under, the Note
Indenture. Without limiting the foregoing sentence, on the Closing Date and assuming the
accuracy of the representations and warranties contained in Section&nbsp;4.4 and Section&nbsp;4.12,
the Transaction will satisfy all requirements of Section&nbsp;4.1 of the Note Indenture,
including the requirements with respect to &#147;Indebtedness&#148; (as defined in the Note Indenture) and the &#147;Consolidated
Coverage Ratio&#148; (as defined in the Note Indenture) in Section&nbsp;4.1 of the Note Indenture.
</DIV>

<DIV align="justify" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.7 <U>SEC Reports; Undisclosed Liabilities; Sarbanes-Oxley</U>
</DIV>



<DIV align="justify" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) Except as set forth in Section&nbsp;3.7(a) of the Company Disclosure Schedule, the
Company has timely filed or otherwise furnished, all forms, registration statements,
prospectuses, certifications, reports, schedules and documents required to be filed or
furnished by it with or to the SEC under the Exchange Act, the Securities Act and the
Sarbanes-Oxley Act and the rules and regulations promulgated thereunder (the &#147;<U>Securities
Laws</U>&#148;) since September&nbsp;30, 2008 (such documents and any other documents filed by the
Company or any Company Subsidiary with the SEC, as have been supplemented, modified or
amended since the time of filing, collectively, the &#147;<U>Company SEC Reports</U>&#148;), all of
which were prepared in all material respects in accordance with the applicable requirements
of the Securities Laws. As of their respective dates, the Company SEC Reports (a)&nbsp;complied
as to form in all material respects with the applicable requirements of the Securities Laws
and (b)&nbsp;did not contain any untrue statement of a material fact or omit to state a material
fact required to be stated therein or necessary to make the statements made therein, in the
light of the circumstances under
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->14<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="justify" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">which they were made, not misleading. To the Company&#146;s Knowledge, as of the date hereof, none of the Company SEC Reports is the subject of ongoing
SEC review or outstanding SEC comment. None of the Company Subsidiaries is required to file
periodic reports with the SEC pursuant to the Exchange Act.
</DIV>



<DIV align="justify" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) Each of the consolidated balance sheets included in or incorporated by reference
into the Company SEC Reports (including the related notes and schedules) fairly presents in
all material respects the consolidated financial position of the Company and the Company
Subsidiaries as of its date and each of the consolidated statements of income, retained
earnings and cash flows of the Company included in or incorporated by reference into the
Company SEC Reports (including any related notes and schedules) fairly presents in all
material respects the results of operations, retained earnings or cash flows, as the case
may be, of the Company and the Company Subsidiaries for the periods set forth therein, in
each case, consistent with the books and records of the Company and the Company Subsidiaries
and in accordance with GAAP consistently applied during the periods involved, except as may
be noted therein and except, in the case of the unaudited statements, as permitted by Form
10-Q pursuant to Sections&nbsp;13 or 15(d) of the Exchange Act and for normal year-end audit
adjustments which would not be material in amount or effect. The consolidated unaudited
balance sheet of the Company as of June&nbsp;30, 2010 included in the financial statements set
forth in the Company&#146;s Quarterly Report on Form 10-Q for the quarter ended June&nbsp;30, 2010 is
referred to herein as the &#147;<U>Company Balance Sheet</U>.&#148;
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) The Company has no liabilities of any nature, whether accrued, absolute, contingent
or otherwise, required to be disclosed or reflected on a balance sheet prepared in
accordance with GAAP, other than liabilities (a)&nbsp;adequately reserved or reflected on the
Company Balance Sheet, (b)&nbsp;set forth in Sections&nbsp;3.7(c) or 3.8 of the Company Disclosure Schedule or (c)&nbsp;incurred since the date of the Company Balance Sheet in the
ordinary course of business consistent with past practice.
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) The Company is in compliance in all material respects with (i)&nbsp;the applicable
provisions of the Sarbanes-Oxley Act of 2002 (the &#147;<U>Sarbanes-Oxley Act</U>&#148;) and (ii)&nbsp;the
applicable listing and corporate governance rules and regulations of Nasdaq. Each required
form, report and document (including any amendment thereof and supplement thereto)
containing financial statements that has been filed with or submitted to the SEC since
September&nbsp;30, 2007 was accompanied by the certifications required to be filed or submitted
by the Company&#146;s principal executive officer and principal financial officer pursuant to the
Sarbanes-Oxley Act and Rule&nbsp;13a-14 or 15d-14 promulgated under the Exchange Act and, at the
time of filing or submission of each such certification, such certification complied in all
material respects with the applicable provisions of the Sarbanes-Oxley Act and Rule&nbsp;13a-14
or 15d-14 promulgated under the Exchange Act. Neither the Company nor any of its executive
officers has received notice from any Governmental Entity challenging or questioning the
accuracy, completeness, form or manner of filing of such certifications. To the Company&#146;s
Knowledge, there are no facts or circumstances that would prevent its principal executive
officer and principal financial officer from giving the certifications and attestations
required pursuant to the rules and
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->15<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="justify" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">regulations adopted pursuant to Section&nbsp;404 of the Sarbanes-Oxley Act, without qualification, when next due.
</DIV>



<DIV align="justify" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e) Neither the Company nor any of the Company Subsidiaries has outstanding &#147;extensions
of credit&#148; to directors or executive officers of the Company within the meaning of Section
402 of the Sarbanes-Oxley Act.
</DIV>

<DIV align="justify" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.8 <U>Litigation</U>. Except as set forth in Section&nbsp;3.8 of the Company Disclosure
Schedule, as of the date hereof, there is no suit, claim, action, proceeding, arbitration,
mediation or investigation (&#147;<U>Action</U>&#148;) pending or, to the Company&#146;s Knowledge, threatened
against the Company or any of the Company Subsidiaries or any properties or assets of the Company
or any Company Subsidiaries that (i)&nbsp;involves an amount in controversy that would reasonably be
expected to exceed $250,000, (ii)&nbsp;would reasonably be expected to result in material injunctive
relief, or (iii)&nbsp;seeks to impose any material legal restraint on or prohibition against or limit
the Surviving Corporation&#146;s ability to operate the business of the Company and the Company
Subsidiaries substantially as it was operated immediately prior to the date of this Agreement.
There is no Action pending or, to the Company&#146;s Knowledge, threatened against the Company or any of
the Company Subsidiaries or any properties or assets of the Company or any Company Subsidiaries
that would be reasonably likely to, individually or in the aggregate (a)&nbsp;prevent or materially
delay the consummation of the Merger, (b)&nbsp;otherwise prevent or materially delay performance by the
Company of any of its material obligations under this Agreement or (c)&nbsp;have a Company Material
Adverse Effect. Except as set forth in Section&nbsp;3.8 of the Company Disclosure Schedule, as of the
date hereof, to the Company&#146;s Knowledge, no executive officer or director of the Company or any
Company Subsidiary is a defendant in any Action in connection with his or her status as an officer
or director of the Company or any of its Subsidiaries.
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.9 <U>Absence of Certain Changes</U>.
</DIV>



<DIV align="justify" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) Since  June&nbsp;30, 2010, the Company and the Company Subsidiaries have conducted their
respective businesses in the ordinary course of business (except for the process leading to
the execution of the Agreement and as otherwise expressly provided in this Agreement
(including Section&nbsp;5.1)) and there has not been: (i)&nbsp;any declaration, setting aside or
payment of any dividend or other distribution with respect to any shares of capital stock of
the Company; (ii)&nbsp;a Company Material Adverse Effect and there has not been any effect,
event, development or change which has had or is reasonably likely to have a Company
Material Adverse Effect, (iii)&nbsp;a material change in the Company&#146;s relations with its
employees or (iv)&nbsp;any material change in the Company&#146;s accounting principles, practices or
methods except insofar as may have been required by a change in GAAP.
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) Since June&nbsp;30, 2010, neither the Company nor any Company Subsidiary has taken any
action that, if taken after the date of this Agreement without the prior written consent of
Parent, would constitute a breach of Section&nbsp;5.1.
</DIV>

<DIV align="justify" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.10 <U>Taxes</U>.
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->16<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">





<DIV align="justify" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) Each of the Company and the Company Subsidiaries (i)&nbsp;has timely filed (or had filed
on their behalf) all material Tax Returns required to be filed by any of them (after giving
effect to any filing extension granted by a Governmental Entity) and (ii)&nbsp;has paid (or had
paid on their behalf) all Taxes shown on such Tax Returns as required to be paid by it. The
most recent financial statements contained in the Company SEC Reports reflect an adequate
reserve for all Taxes payable by the Company and the Company Subsidiaries for all Taxable
periods and portions thereof through the date of such financial statements in accordance
with GAAP, whether or not shown as being due on any Tax Returns.
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) True, correct and complete (in all material respects) copies of all material income
Tax Returns and all other material Tax Returns for the Company and each Company Subsidiary
with respect to the Company&#146;s 2007, 2008 and 2009 fiscal years have been delivered or made
available to representatives of Parent.
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) No deficiencies for any material amount of Taxes have been asserted or assessed in
writing against the Company or any of the Company Subsidiaries as of the date of this
Agreement and no requests for waivers of the time to assess any Taxes are pending, and
neither the Company nor any of the Company Subsidiaries has received written notice from a
Taxing authority in a jurisdiction in which it does not file a Tax Return that it is or may
be liable for Taxes that would be the subject of such Tax Return.
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) Except as set forth in Section&nbsp;3.10(d) of the Company Disclosure Schedule, neither
the Company nor any of the Company Subsidiaries (i)&nbsp;has been a member of an affiliated group filing a consolidated federal income tax return (other
than a group the common parent of which was the Company) or (ii)&nbsp;has any liability for the
Taxes of any person (other than the Company or any Company Subsidiary) under Treasury
Regulations Section&nbsp;1.1502-6 (or any similar provision of state, local or foreign law), as a
transferee, successor, by contract or otherwise.
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e) None of the Company, any Company Subsidiary, any of their Affiliates nor any of
their predecessors by merger or consolidation has within the past two (2)&nbsp;years been a party
to a transaction intended to qualify under Section&nbsp;355 of the Code or under so much of
Section&nbsp;356 of the Code as relates to Section&nbsp;355 of the Code.
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f) Neither the Company nor any of the Company Subsidiaries has engaged in, or is
required to make any disclosure to the Internal Revenue Service with respect to, a &#147;listed
transaction&#148; pursuant to Treasury Regulations Section&nbsp;1.6011-4(b)(2).
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(g) None of the Company Subsidiaries (i)&nbsp;is or was a &#147;surrogate foreign corporation&#148;
within the meaning of Section&nbsp;7874(a)(2)(B) of the Code or is treated as a U.S. corporation
under Section 7874(b) of the Code or (ii)&nbsp;was created or organized in the United States such
that such entity would be taxable in the United States as a domestic entity pursuant to
United States Treasury Regulation&nbsp;Section&nbsp;301.7701-5(a).
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->17<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="justify" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(h) The Company has not been a &#147;United States real property holding corporation&#148; within
the meaning of Section&nbsp;897(c)(2) of the Code during the applicable period in Section
897(c)(1)(a)(ii) of the Code.
</DIV>

<DIV align="justify" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.11 <U>Properties</U>.<U></U>
</DIV>



<DIV align="justify" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) Section&nbsp;3.11(a) of the Company Disclosure Schedule sets forth a complete list of
the real estate (&#147;<U>Owned Real Properties</U>&#148;) owned by the Company or any Company
Subsidiary. The Company or a Company Subsidiary has good and valid fee simple title to each
of the Owned Real Properties free and clear of any liens or encumbrances other than the
Permitted Liens.
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) Section&nbsp;3.11(b) of the Company Disclosure Schedule sets forth a correct and
complete list of each material lease pursuant to which the Company or any Company Subsidiary
is a lessee (collectively, the &#147;<U>Leases</U>&#148;). The Company has made available to Parent
true, correct and complete copies of all Leases, including all amendments, modifications,
supplements, renewals, extensions and guarantees related thereto, as of the date hereof
(except for discrepancies or omissions that would not have and would not reasonably be
expected to have, individually or in the aggregate, a Company Material Adverse Effect).
Except as has not had, and would not reasonably be expected to have, individually or in the
aggregate, a Company Material Adverse Effect, none of the premises covered by the Leases is
subject to any sublease, license or other agreement granting to any person or entity (other
than the Company) any right to the use, occupancy or enjoyment of the premises or any
portion thereof. Each of the Leases is in full force and effect and is valid, binding and
enforceable in accordance with its terms, except as enforceability may be limited by
applicable bankruptcy, insolvency, reorganization, moratorium, fraudulent transfer and similar Laws of general applicability relating to
or affecting creditors&#146; rights or by general equity principles. Neither the Company nor any
Company Subsidiary, on the one hand, nor, to the Company&#146;s Knowledge, any other party, on
the other hand, is in default under any Lease, except for defaults that have not had, and
would not reasonably be expected to have, individually or in the aggregate, a Company
Material Adverse Effect.
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) The buildings, facilities and other improvements and fixtures owned or leased by
the Company and any Company Subsidiary or otherwise used by the Company or any Company
Subsidiary in connection with the operation of their businesses are (i)&nbsp;to the Company&#146;s
Knowledge (as to physical plant and structure), structurally sound, in good operating
condition and repair, ordinary wear and tear excepted, and (ii)&nbsp;adequate for the uses to
which they are being put, in each case with such exceptions as have not had, and would not
reasonably be expected to have, individually or in the aggregate, a Company Material Adverse
Effect.
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) Neither the Company nor a Company Subsidiary has received written notice of any
pending condemnation, expropriation, eminent domain or similar Action affecting all or any
portion of the Owned Real Property or the premises covered by the Leases, and, to the
Company&#146;s Knowledge, no such Action is threatened.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->18<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="justify" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e) Except as has not had, and would not reasonably be expected to have, individually
or in the aggregate, a Company Material Adverse Effect, all Permits necessary in connection
with the construction upon, and present use and operation of, the Owned Real Property and
the premises covered by the Leases and the lawful occupancy thereof in the business of the
Company and the Company Subsidiaries have been issued by the appropriate Governmental
Entities. The current use of the Owned Real Property and the premises covered by the Leases
is, in all material respects, in accordance with the certificates of occupancy relating
thereto and the terms of any such Permits. Except as has not had, and would not reasonably
be expected to have, individually or in the aggregate, a Company Material Adverse Effect,
neither the Company nor any Company Subsidiary has received a written notice from any
Governmental Entity having jurisdiction over the Owned Real Property or the premises covered
by the Leases that the Owned Real Property or the premises covered by the Leases is in
violation of any Law relating to Owned Real Property or the premises covered by the Leases,
including setback requirements and zoning restrictions and ordinances, except to the extent
that a requirement may be satisfied by virtue of being &#147;grandfathered&#148; or otherwise
permitted to continue in its current status.
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f) Except as has not had, and would not reasonably be expected to have, individually
or in the aggregate, a Company Material Adverse Effect, each parcel of Owned Real Property
and premises covered by the Leases is supplied with utilities and other services necessary
for the operation of such Owned Real Property and premises as the same is currently
operated, all of which utilities and other services are provided via public roads or via
permanent, irrevocable appurtenant easements benefiting such Owned Real Property and
premises. Each parcel of Owned Real Property premises covered by the Leases abuts on, and
has direct vehicular access to, a public road, or has access to a public road via a permanent, irrevocable appurtenant easement benefiting the parcel of
Owned Real Property and premises, in each case, to the extent necessary for the conduct of
the business of the Company and the Company Subsidiaries as it is currently being conducted.
</DIV>

<DIV align="justify" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.12 <U>Environmental Matters</U>.
</DIV>



<DIV align="justify" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) Except as set forth in any environmental reports listed on Section&nbsp;3.12(a) of the
Company Disclosure Schedule and made available to Parent prior to the date hereof, neither
the Company nor any Company Subsidiary has received any written notice (i)&nbsp;of any
administrative or judicial enforcement proceeding that is pending, or to the Company&#146;s
Knowledge threatened, against the Company or any Company Subsidiary under any Environmental
Law or (ii)&nbsp;that it is potentially responsible under any Environmental Law for costs of
response or for damages to natural resources (as &#147;response&#148; and &#147;natural resources&#148; are
defined under Environmental Laws) including any investigation related thereto, at any
location.
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) Except as individually or in the aggregate would not reasonably be expected to have
a Company Material Adverse Effect, no Hazardous Materials have been used, stored, treated or
released by the Company at, on, under or in the real property leased by the Company or any
Company Subsidiary that has resulted or would be
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->19<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="justify" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">reasonably expected to result in a requirement under any Environmental Laws to perform a response action (including any
investigation related thereto) or result in liability under any Environmental Laws.
</DIV>



<DIV align="justify" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) Except as has not had, and would not reasonably be expected to have, individually
or in the aggregate, a Company Material Adverse Effect, neither the Company nor any Company
Subsidiary has been a party to or otherwise bound by any agreement, contract, obligation or
instrument under which the Company or Company Subsidiary is obligated to indemnify or
otherwise assume responsibility for any liability of any other Person arising under
Environmental Laws.
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) The Company has made available to Parent and Merger Sub all material environmental
audits, studies, reports, analyses and results of investigations that are, to the Company&#146;s
Knowledge, in the possession, custody or control of the Company or any Company Subsidiary
since May&nbsp;1, 2008 with respect to the real property presently or formerly leased by the
Company or any Company Subsidiary or the operations conducted thereon.
</DIV>

<DIV align="justify" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.13 <U>Employee Benefit Plans</U>.
</DIV>



<DIV align="justify" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) Section&nbsp;3.13(a) of the Company Disclosure Schedule sets forth a true, correct and
complete list of each material pension, profit-sharing, savings, retirement, employment,
collective bargaining, consulting, severance pay, termination, executive compensation, incentive compensation, deferred compensation, bonus, stock purchase,
stock option, phantom stock or other equity-based compensation, change-in-control,
retention, salary continuation, vacation, sick leave, disability, death benefit, group
insurance, hospitalization, medical, dental, life, Code Section&nbsp;125 &#147;cafeteria&#148; or
&#147;flexible&#148; benefit, employee benefit, or material fringe benefit plan, program, policy,
practice, agreement or arrangement, whether written or oral, formal or informal, legally
binding or not (including every &#147;employee benefit plan&#148;, within the meaning of ERISA Section
3(3)) (i)&nbsp;currently maintained, sponsored or contributed to (or with respect to which any
obligation to maintain, sponsor or contribute has been undertaken) by the Company, any
Company Subsidiary or any ERISA Affiliate, (ii)&nbsp;under which any current or former employee,
director, consultant or independent contractor of the Company or any Company Subsidiary has
any present or future right to benefits, and (iii)&nbsp;with respect to which the Company or any
Company Subsidiary has any direct or indirect liability, whether contingent or otherwise
(collectively, the &#147;<U>Employee Programs</U>&#148;). No Employee Program is maintained outside
the jurisdiction of the United States, or covers any employee residing or working outside
the United States.
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) Except with respect to the VCP Filing and the 5330 Filing, each Employee Program
that is intended to qualify under Section 401(a) of the Code is so qualified and has
received a favorable determination or opinion letter from the IRS regarding its
qualification thereunder and, to the Company&#146;s Knowledge, no event has occurred and no
condition exists that is reasonably expected to result in the revocation of any such
determination or the imposition of any liability, penalty or tax under ERISA, the Code or
any other applicable Laws. With respect to each Employee Program all reports, returns,
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->20<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="justify" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">notices and other documentation that are required to have been filed with or furnished to
the IRS, the DOL, the PBGC, the SEC or any other governmental authority, or to the
participants or beneficiaries of such Employee Program, have been filed or furnished on a
timely basis, including all documents relating to any IRS Voluntary Correction Program
submission or similar filing made with respect to any Employee Program, including that
certain Voluntary Correction Program submission made with respect to the Brotman Medical
Center 401(k) Retirement Plan<I>, </I>originally filed on March&nbsp;30, 2010 (the &#147;<U>VCP Filing</U>&#148;)
and that certain 5330 submission made with respect to Brotman Medical Center 401(k)
Retirement Plan, originally filed on March&nbsp;29, 2010 (the &#147;<U>5330 Filing</U>&#148;).
</DIV>



<DIV align="justify" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) With respect to each Employee Program, the Company has made available to Parent (if
applicable to such Employee Program): (i)&nbsp;all material documents embodying or governing
such Employee Program, and any funding medium for the Employee Program (including plan
documents, trust agreements and amendments thereto); (ii)&nbsp;the most recent IRS determination
letter with respect to such Employee Program under Code Section&nbsp;401(a); (iii)&nbsp;IRS Forms 5500
filed with the IRS for the three (3)&nbsp;most recent plan years, together with audited financial
statements and actuarial reports; (iv)&nbsp;the summary plan description for such Employee
Program and all modifications thereto; (v)&nbsp;any insurance policy related to such Employee
Program; and (vi)&nbsp;for the last three (3)&nbsp;years, all material correspondence with the IRS,
the United States Department of Labor (the &#147;<U>DOL</U>&#148;), the Pension Benefit Guaranty
Corporation (the &#147;<U>PBGC</U>&#148;), the SEC or any other governmental authority regarding the
operation or the administration of any Employee Program, including all correspondence and all filings
made in connection with the VCP Filing and the 5330 Filing.
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) Each Employee Program has been established, operated and administered in accordance
with the requirements of applicable Law, including ERISA and the Code, and is being
administered and operated in all material respects in accordance with its terms. No
Employee Program is subject to Title IV of ERISA or is a multiemployer plan, within the
meaning of ERISA Section&nbsp;3(37) and none of the Company, any Company Subsidiary or any ERISA
Affiliate has within the past six (6)&nbsp;years sponsored, maintained, contributed to or had any
liability in respect of any employee benefit plan subject to Title IV of ERISA or any
multiemployer plan.
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e) Except as set forth in Section&nbsp;3.13(e) of the Company Disclosure Schedule, full
payment has been made, or otherwise properly accrued on the books and records of the Company
and any ERISA Affiliate, of all amounts that the Company and any ERISA Affiliate are
required under the terms of the Employee Programs to have paid as contributions to such
Employee Programs on or prior to the date hereof (excluding any amounts not yet due) and the
contribution requirements, on a prorated basis, for the current year have been made or
otherwise properly accrued on the books and records of the Company through the Closing Date.
Full payment has been made, or otherwise properly accrued, of all amounts that the Company,
any Company Subsidiary or any Employee Program is reasonably expected to pay or contribute
(including any compliance fees) as a result of the failures giving rise to the VCP Filing
and the 5330 Filing, and the Company, each Company Subsidiary and Employee Program will
timely pay or contribute any additional amounts and timely perform any actions required by
the
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->21<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="justify" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">IRS in order to obtain a compliance statement from the IRS. To the Company&#146;s Knowledge,
none of the Company, any Company Subsidiary or any Employee Program has any additional
liability with respect to compliance failures related to the Brotman Medical Center 401(k)
Retirement Plan, whether pursuant to the VCP Filing, the 5330 Filing or otherwise.
</DIV>



<DIV align="justify" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f) Neither the Company, an ERISA Affiliate or any Person appointed or otherwise
designated to act on behalf of the Company, or an ERISA Affiliate, has engaged in any
transactions in connection with any Employee Program that is reasonably expected to result
in the imposition of a material penalty pursuant to Section 502(i) of ERISA, material
damages pursuant to Section&nbsp;409 of ERISA or a material Tax pursuant to Section 4975(a) of
the Code.
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(g) No material liability, claim, complaint, action, lien or litigation has been made,
commenced or, to the Company&#146;s Knowledge, threatened with respect to any Employee Program
(other than routine claims for benefits payable in the ordinary course of business) and to
the Company&#146;s Knowledge no facts or circumstances exist that are reasonably likely to give
rise to any such liability, claim, complaint, action lien or litigation. No administrative
investigation, audit or other administrative proceeding by the DOL, the PBGC, the IRS or any
other governmental agency is pending, threatened or in progress (including any routine
requests for information from the PBGC) and there are no audits or proceedings initiated
pursuant to the Voluntary Fiduciary Correction Program, the Employee Plans Compliance Resolution System or similar proceedings pending
with the IRS or DOL with respect to any Employee Program.
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(h) No Employee Program provides for health or welfare benefits (other than as required
pursuant to Section&nbsp;4980B of the Code or pursuant to state health continuation laws) to any
current or future retiree or former employee.
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) Except as contemplated in Section&nbsp;2.1 of this Agreement and as set forth in Section
3.13(i) of the Company Disclosure Schedule, neither the execution and delivery of this
Agreement, obtaining the Company Stockholder Approval nor the consummation of the
Transaction will (either alone or in combination with a termination of employment prior to
the second anniversary of the Effective Time) result in (A)&nbsp;any increase in severance pay
upon any termination of employment after the date of this Agreement; (B)&nbsp;the acceleration of
the time of payment or vesting or result in any funding of compensation or benefits; (C)
result in any payment, compensation or benefit becoming due, or increase in the amount of
any payment, compensation or benefit due, to any current or former employee of the Company
or any Company Subsidiary; (D)&nbsp;any new obligation pursuant to any Employee Program; or (E)
any limitation or restriction on the right of the Company to merge, amend or terminate any
Employee Program.
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(j) Except as set forth in Section&nbsp;3.13(j) of the Company Disclosure Schedule, none of
the execution and delivery of this Agreement, obtaining the Company Stockholder Approval or
the consummation of the Transaction could (either alone or in combination with another
event) (A)&nbsp;require a &#147;gross-up&#148; or other payment to any &#147;disqualified individual&#148; within the
meaning of Section&nbsp;280G(c) of the Code due to the
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->22<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="justify" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">imposition of the excise tax under Section&nbsp;4999 of the Code on any payment to such disqualified individual or due to the failure of any
payment to such disqualified individual to be deductible under of Section&nbsp;280G of the Code
or (B)&nbsp;result in the payment of any amount that could, individually or in combination with
any other such payment, constitute an &#147;excess parachute payment&#148; as defined in Section
280G(b)(1) of the Code.
</DIV>



<DIV align="justify" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(k) Each Employee Program that is a &#147;nonqualified deferred compensation plan&#148; (as such
term is defined in Section&nbsp;409A(d)(1) of the Code) has at all times been administered in
compliance with the requirements of Section&nbsp;409A of the Code and applicable guidance issued
thereunder, and neither the Company nor any Company Subsidiary has any obligation to make
any tax gross-up payments as a result of the interest and penalty provisions of Section&nbsp;409A
of the Code to any individual.
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(l) No amount has been paid by the Company or any Company Subsidiary, and no amount is
expected to be paid by the Company or any Company Subsidiary, which would be subject to the
provisions of Section 162(m) of the Code such that all or a part of such payments would not
be deductible by the payor.
</DIV>

<DIV align="justify" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.14 <U>Labor and Employment Matters</U>.
</DIV>



<DIV align="justify" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) Except as set forth in Section&nbsp;3.14(a) of the Company Disclosure Schedule, neither
the Company nor any Company Subsidiary is a party to, or bound by, any collective bargaining
agreement, contract or other agreement or understanding with a labor union or labor union
organization, nor are there any negotiations or discussions currently pending or occurring
between the Company, or any of the Company Subsidiaries, and any union or employee
association regarding any collective bargaining agreement or any other work rules or
polices. There is no material unfair labor practice charge or complaint or labor
arbitration proceeding pending or, to the Company&#146;s Knowledge, threatened against the
Company or any of the Company Subsidiaries. To the Company&#146;s Knowledge, there are no
organizational efforts with respect to the formation of a collective bargaining unit
presently being made or threatened involving employees of the Company or any of the Company
Subsidiaries. There is no labor strike, material labor dispute, or concerted work stoppage
pending as of the date of this Agreement or, to the Company&#146;s Knowledge, threatened, and
neither the Company nor any Company Subsidiary has experienced any labor strike or concerted
labor dispute.
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) The Company and each of the Company Subsidiaries are in material compliance with
all applicable federal, state, local and foreign Laws concerning the employer-employee
relationship and with all agreements relating to the employment of employees of the Company
and each of the Company Subsidiaries, including applicable wage and hour Laws, labor
relations, employment discrimination, employment conditions, employment practices, fair
employment Laws, safety Laws, workers&#146; compensation statutes, unemployment Laws and social
security Laws. There are no proceedings pending or, to the Company&#146;s Knowledge, threatened
against the Company or any of the Company Subsidiaries in any forum by or on behalf of any
present or former employee of the Company or any of the Company Subsidiaries, any applicant
for
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->23<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="justify" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">employment or classes of the foregoing alleging breach of any express or implied
employment contract, violation of any Law governing employment or the termination thereof,
or any other discriminatory, wrongful or tortious conduct on the part of the Company of any
of the Company Subsidiaries in connection with the employment relationship. Neither the
Company nor any of the Company Subsidiaries has incurred any liability or obligation under
the Worker Adjustment and Retraining Notification Act and the regulations promulgated
thereunder (the &#147;<U>WARN Act</U>&#148;) or any similar state or local Law that remains
unsatisfied and, to the extent that, after the Effective Time, Parent operates the business
of the Company and the Company Subsidiaries in the same manner as the Company and the
Company Subsidiaries have been operated in the six (6)&nbsp;month period prior to the Effective
Time, Parent will not incur any material liability under the WARN Act or any other
applicable Law.
</DIV>



<DIV align="justify" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) No individual who has performed services for the Company or any of the Company
Subsidiaries has been improperly excluded from participation in any Employee Program, and
neither the Company nor any of the Company Subsidiaries has any material direct or indirect
liability, whether absolute or contingent, with respect to any misclassification of any
person as an independent contractor rather than as an employee, with respect to the
classification of any employee as exempt versus non-exempt, or with respect to any employee
leased from another employer.
</DIV>

<DIV align="justify" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.15 <U>No Brokers</U>. Other than with respect to UBS Securities LLC (the &#147;<U>Financial
Advisor</U>&#148;), which the Special Committee has retained as its financial advisor in connection with
the Merger, or as set forth in Section&nbsp;3.15 of the Company Disclosure Schedule, neither the Company
nor any of the Company Subsidiaries has entered into any contract, arrangement or understanding
with any Person or firm which may result in the obligation of such entity or Parent or Merger Sub
to pay any finder&#146;s fees, brokerage or agent&#146;s commissions or other like payments in connection
with the negotiations leading to this Agreement or consummation of the Merger.
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.16 <U>Opinion of Financial Advisor</U>. The Special Committee has received an opinion of
the Financial Advisor to the effect that, as of the date of such opinion, the Per Share Merger
Consideration to be received by the holders of shares of Company Common Stock is fair, from a
financial point of view, to such holders (other than such holders as are referenced in the
opinion). The Company shall forward to Parent, solely for informational purposes, a copy of the
written version of such opinion promptly following the Company&#146;s receipt thereof.
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.17 <U>Vote Required</U>. The affirmative vote of the holders of a majority of the shares
of Company Common Stock outstanding and entitled to vote on the adoption of this Agreement shall be
required for the stockholders of the Company to adopt this Agreement (the &#147;<U>Company Stockholder
Approval</U>&#148;). No other vote of the holders of any class or series of capital stock of the
Company or any Company Subsidiary is necessary to adopt this Agreement.
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.18 <U>Material Contracts</U>.
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) Section&nbsp;3.18(a) of the Company Disclosure Schedule sets forth a true and complete
list of all Material Contracts. Each of the Company and the Company Subsidiaries, and to
the Company&#146;s Knowledge, any other party thereto, is not in
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->24<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="justify" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">violation of or in default under any Material Contract to which it is a party or by which it or any of its properties or
assets is bound, except for violations or defaults that would not, individually or in the
aggregate, have a Company Material Adverse Effect, nor will the consummation of the Merger
result in any third party having any right to terminate, amend, accelerate, cancel or
deprive the Company of a material benefit under any Material Contract, except for such
rights that, if exercised, would not reasonably be expected to, individually or in the
aggregate, result in a material liability of the Company or the Company Subsidiaries.
</DIV>



<DIV align="justify" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) Each Material Contract is valid and binding on the Company and each Company
Subsidiary party thereto and, to the Company&#146;s Knowledge, each other party thereto, and is
in full force and effect, except to the extent such Material Contract has previously expired
in accordance with its terms or does not, and would not reasonably be expected to, result in
termination of such Material Contract or result in a material liability. To the Company&#146;s Knowledge, (i)&nbsp;there are no events or conditions which
constitute, or after notice or lapse of time or both, will constitute a default on the part
of any counterparty under such Material Contract, (ii)&nbsp;the Company has not received any
notice from any counterparty that such counterparty intends to terminate, or not renew, any
Material Contract, or is seeking the renegotiation thereof in any material respect or
substitute performance thereunder in any material respect and (iii)&nbsp;the completion of the
transactions contemplated by this Agreement will not cause the expiration, termination or
material breach of any Material Contract or the acceleration of payment obligation or the
alteration of any material terms of any Material Contract. Complete and correct copies of
each Material Contract are filed as exhibits to the Filed SEC Documents or otherwise have
been delivered or made available to Parent prior to the date hereof.
</DIV>

<DIV align="justify" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.19 <U>Insurance</U>. The Company and each Company Subsidiary maintains insurance coverage
with reputable insurers, or maintains self-insurance practices, in such amounts and covering such
risks as are in accordance with normal industry practice for companies engaged in businesses
similar to that of the Company (taking into account the cost and availability of such insurance),
except to the extent the failure to maintain such insurance has not had, and would not reasonably
be expected to have, individually or in the aggregate a Company Material Adverse Effect. There is
no claim by the Company or any Company Subsidiary pending under any such policies which (a)&nbsp;has
been denied or disputed by the insurer or (b)&nbsp;if not paid would have, individually or in the
aggregate, a Company Material Adverse Effect. All such insurance policies are in full force and
effect, reasonably adequate for the businesses engaged in by the Company and the Company
Subsidiaries, all premiums due and payable thereon have been paid, and no written notice of
cancellation or termination has been received by the Company with respect to any such policy which
has not been replaced on substantially similar terms prior to the date of such cancellation.
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.20 <U>Proxy Statement and Schedule&nbsp;13E-3</U>. The information relating to the Company and
the Company Subsidiaries to be contained in the Proxy Statement and the Schedule&nbsp;13E-3 will, in the
case of Schedule&nbsp;13E-3, as of the date thereof, the date of any amendments thereto and as of the
time of the Company Stockholders&#146; Meeting, and, in the case of the Proxy Statement, as of the time
the Proxy Statement (or any amendment thereof or supplement thereto) is first mailed to the
Company&#146;s stockholders and as of the date of the Company Stockholders&#146;
</DIV>



<P align="center" style="font-size: 10pt"><!-- Folio -->25<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="justify" style="font-size: 10pt; margin-top: 6pt">Meeting, not contain any untrue statement of any material fact, or omit to state any material fact required to be stated
therein or necessary in order to make the statements therein not false or misleading at the time
and in light of the circumstances under which such statement is made. The Proxy Statement and the
Schedule&nbsp;13E-3 will comply as to form in all material respects with the applicable requirements of
the Exchange Act. Notwithstanding the foregoing, no representation is made by the Company with
respect to the information supplied by Parent or Merger Sub for inclusion therein.
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.21 <U>No Payments to Employees, Officers, Directors or Consultants</U>. Except as
contemplated by Section&nbsp;2.1 of this Agreement or as set forth on Section&nbsp;3.21 of the Company
Disclosure Schedule, there is no employment or severance payment payable or other benefit due on a change of control or otherwise as a result of obtaining the Company
Stockholder Approval or the consummation of the Merger or any of the other transactions
contemplated hereby, with respect to any employee, officer, director or consultant of the Company
or any Company Subsidiary.
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.22 <U>Intellectual Property</U>.
</DIV>



<DIV align="justify" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) Section&nbsp;3.22(a) of the Company Disclosure Schedule sets forth a list of all
material patents, patent applications, registered copyrights, registered marks (including
trademarks and service marks, to the extent registered) and applications to register marks,
in each case that are owned by the Company or the Company Subsidiaries (collectively, the
&#147;<U>Registered Intellectual Property</U>&#148;). Except as would not have a Company Material
Adverse Effect, no Action is pending, or to the Company&#146;s Knowledge, is threatened,
challenging the validity, enforceability, registration, ownership or use of any material
Registered Intellectual Property. The Company or a Company Subsidiary is the sole and
exclusive owner of the Registered Intellectual Property. To the Company&#146;s Knowledge, no
item of material Registered Intellectual Property is being misappropriated, infringed,
diluted or otherwise violated by any third party.
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) (i)&nbsp;The Company and the Company Subsidiaries own or have a valid and enforceable
right to use all intellectual property used in and material to the conduct of the business
of the Company and the Company Subsidiaries as currently conducted, (ii)&nbsp;no claims are
pending or, to the Company&#146;s Knowledge, threatened, alleging that the Company or any of the
Company Subsidiaries is misappropriating, infringing, diluting or otherwise violating the
rights of any Person with regard to any intellectual property and neither the Company nor
any Company Subsidiary has received any notices during the preceding twelve (12)&nbsp;months
regarding the foregoing, and (iii)&nbsp;to the Company&#146;s Knowledge, the operation of the business
of the Company and the Company Subsidiaries as currently conducted does not misappropriate,
infringe, dilute or otherwise violate the intellectual property of any other Person.
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) The Company and the Company Subsidiaries have taken commercially reasonable steps
to (i)&nbsp;maintain, police and protect their intellectual property, (ii)&nbsp;protect the security
of their information technology assets and systems (including all data contained therein)
against any unauthorized use or access and (iii)&nbsp;protect all confidential and
personally-identifiable information of their customers and clients against any
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->26<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="justify" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">unauthorized disclosure or use. The Company and the Company Subsidiaries have implemented commercially
reasonable data backup, data storage and data recovery procedures, as well as a commercially
reasonable business continuity plan, in each case consistent with industry practices.
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.23 <U>Affiliate Transactions</U>. Since September&nbsp;30, 2009, there have been no
transactions or series of related transactions, agreements, arrangements or understandings, nor are
there any currently proposed transactions or series of related transactions, that would be required to be disclosed under
Item&nbsp;404 of Regulation&nbsp;S-K under the Securities Act that have not been so disclosed in the Filed
SEC Documents.
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.24 <U>Questionable Payments</U>. Neither the Company nor any Company Subsidiary (nor, to
the Company&#146;s Knowledge, any of their respective directors, executives, or to the Company&#146;s
Knowledge, representatives, agents or employees) (a)&nbsp;has used or is using any corporate funds for
any illegal contributions, gifts, entertainment or other unlawful expenses relating to political
activity, (b)&nbsp;has used or is using any corporate funds for any direct or indirect unlawful payments
to any foreign or domestic government officials or employees, (c)&nbsp;has violated or is violating any
provision of the Foreign Corrupt Practices Act of 1977, (d)&nbsp;has established or maintained, or is
maintaining, any unlawful fund of corporate monies or other properties or (e)&nbsp;has made any bribe,
unlawful rebate, payoff, influence payment, kickback or other unlawful payment of any nature.
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.25 <U>Internal Controls</U>. Since the first reporting period covered by the Company SEC
Reports, except as set forth in Section&nbsp;3.25 of the Company Disclosure Schedule, the Company has
designed and maintains a system of internal controls over financial reporting (as defined in Rules
13a-15(f) and 15d-15(f) of the Exchange Act) sufficient to provide reasonable assurances regarding
the reliability of financial reporting for the Company and the Company Subsidiaries. The Company
(i)&nbsp;has designed and maintains disclosure controls and procedures (as defined in Rules&nbsp;13a-15(e)
and 15d-15(e) of the Exchange Act) to ensure that material information required to be disclosed by
the Company in the reports that it files or submits under the Exchange Act is recorded, processed,
summarized and reported within the time periods specified in the SEC&#146;s rules and forms and is
accumulated and communicated to the Company&#146;s management as appropriate to allow timely decisions
regarding required disclosure and (ii)&nbsp;has disclosed to the Company&#146;s auditors and the audit
committee of the Company Board (and made summaries of such disclosures available to Parent) (A)&nbsp;any
significant deficiencies and material weaknesses in the design or operation of internal controls
over financial reporting that are reasonably likely to adversely affect in any material respect the
Company&#146;s ability to record, process, summarize and report financial information and (B)&nbsp;any fraud,
whether or not material, that involves management or other employees who have a significant role in
the Company&#146;s internal controls over financial reporting. Since the first reporting period covered
by the Company SEC Reports, except as set forth in Section&nbsp;3.25 of the Company Disclosure Schedule,
neither the Company nor, to the Company&#146;s Knowledge, the Company&#146;s independent registered public
accounting firm, has identified or been made aware of &#147;significant deficiencies&#148; or &#147;material
weaknesses&#148; (as defined by the Public Company Accounting Oversight Board) in the design or
operation of the Company&#146;s internal controls and procedures which could reasonably adversely affect
the Company&#146;s ability to record, process, summarize and report financial data, in each case which
has not been subsequently remediated. To the Company&#146;s Knowledge, there is no fraud, whether
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->27<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="justify" style="font-size: 10pt; margin-top: 6pt">or not material, that involves the Company&#146;s management or other employees who have a significant role
in the preparation of financial statements or the internal control over financial reporting
utilized by the Company and the Company Subsidiaries.
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.26 <U>Regulatory Matters.</U>
</DIV>



<DIV align="justify" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) Except as set forth in Section&nbsp;3.26(a) of the Company Disclosure Schedule, to the
Company&#146;s Knowledge, neither the Company nor any of the Company Subsidiaries is in violation
of, or has violated, any applicable provisions of any Laws, including health codes,
regulations and ordinances, state corporate practice of medicine laws and regulations
(including common law), state professional fee-splitting laws and regulations (including
common law), the Patient Protection and Affordable Care Act, as amended by the Health Care
and Education Affordability Reconciliation Act, the federal Anti-kickback Statute (42 U.S.C.
&#167; 1320a-7b(b)), the Stark Law (42 U.S.C. &#167;&#167; 1395nn), any applicable state fraud and abuse
prohibitions, including those that apply to all payors (governmental, commercial insurance
and self-payors), the Anti-Inducement Law (42 U.S.C. &#167; 1320a-7a(a)(5)), the civil False
Claims Act (31 U.S.C. &#167;&#167; 3729 <I>et seq</I>.), the administrative False Claims Law (42 U.S.C. &#167;
1320a-7b(a)), the civil monetary penalty laws (42 U.S.C. &#167; 1320a-7a), the Health
Insurance Portability and Accountability Act of 1996 (42 U.S.C. &#167; 1320d <I>et seq</I>.), as amended
by the Health Information, Technology for Economic and Clinical Health Act of 2009
(collectively, &#147;<U>HIPAA</U>&#148;), the exclusion laws (42 U.S.C. 1320a-7), and any comparable
state or local Laws, and the regulations promulgated pursuant to such Laws, each as amended
from time to time, and any other state or federal law, regulation, guidance document, manual
provision, program memorandum, opinion letter, or other public issuance which regulates
kickbacks, patient or program charges, recordkeeping, claims process, documentation
requirements, medical necessity, referrals, the hiring of employees or acquisition of
services or supplies from those who have been excluded from government health care programs,
quality, safety, privacy, security, licensure, accreditation or any other aspect of
providing health care services (each, a &#147;<U>Health Care Law</U>&#148;), other than violations
which have not had, and would not reasonably be expected to have, individually or in the
aggregate, a material adverse effect on the ability of the Company and the Company
Subsidiaries to conduct their respective businesses in the ordinary course consistent with
past practice.
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) Each of the Company and the Company Subsidiaries possess all their respective
Permits except where the failure to obtain such Permits has not had, and would not
reasonably be expected to have, individually or in the aggregate, a material adverse effect
on the ability of the Company and the Company Subsidiaries to conduct their respective
businesses in the ordinary course consistent with past practice. Each of the Company and
the Company Subsidiaries has fulfilled and performed all of its obligations with respect to
such Permits (including timely filing of any necessary applications for permit renewals) and
no event has occurred that allows, or after notice or lapse of time would allow, revocation
or termination thereof or results in any other material impairment of the rights of the
holder of any such Permit, except where such non-fulfillment, nonperformance, revocation,
termination or material impairment has not had, and would not reasonably be expected to
have, individually or in the aggregate, a material adverse effect on the ability of the
Company and the Company Subsidiaries to conduct
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->28<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="justify" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">their respective businesses in the ordinary
course consistent with past practice and, to the Company&#146;s Knowledge, none of the Company or
the Company Subsidiaries has received any notice of any proceeding relating to revocation,
suspension, modification or limitation of any such Permit, except where such revocation,
suspension, modification or limitation has not had, and would not reasonably be expected to have, individually or
in the aggregate, a material adverse effect on the ability of the Company and the Company
Subsidiaries to conduct their respective businesses in the ordinary course consistent with
past practice. All Permits are in full force and effect and the Company and the Company
Subsidiaries are in material compliance with each such Permit held by or issued to it,
except where the failure to comply has not had, and would not reasonably be expected to
have, individually or in the aggregate, a Company Material Adverse Effect.
</DIV>



<DIV align="justify" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) Except as has not had, and would not reasonably be expected to have, individually
or in the aggregate, a material adverse effect on the ability of the Company and the Company
Subsidiaries to conduct their respective businesses in the ordinary course consistent with
past practice, and except as set forth in Section&nbsp;3.26(c) of the Company Disclosure
Schedule, each of the Company and the Company Subsidiaries, as applicable, to the Company&#146;s
Knowledge, meet all requirements of participation, claims submission and payment of the
Programs and other third party payment programs and are a party to valid participation
agreements for payment by such Programs and other third party payment programs. None of the
Company and the Company Subsidiaries, or their respective officers, directors, employees,
agents and contractors has been or is currently excluded from participation in any such
Program. &#147;<U>Programs</U>&#148; shall mean the Medicare and Medicaid programs and any other
state or federal health care program, as defined in 42 U.S.C. &#167; 1320a-7b(f).
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) Except as has not had, and would not reasonably be expected to have, individually
or in the aggregate, a material adverse effect on the ability of the Company and the Company
Subsidiaries to conduct their respective businesses in the ordinary course consistent with
past practice and except as set forth in Section&nbsp;3.26(d) of the Company Disclosure Schedule,
there are no material Program recoupments or material recoupments of any third-party payor
being sought, requested or claimed, or to the Company&#146;s Knowledge, threatened against the
Company or any of the Company Subsidiaries. Except as set forth in Section&nbsp;3.26(d) of the
Company Disclosure Schedule, to the Company&#146;s Knowledge (i)&nbsp;there is no Action pending,
received or threatened against the Company or the Company Subsidiaries which relates in any
way to a violation of any legal requirement pertaining to the Programs or which could result
in the imposition of material penalties or the exclusion by the Company or the Company
Subsidiaries from participation in any Programs, and (ii)&nbsp;none of the Company, the Company
Subsidiaries or any of their respective officers, directors, employees or agents have
engaged in any activities which are cause for civil penalties or mandatory or permissive
exclusion from any Program. Except as set forth in Section&nbsp;3.26(d) of the Company
Disclosure Schedule, neither the Company nor any of the Company Subsidiaries is a party to
any corporate integrity agreements, monitoring agreements, consent decrees, settlement
orders, or similar agreements imposed by any Governmental Entity.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->29<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="justify" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e) Except as has not had, and would not reasonably be expected to have, individually
or in the aggregate, a material adverse effect on the ability of the Company and the Company
Subsidiaries to conduct their respective businesses in the ordinary course consistent with
past practice, each of the Company and the Company Subsidiaries is in material compliance with all applicable Health Care Laws regarding the selection,
deselection, and credentialing of contracted providers, including, but not limited to,
verification of licensing status and eligibility for reimbursement under the Programs.
Except as has not had, and would not reasonably be expected to have, individually or in the
aggregate, a material adverse effect on the ability of the Company and the Company
Subsidiaries to conduct their respective businesses in the ordinary course consistent with
past practice and to the Company&#146;s Knowledge, all of Company&#146;s and the Company Subsidiaries&#146;
contracted providers are properly licensed and hold appropriate clinical privileges, as
applicable, for the services which they provide, and, with respect to providers that perform
services eligible for reimbursement under any Program, are not debarred or excluded from any
such Program.
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f) Except as has not had, and would not reasonably be expected to have, individually
or in the aggregate, a material adverse effect on the ability of the Company and the Company
Subsidiaries to conduct their respective businesses in the ordinary course consistent with
past practice, to the Company&#146;s Knowledge, all reports, data, and information required to be
filed by the Company and the Company Subsidiaries in connection with any Program have been
timely filed and were true and complete at the time filed (or were corrected in or
supplemented by a subsequent filing). There are no claims, actions or appeals pending (and
the Company and the Company Subsidiaries have not made any filing or submission that would
result in any claims, actions or appeals) before any court, regulatory body, administrative
agency, governmental body, arbitrator or other authority (including governmental fiscal
agents) with respect to any Program reports or claims filed by the Company or any of the
Company Subsidiaries on or before the date hereof, or with respect to any disallowances by
any regulatory body, administrative agency, governmental body or other authority (including
governmental fiscal agents) in connection with any audit or any claims that, if adversely
determined, which have had and would reasonably be expected to have, individually or in the
aggregate, a material adverse effect on the ability of the Company and the Company
Subsidiaries to conduct their respective businesses in the ordinary course consistent with
past practice. Except as set forth in Section&nbsp;3.26(f) of the Company Disclosure Schedule, no
validation review or program integrity review related to the Company or any of the Company
Subsidiaries has been conducted by any regulatory body, administrative agency, governmental
body or other authority (including governmental fiscal agents) in connection with any
Program within the past three (3)&nbsp;years which, if determined adversely to the Company or any
such Company Subsidiary, has had, or would reasonably be expected to have, individually or
in the aggregate, a material adverse effect on the ability of the Company and the Company
Subsidiaries to conduct their respective businesses in the ordinary course consistent with
past practice, and to the Company&#146;s Knowledge, no such reviews are scheduled, pending,
threatened against or affecting the Company or any of the Company Subsidiaries.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->30<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="justify" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(g) The Company and certain of the Company Subsidiaries are considered to be &#147;Covered
Entities,&#148; as that term is defined in 45 C.F.R. &#167; 160.103, and are covered by the HIPAA
Administrative Requirements codified at 45 C.F.R. Parts 160 and 162 (the &#147;<U>Transactions
Rule</U>&#148;) and/or the HIPAA Security and Privacy Requirements codified at 45 C.F.R. Parts
160 and 164 (the &#147;<U>Privacy and Security Rules</U>&#148;). The Company, on its behalf and on behalf of any of the Company Subsidiaries subject to HIPAA, represents
and warrants that it or they (i)&nbsp;are currently compliant in all material respects with any
and all of the applicable requirements of HIPAA, including all requirements of the
Transactions Rule and the Privacy and Security Rules, and (ii)&nbsp;are not subject to, and are
not aware of any facts or circumstances that could reasonably be expected to give rise to,
any civil or criminal penalty or any investigation, claim or process by the Office of Civil
Rights of the United States Department of Health and Human Services or any other
governmental agency enforcing HIPAA, except in the case of (i)&nbsp;and (ii)&nbsp;above as has not
had, and would not reasonably be expected to have, individually or in the aggregate, a
material adverse effect on the ability of the Company and the Company Subsidiaries to
conduct their respective businesses in the ordinary course consistent with past practice.
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(h) Except as has not had, and would not reasonably be expected to have, individually
or in the aggregate, a material adverse effect on the ability of the Company and the Company
Subsidiaries to conduct their respective businesses in the ordinary course consistent with
past practice, all forms of contracts with providers and other third parties which are
currently in use by the Company and the Company Subsidiaries conform in all material
respects to the requirements of all applicable Laws and have been properly approved, or
deemed approved, by the appropriate Governmental Entities where such approval is required.
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt">ARTICLE IV
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><U>Representations and Warranties of Parent and Merger Sub</U>
</DIV>

<DIV align="justify" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Parent and Merger Sub hereby jointly and severally represent and warrant to the Company as
follows:
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.1 <U>Corporate Organization</U>.
</DIV>



<DIV align="justify" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) Each of Parent and Merger Sub is a corporation duly organized, validly existing and
in good standing under the Laws of the jurisdiction of its incorporation or organization and
has all requisite power and authority to own, lease and operate its properties and to carry
on its businesses as now conducted and proposed by Parent to be conducted, except where the
failure to be duly organized, existing and in good standing or to have such power and
authority would not have or would not reasonably be likely to have, individually or in the
aggregate, a Parent Material Adverse Effect.
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) The certificate of incorporation of each of Parent and Merger Sub is in effect, and
no dissolution, revocation or forfeiture proceedings regarding Parent or Merger Sub have
been commenced.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->31<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="justify" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) Parent has made available to the Company correct and complete copies of the
certificate of incorporation and bylaws of Parent and the certificate of incorporation and
bylaws of Merger Sub, in each case as currently in effect.
</DIV>

<DIV align="justify" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.2 <U>Authority Relative to this Agreement</U>.
</DIV>



<DIV align="justify" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) The Boards of Directors of each of Parent and Merger Sub have duly and validly
authorized the execution and delivery of this Agreement and approved the consummation of the
Transaction and taken all corporate actions required to be taken by the Boards of Directors
of each Parent and Merger Sub for the consummation of the Transaction.
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) Each of Parent and Merger Sub has all necessary corporate power and authority to
execute and deliver this Agreement and to consummate the Transaction. Other than the
adoption of this Agreement (following its execution) by Parent as the sole stockholder of
Merger Sub, no further corporate proceedings on the part of Parent or Merger Sub, or any of
their respective subsidiaries, are necessary to authorize this Agreement or to consummate
the Transaction. This Agreement has been duly and validly executed and delivered by each of
Parent and Merger Sub and constitutes a valid, legal and binding agreement of each of Parent
and Merger Sub, enforceable against each of Parent and Merger Sub in accordance with and
subject to its terms and conditions, except as enforceability may be limited by applicable
bankruptcy, insolvency, reorganization, moratorium, fraudulent transfer and similar Laws of
general applicability relating to or affecting creditors&#146; rights or by general equity
principles. No vote of the holders of capital stock of Parent is necessary to approve this
Agreement and the Transaction.
</DIV>

<DIV align="justify" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.3 <U>Consents and Approvals; No Violations</U>. Except for filings, permits,
authorizations, consents and approvals as may be required under, and other applicable requirements
of, (a)&nbsp;the Exchange Act and (b)&nbsp;the HSR Act, none of the execution, delivery or performance of
this Agreement by Parent or Merger Sub, the consummation by Parent or Merger Sub of the Transaction
or compliance by Parent or Merger Sub with any of the provisions herein do or will (i)&nbsp;violate,
conflict with or result in any breach of any provision of the organizational documents of Parent or
Merger Sub, (ii)&nbsp;require any filing by Parent or Merger Sub with, notice to, or permit,
authorization, consent or approval of, any Governmental Entity, (iii)&nbsp;result in a material
violation or breach by Parent or Merger Sub of, or constitute (with or without due notice or lapse
of time or both) a default (or give rise to any right of termination, cancellation or acceleration)
under, any of the terms, conditions or provisions of any loan note, bond, mortgage, credit
agreement, reciprocal easement agreement, permit, concession, franchise, indenture, lease, license,
contract, agreement or other instrument or obligation to which Parent or Merger Sub or any of their
respective subsidiaries is a party or by which the respective properties or assets of any of the
foregoing may be bound, or (iv)&nbsp;violate any Law, excluding from the foregoing clauses (ii), (iii)
and (iv)&nbsp;such filings, notices, permits, authorizations, consents, approvals, violations, breaches
or defaults which would not, individually or in the aggregate, (A)&nbsp;prevent or materially delay
consummation of the Merger, (B)&nbsp;otherwise prevent or materially delay performance by Parent or
Merger Sub of its material obligations under this Agreement or (C)&nbsp;have a Parent Material Adverse
Effect.
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->32<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV align="justify" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.4 <U>Ownership and Operations of Parent and Merger Sub</U>. Parent indirectly owns beneficially all of the outstanding capital stock of Merger Sub.
Each of Parent and Merger Sub was formed solely for the purpose of engaging in the Transaction, the
financing therefor and related transactions, and has engaged in no other business activities and
has conducted its operations only as contemplated hereby.
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.5 <U>Litigation</U>. There is no claim, action, suit, hearing, arbitration, alternative
dispute resolution action or any other judicial or administrative proceeding pending against (or,
to Parent&#146;s Knowledge, threatened against or naming as a party thereto) Parent or any of its
Subsidiaries, nor, to Parent&#146;s Knowledge, is there any investigation of a Governmental Entity
pending or threatened against Parent or any of its Subsidiaries, and none of Parent or any of its
Subsidiaries is subject to any outstanding order, writ, injunction or decree, in each case, which
would, individually or in the aggregate, reasonably be expected to result in a Parent Material
Adverse Effect.
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.6 <U>Sufficient Funds</U>. Parent has delivered to the Company true, complete and correct
copies of an executed equity commitment letter (the &#147;<U>Financing Commitment</U>&#148;), pursuant to
which funds have been committed, subject to the terms and conditions thereof, to invest the amount
set forth therein (the &#147;<U>Financing</U>&#148;). The Financing Commitment is in full force and effect
as of the date of this Agreement and is the legal, valid and binding obligation of Parent. As of
the date of this Agreement, the Financing Commitment has not been amended or modified, and no such
amendment or modification is contemplated or will be undertaken except as permitted pursuant to
this Agreement. The Financing Commitment has not been withdrawn or rescinded in any respect as of
the date hereof. There are no conditions precedent to the funding or investing, as applicable, of
the full amount of the Financing other than as expressly set forth in or contemplated by the
Financing Commitment. The obligations of Parent and Merger Sub under this Agreement are not
contingent in any respect upon the funding of the amounts contemplated to be funded pursuant to the
Financing Commitment. At the Effective Time, after giving effect to the amounts expected to be
funded under the Financing Commitment and assuming the satisfaction of the Closing condition set
forth in Section&nbsp;7.2(a) and compliance by the Company with its obligations under Section&nbsp;6.8,
Parent will have the funds necessary to pay the Merger Consideration and all fees and expenses
incurred by Parent and Merger Sub in connection with this Agreement and the Transaction.
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.7 <U>Information in the Proxy Statement and Schedule&nbsp;13E-3</U>. None of the information
supplied by Parent or Merger Sub expressly for inclusion or incorporation by reference in the Proxy
Statement (or any amendment thereof or supplement thereto) will, in the case of the Schedule&nbsp;13E-3,
as of the date thereof, the date of any amendment thereto and as of the time of the Company
Stockholders&#146; Meeting, and, in the case of the Proxy Statement, as of the time the Proxy Statement
(or any amendment thereof or supplement thereto) is first mailed to the Company&#146;s stockholders and
as of the time of the Company Stockholders&#146; Meeting, not contain any untrue statement of a material
fact or omit to state any material fact required to be stated therein or necessary in order to make
the statements made therein, in light of the circumstances under which they are made, not
misleading. Notwithstanding the foregoing, neither Parent nor Merger Sub make any representation or
warranty with respect to any statement made or incorporated by reference in the Proxy Statement or
Schedule&nbsp;13E-3 based on information supplied by the Company for inclusion or incorporation by
reference therein.
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->33<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV align="justify" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.8 <U>Fund Guarantee</U>. Concurrently with the execution of this Agreement, Parent has
delivered to the Company a duly executed Fund Guarantee in the form attached as <U>Exhibit&nbsp;C</U>
hereto. The Fund Guarantee is in full force and effect and is the valid, binding and enforceable
obligation of the Guarantors, and no event has occurred, which, with or without notice, lapse of
time or both, would constitute a default on the part of the Guarantors under such Fund Guarantee.
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.9 <U>Brokers</U>. No broker, finder or investment banker is entitled to any brokerage,
finders&#146; or other fee or commission payable by the Company in connection with the Merger based upon
arrangements made by and on behalf of Parent or Merger Sub or any of their subsidiaries.
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.10 <U>Investigation and Agreement by Parent and Merger Sub; No Other Representations or
Warranties</U>.
</DIV>



<DIV align="justify" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) Parent and Merger Sub acknowledge and agree that they have made their own inquiry
and investigation into, and, based thereon, have formed an independent judgment concerning
the Company and the Company Subsidiaries and their businesses and operations. Parent and
Merger Sub acknowledge and agree that, except as expressly set forth in this Agreement,
neither the Company or any of the Company Subsidiaries, nor any of their respective
Representatives, will have or be subject to any liability or indemnification obligation to
Parent, Merger Sub, any of their respective Representatives, or any other person resulting
from the delivery, dissemination or any other distribution to Parent, Merger Sub, or any
other person, or the use by Parent, Merger Sub, or any other person, of any such information
provided or made available to them by or on behalf of the Company, its Subsidiaries, or
their respective Representatives, including any information, documents, projections,
forecasts, estimates, or other forward-looking information, business plans, or other
material provided for or made available to Parent, Merger Sub or any of their
Representatives in any physical or on-line data rooms, confidential information memoranda or
in-person presentations or teleconferences in connection with the transactions contemplated
by this Agreement.
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) Each of Parent and Merger Sub acknowledges and agrees that, except for the
representations and warranties made by the Company that are expressly set forth in this
Agreement, the Company does not make, and has not made, and neither Parent nor Merger Sub
has relied upon, any representation, warranty or statements by any person on behalf of the
Company or any of the Company Subsidiaries in connection with the Merger and the
transactions contemplated hereby. Except as expressly set forth herein, no person has been
authorized by the Company to make any representation or warranty relating to the Company or any of its Subsidiaries or their respective businesses, or
otherwise in connection with the Merger and the transactions contemplated hereby, and, if
made, such representation or warranty may not be relied upon as having been authorized by
the Company. Without limiting the generality of the foregoing, Parent and Merger Sub
acknowledge and agree that, except as provided in this Agreement, neither the Company or any
of its Subsidiaries, nor any of their respective Representatives nor any holder of Company
Common Stock, makes or has made any representation or
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->34<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="justify" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;warranty to Parent and Merger Sub or any of their Representatives or affiliates with respect to:
</DIV>



<DIV align="justify" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) any forward-looking information such as projections, forecasts, estimates, plans or
budgets of future revenues, expenses or expenditures, future results of operations (or any
component thereof), future cash flows (or any component thereof) or future financial
condition (or any component thereof) of the Company or any of the Company Subsidiaries or
the future business, operations or affairs of the Company or any of the Company Subsidiaries
heretofore or hereafter delivered to or made available to Parent and Merger Sub or their
respective Representatives or Affiliates, except to the extent of and as expressly covered
by a representation and warranty made by the Company and contained in this Agreement; or
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii) any other information, statement or documents heretofore or hereafter delivered to
or made available to Parent and Merger Sub or their respective Representatives or
Affiliates, including the information in the on-line data room maintained by the Company
through Deal Interactive, with respect to the Company or any of the Company Subsidiaries or
the business, operations or affairs of the Company or any of the Company Subsidiaries,
except to the extent and as expressly covered by a representation and warranty made by the
Company and contained in this Agreement.
</DIV>

<DIV align="justify" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.11 <U>Ownership of Company Common Stock</U>. As of the date of this Agreement, neither
Parent nor Merger Sub owns any shares of Company Common Stock.
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.12 <U>Financial Condition of Merger Sub</U>. As of the Closing Date, Merger Sub shall not
have incurred any Indebtedness that would prevent the Surviving Corporation from complying with the
terms of Section&nbsp;4.1 (&#147;Merger and Consolidation&#148;) of the Note Indenture.
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt">ARTICLE V
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><U>Conduct of Business Pending the Merger</U>
</DIV>

<DIV align="justify" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.1 <U>Conduct of Business by the Company</U>. During the period from the date of this
Agreement to the Effective Time, except as contemplated by this Agreement, as set forth in Section
5.1 of the Company Disclosure Schedule or with the prior consent of Parent (which consent shall not be unreasonably withheld,
conditioned or delayed), the Company shall, and shall cause each of the Company Subsidiaries to,
carry on their respective businesses in the usual, regular and ordinary course, consistent with
past practice, and, to the extent substantially consistent therewith, use their commercially
reasonable efforts to preserve intact their present business organizations, keep available the
services of their present officers and employees and preserve their relationships and goodwill with
Governmental Entities and significant customers. Without limiting the generality of the foregoing,
neither the Company nor any of the Company Subsidiaries will, directly or indirectly (except as
expressly permitted by this Agreement, as set forth in Section&nbsp;5.1 of the Company Disclosure
Schedule or to the extent that Parent shall otherwise consent in writing (it being understood that
Parent shall respond within five (5)&nbsp;Business Days to the Company&#146;s communications soliciting such
consent from Parent)):
</DIV>



<P align="center" style="font-size: 10pt"><!-- Folio -->35<!-- /Folio -->
</DIV>



<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="justify" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) (i)&nbsp;split, combine, subdivide or reclassify any shares of capital stock of
the Company or (ii)&nbsp;declare, set aside or pay any dividend or other distribution (whether in
cash, stock, or property or any combination thereof) in respect of any shares of capital
stock of the Company, or make any other distribution in respect of shares of capital stock,
except for dividends or distributions declared, set aside or paid by any Company Subsidiary
to the Company or to any Company Subsidiary that is, directly or indirectly, wholly owned by
the Company;
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) authorize for issuance, issue, deliver, sell, redeem or repurchase or agree or
commit to issue, deliver, sell, redeem or repurchase (whether through the issuance or
granting of, or accelerating the exercisability of, options, warrants, commitments,
subscriptions, rights to purchase or otherwise), other than the repurchase of Company
Restricted Shares on termination of employment, any stock of any class or any other
securities or equity equivalents (including stock appreciation rights) other than the
issuance of shares of Company Common Stock (i)&nbsp;upon the exercise of Company Stock Options
and Company Warrants outstanding on the date of this Agreement in accordance with their
present terms and the provisions hereof and (ii)&nbsp;in accordance with commitments to issue
such shares under any long-term incentive plan awards outstanding on the date of this
Agreement in accordance with their present terms and the provisions hereof;
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) except as set forth on Schedule&nbsp;5.1(c), acquire, sell, pledge, grant a security
interest in, license, lease, transfer or dispose of any assets outside the ordinary course
of business with a value or purchase price in excess of (i) $500,000 per individual
incurrence or (ii) $2,000,000 in the aggregate (whether by asset acquisition, stock
acquisition or otherwise);
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) other than in the ordinary course of business consistent with past practices, incur
any amount of Indebtedness for borrowed money, guarantee any Indebtedness of a third party,
issue or sell debt securities, make any loans, advances or capital contributions (except as
permitted by paragraph (m)&nbsp;below), or, except for Permitted Liens, mortgage, pledge or
otherwise encumber any material assets, or create or suffer any lien thereupon, in excess of
(i) $1,000,000 per individual incurrence or (ii) $2,500,000 in the aggregate;
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e) amend or otherwise modify the terms of the Credit Facilities, except in a manner
favorable to the Company;
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f) commence, settle or compromise any pending or threatened suit, action or claim
which (i)&nbsp;is material to the business of the Company and the Company Subsidiaries, taken as
a whole, or that otherwise involves the payment by the Company of an amount in excess of
$500,000, in the aggregate, for all such suits, actions or claims, (ii)&nbsp;would involve
restrictions on the business activities of the Company or any Company Subsidiary or (iii)
would involve the issuance of Company securities;
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(g) except pursuant to any mandatory payments (including each sweep arrangement) under
any Credit Facilities in existence on the date hereof entered into in compliance with the
terms hereof, pay, discharge or satisfy outside the ordinary course
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->36<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="justify" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">of business any claims, pending or threatened litigations, proceedings, liabilities or
obligations (absolute, accrued, asserted or unasserted, contingent or otherwise) in excess
of $500,000 in the aggregate with respect to other matters;
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(h) change any of the accounting principles or practices used by it except as required
by GAAP;
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) increase the compensation or benefits of any director or &#147;named executive officer&#148;
of the Company or increase the compensation or benefits of any director or officer of any of
the Company Subsidiaries, except in the ordinary course of business consistent with past
practices;
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(j) grant to any director or &#147;named executive officer&#148; of the Company the right to
receive any new severance, change of control or termination pay or termination benefits, or
grant any increase in any existing severance, change of control or termination pay or
termination benefits to any director or &#147;named executive officer&#148; of the Company;
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(k) grant to any director or officer of any of the Company Subsidiaries the right to
receive any new severance, change of control or termination pay or termination benefits, or
grant any increase in any existing severance, change of control or termination pay or
termination benefits, except for (x)&nbsp;any grants of new severance or termination pay or
termination benefits, or (y)&nbsp;any grants of increases in any existing severance or
termination pay or termination benefits, in each case, in the ordinary course consistent
with past practices;
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(l) except to the extent required to comply with its obligations hereunder or with
applicable Law, amend the certificate of incorporation or bylaws of the Company;
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(m) adopt a plan or agreement of complete or partial liquidation or resolutions
providing for or authorizing such a liquidation or a dissolution, merger, consolidation,
restructuring, recapitalization or reorganization of the Company or any Company Subsidiary
other than the complete or partial liquidation or dissolution of any Company Subsidiary that
is not a wholly owned subsidiary;
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(n) make or change any material Tax election, forego any material Tax refund or change
any material Tax accounting method, amend any material Tax Return, or enter into any
material Tax allocation agreement, material Tax sharing agreement, material Tax indemnity
agreement or closing or settlement agreement relating to any material Tax, or agree to an
extension or waiver of the statute of limitations with respect to the assessment or
determination of material Taxes;
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(o) make any loans, advances or capital contributions to or investments in any Person
(other than the Company or any direct or indirect wholly-owned Subsidiary of the Company) in
excess of $500,000 in the aggregate;
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(p) forgive any loans to employees, officers, directors or any of their Affiliates;
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->37<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="justify" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(q) make or authorize any capital expenditures in excess of $2,000,000 in the
aggregate;
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(r) enter into any new line of business or exit any existing line of business that is
material to the Company and the Company Subsidiaries, taken as a whole;
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(s) convene any regular or special meeting (or adjournment thereof) of the stockholders
of the Company other than the Company Stockholders&#146; Meeting;
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(t) modify, amend or terminate, or waive, release or assign any material rights or
claims with respect to any confidentiality or non-competition agreement to which the Company
is a party;
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(u) enter into any agreement to purchase or sell any interest in real property, grant
any security interest in real property, enter into any material lease, sublease, license or
other occupancy agreement with respect to any real property or materially alter, amend,
modify or terminate any of the terms of any Leases;
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(v) (i)&nbsp;make any material acquisition, by purchase or other acquisition of stock or
other equity interests, by merger, consolidation or other business combination (including by
formation of a material joint venture) outside of the ordinary course of business with a
value in excess of $3,000,000; or
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(w) authorize, commit or enter into an agreement to take any of the foregoing actions.
</DIV>
<DIV align="justify" style="font-size: 10pt; margin-top: 6pt">Notwithstanding the foregoing, none of the restrictions contained in this Section&nbsp;5.1 shall be
deemed to limit the ability of the Company or any Company Subsidiary to undertake or otherwise
conduct any activity if any such restriction would violate Section&nbsp;7.09(a) of the Revolving Credit
Agreement.
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt">ARTICLE VI
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><U>Covenants</U>
</DIV>

<DIV align="justify" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.1 <U>Proxy Statement and Schedule&nbsp;13E-3; Stockholders Meeting.</U>
</DIV>



<DIV align="justify" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) As soon as practicable (and in any event within twenty (20)&nbsp;Business Days)
following the date of this Agreement, the Company shall prepare and file with the SEC,
subject to the prior review and comment by Parent, a proxy statement in preliminary form
relating to the Company Stockholders&#146; Meeting (the &#147;<U>Proxy Statement</U>&#148;) and a Rule
13e-3 Transaction Statement on Schedule&nbsp;13E-3 (together with any amendments thereof or
supplements thereto, the &#147;<U>Schedule&nbsp;13E-3</U>&#148;), and the Company shall use its reasonable
best efforts to respond (with the assistance of Parent) as promptly as practicable to any
comments of the SEC with respect thereto. Parent and Merger Sub shall cooperate with the
Company in connection with the preparation of the
Proxy Statement and Schedule&nbsp;13E-3, including, but not limited to, furnishing to the
Company any and all information regarding Parent and Merger Sub and their respective
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->38<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="justify" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">Affiliates as may be required to be disclosed therein as promptly as possible after the date
hereof. The parties shall notify each other promptly of the receipt of any comments from
the SEC or its staff and of any request by the SEC or its staff for amendments or
supplements to the Proxy Statement and the Schedule&nbsp;13E-3 or for additional information and
shall supply each other with copies of all correspondence between such or any of its
representatives, on the one hand, and the SEC or its staff, on the other hand, with respect
to the Proxy Statement, the Merger or Schedule&nbsp;13E-3.
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) If, at any time prior to the Company Stockholder Approval, any event occurs with
respect to the Company, any Company Subsidiary, Parent or Merger Sub, or any change occurs
with respect to other information to be included in the Proxy Statement, which is required
to be described in an amendment of, or a supplement to, the Proxy Statement, the Company or
Parent, as the case may be, shall promptly notify the other party of such event and the
Company shall promptly file, with Parent&#146;s cooperation, any necessary amendment or
supplement to the Proxy Statement.
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) The Company shall, as soon as practicable following the date of this Agreement, but
subject to the penultimate sentence of this Section&nbsp;6.1(c), duly call, give notice of,
convene and hold a meeting of the holders of the Company Common Stock (the &#147;<U>Company
Stockholders&#146; Meeting</U>&#148;) for the purpose of seeking the Company Stockholder Approval;
<U>provided</U>, <U>however</U>, for the avoidance of doubt, the Company may postpone or
adjourn the Company Stockholders&#146; Meeting with the consent of Parent, (i)&nbsp;to the extent
necessary to ensure that any required supplement or amendment to the Proxy Statement is
provided to the Company&#146;s stockholders within a reasonable period of time in advance of the
Company Stockholders&#146; Meeting or (ii)&nbsp;if as of the time for which the Company Stockholders&#146;
Meeting is originally scheduled (as set forth in the Proxy Statement) there are insufficient
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of Company Common Stock represented (either in person or by proxy) to constitute a
quorum necessary to conduct the business of the Company Stockholders&#146; Meeting. The Company
shall use its reasonable best efforts to cause the Proxy Statement to be mailed to such
holders as promptly as practicable after the date of this Agreement; <U>provided</U> that
the Company shall not be required to mail the Proxy Statement prior to the No-Shop Period
Start Date or, in the event the Company is continuing to engage in activities described in
Section&nbsp;6.4(a)(ii) with respect to a Takeover Proposal submitted by an Excluded Party prior
to the No-Shop Period Start Date, the Cut-off Date. Subject to Section&nbsp;6.4, the Proxy
Statement shall include the Company Recommendation and the Company Board shall take all
reasonable lawful action to solicit the Company Stockholder Approval.
</DIV>

<DIV align="justify" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.2 <U>Other Filings</U>.
</DIV>



<DIV align="justify" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) Subject to the terms and conditions of this Agreement, as soon as practicable
following the date of this Agreement, the Company, Parent and Merger Sub each shall properly
prepare and file any other filings required under the Exchange Act or
any other federal, state or other Law relating to the Merger (collectively, the
&#147;<U>Other Filings</U>&#148;). Each of the Company, Parent and Merger Sub shall promptly notify
the other of the receipt of any comments on, or any request for amendments or supplements
to, any of the Other Filings by the SEC or any other Governmental Entity or official, and
each of
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->39<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="justify" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">the Company, Parent and Merger Sub shall supply the other with copies of all
correspondence between it and each of its Subsidiaries and representatives, on the one hand,
and the SEC or the members of its staff or any other appropriate governmental official, on
the other hand, with respect to any of the Other Filings. The Company, Parent and Merger
Sub each shall promptly obtain and furnish the other (a)&nbsp;the information which may be
reasonably required in order to make such Other Filings and (b)&nbsp;any additional information
which may be requested by a Governmental Entity and which the parties reasonably deem
appropriate.
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) Without limitation of Section&nbsp;6.2(a), Parent and the Company shall (i)&nbsp;not later
than fifteen (15)&nbsp;Business Days after the date hereof, make the filings required of such
party under the HSR Act with respect to the Transaction, (ii)&nbsp;comply at the earliest
practicable date with any request under the HSR Act for additional information, documents or
other materials received by such party from the Federal Trade Commission or the Department
of Justice or any other Governmental Entity in respect of such filings or the Transaction
and (iii)&nbsp;cooperate with the other in connection with making any filing under the HSR Act or
any other Law in connection with any filings, conferences or other submissions related to
resolving any investigation or other inquiry by any such Governmental Entity under the HSR
Act or any other Law with respect to the Transaction. Each of Parent and the Company shall,
and Parent shall cause Merger Sub and the Company shall cause each Company Subsidiary to,
use its reasonable best efforts to obtain the termination of all waiting periods under the
HSR Act and not to extend any waiting period under the HSR Act. Prior to the termination of
this Agreement, each party hereto shall prosecute, cooperate in and defend against any
litigation instituted by the Federal Trade Commission or the Department of Justice or any
other Governmental Entity that seeks to restrain or prohibit the consummation of the
Transaction.
</DIV>

<DIV align="justify" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.3 <U>Reasonable Best Efforts</U>. Subject to the terms and conditions herein provided, but
subject to the obligation to act in good faith, and subject at all times to the Company&#146;s and its
directors&#146; right and duty to act in a manner consistent with their fiduciary duties, each of the
parties hereto agrees to use its reasonable best efforts to take, or cause to be taken, all actions
and to do, or cause to be done, all things necessary, proper or advisable to consummate and make
effective as promptly as practicable the Merger and to cooperate with each other in connection with
the foregoing, including the taking of such actions as are reasonably necessary to obtain any
necessary consents, approvals, orders, exemptions and authorizations by or from any Governmental
Entities and any private third party listed in Section&nbsp;6.3 of the Company Disclosure Schedule, to
defend all lawsuits or other legal proceedings challenging this Agreement or the consummation of
the Merger, to effect all necessary registrations and Other Filings and submissions of information
requested by a Governmental Entity, and to use its reasonable best efforts to cause to be lifted or
rescinded any injunction or restraining order or other order adversely affecting the ability of the
parties to consummate the Merger.
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.4 <U>Solicitation; Change in Recommendation</U>.
</DIV>



<DIV align="justify" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) Notwithstanding any other provision of this Agreement to the contrary, during the
period beginning on the date of this Agreement and continuing until 12:01&nbsp;p.m. (New York
City time) on the fortieth (40<SUP style="FONT-size: 85%; vertical-align: text-top">th</SUP>) day following the date of this
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->40<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="justify" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">Agreement (the &#147;<U>No-Shop Period Start Date</U>&#148;), the Company and the Company Subsidiaries and their
respective officers, directors, employees, consultants, agents, advisors, Affiliates and
other representatives (collectively, &#147;<U>Representatives</U>&#148;) shall have the right to: (i)
initiate, solicit and encourage Takeover Proposals (or inquiries, proposals or offers or
other efforts or attempts that are reasonably expected to lead to a Takeover Proposal),
including by way of providing access to non-public information pursuant to (but only
pursuant to) one or more Acceptable Confidentiality Agreements; <U>provided</U> that the
Company shall promptly (and, in any event within twenty-four (24)&nbsp;hours) provide to Parent
any material non-public information concerning the Company or the Company Subsidiaries that
is provided to any Person given such access which was not previously provided to Parent or
its Representatives; and (ii)&nbsp;enter into, engage in, and maintain discussions or
negotiations with respect to Takeover Proposals or otherwise cooperate with or assist or
participate in, or facilitate any such inquiries, proposals, discussions or negotiations.
</DIV>



<DIV align="justify" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) Except as permitted by this Section&nbsp;6.4, the Company shall and shall cause each of
the Company Subsidiaries and their respective Representatives to, on the No-Shop Period
Start Date, (i)&nbsp;immediately cease and cause to be terminated any and all activities,
solicitations, encouragement, discussions or negotiations with any Persons conducted prior
to the execution of this Agreement by the Company, the Company Subsidiaries or any of their
Representatives with respect to any Takeover Proposal, and (ii)&nbsp;request any such Person to
promptly return or destroy all confidential information concerning the Company and the
Company&#146;s Subsidiaries. Except as permitted by this Section&nbsp;6.4, from the No-Shop Period
Start Date until the Effective Time or, if earlier, the termination of this Agreement in
accordance with Article&nbsp;VIII, the Company shall not, and shall cause each of the Company
Subsidiaries and their respective Representatives not to, directly or indirectly, (A)
solicit, initiate, or knowingly facilitate, cooperate with or encourage (including by way of
furnishing non-public information or data) any inquiries regarding, or the making of any
proposal or offer that constitutes, or could reasonably be expected to lead to, a Takeover
Proposal, (B)&nbsp;engage in, continue or otherwise knowingly participate in any discussions or
negotiations regarding, or furnish to any other party information or data in connection with
or for the purpose of encouraging or facilitating, a Takeover Proposal, (C)&nbsp;enter into any
letter of intent, agreement, contract or agreement in principle with respect to a Takeover
Proposal or (D)&nbsp;enter into any agreement, contract or agreement in principle requiring the
Company to abandon, terminate or breach its obligations hereunder or fail to consummate the
Transaction. No later than two (2)&nbsp;Business Days after the No-Shop Period Start Date, the
Company shall notify Parent in writing of the identity of each party (including any Excluded
Party) that submitted a Takeover Proposal prior to the No-Shop Period Start Date and shall
promptly provide to Parent a written summary of the material terms of any such Takeover
Proposal (including the identity of the Person making the Takeover Proposal). The parties
agree that, notwithstanding the commencement of the obligations of the Company under this Section
6.4(b) on the No-Shop Period Start Date, the Company may continue to engage in the
activities described in Section&nbsp;6.4(a)(ii) with respect to a Takeover Proposal submitted by
an Excluded Party prior to the No-Shop Period Start Date until 12:01&nbsp;p.m. (New York City
time) on the 20<SUP style="FONT-size: 85%; vertical-align: text-top">th</SUP> day following the No-Shop Period Start Date (the &#147;<U>Cut-</U>
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->41<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="justify" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%"><U>off Date</U>&#148;) including with respect to any amended or revised proposal submitted by such
Excluded Party on or before the Cut-off Date.
</DIV>



<DIV align="justify" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) Notwithstanding anything to the contrary contained in Section&nbsp;6.4(a) or 6.4(b), if
at any time on or after the No-Shop Period Start Date and prior to obtaining the Company
Stockholder Approval, (i)&nbsp;the Company or any of its Representatives is in receipt of a bona
fide written Takeover Proposal from any Person, which Takeover Proposal is made or renewed
on or after the No-Shop Period Start Date and has not been subsequently withdrawn, (ii)&nbsp;the
Company has not breached this Section&nbsp;6.4, (iii)&nbsp;the Company Board determines in good
faith, (a)&nbsp;after consultation with independent financial advisors and outside legal
counsel, that such Takeover Proposal constitutes or would reasonably be expected to lead to
a Superior Proposal, and (b)&nbsp;after consultation with outside legal counsel, that failure to
take the action set forth in clauses (x)&nbsp;or (y)&nbsp;below would reasonably be expected to
result in a breach of the directors&#146; fiduciary duties under applicable Law, then the
Company and its Representatives may (x)&nbsp;furnish, pursuant to an Acceptable Confidentiality
Agreement, information (including non-public information) with respect to the Company and
the Company Subsidiaries to the Person or group of Persons that has made such Takeover
Proposal; <U>provided</U> that the Company shall promptly provide to Parent (and in any
event within twenty-four (24)&nbsp;hours) any nonpublic information concerning the Company or
the Company Subsidiaries that is provided to any Person given such access which was not
previously provided to Parent or its Representatives; and (y)&nbsp;engage in or otherwise
participate in discussions or negotiations with the Person or group of Persons making such
Takeover Proposal; <U>provided</U>, <U>further</U> that the Company shall promptly
provide to Parent (and in any event within twenty-four (24)&nbsp;hours) (i)&nbsp;a copy of any
Takeover Proposal made in writing provided to the Company or any Company Subsidiary, and
the identity of the Person making the Takeover Proposal and (ii)&nbsp;a written summary of the
material terms of any such Takeover Proposal not made in writing. From and after the date
hereof, the Company shall not grant any amendment, release or waiver under any standstill
agreement without the prior written consent of Parent.
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) Following the No-Shop Period Start Date, the Company shall keep Parent reasonably
informed of any material developments, discussions or negotiations regarding any Takeover
Proposal (whether made before or after the No-Shop Period Start Date) on a current basis
(and in any event within twenty-four (24)&nbsp;hours) and shall notify Parent of the status of
such Takeover Proposal. The Company agrees that neither it nor any of the Company
Subsidiaries will enter into any agreement with any Person subsequent to the date hereof
which prohibits the Company from providing any information to Parent in accordance with
this Section&nbsp;6.4.
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e) Except as expressly permitted by this Section&nbsp;6.4(e) or Section&nbsp;6.4(f), the Company
Board shall not (i)(A) fail to recommend to its stockholders that the Company
Stockholder Approval be given (the &#147;<U>Company Recommendation</U>&#148;) or fail to include
the Company Recommendation in the Proxy Statement, (B)&nbsp;change, qualify, withhold, withdraw
or modify, or publicly propose to change, qualify, withhold, withdraw or modify, in a manner
adverse to Parent, the Company Recommendation, (C)&nbsp;take any formal action or make any
recommendation or public statement in connection with a
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->42<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="justify" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">tender offer or exchange offer other than a recommendation against such offer or a temporary &#147;stop, look and listen&#148;
communication by the Company Board pursuant to Rule&nbsp;14d-9(f) of the Exchange Act, (D)&nbsp;adopt,
approve or recommend, or publicly propose to approve or recommend to the stockholders of the
Company a Takeover Proposal or (E)&nbsp;enter into any contract or agreement in principle
requiring the Company to abandon, terminate or breach its obligations hereunder or fail to
consummate the Transaction (actions described in this clause (i)&nbsp;being referred to as a
&#147;<U>Company Adverse Recommendation Change</U>&#148;), (ii)&nbsp;authorize, cause or permit the
Company or any of the Company Subsidiaries to enter into any letter of intent, agreement or
agreement in principle with respect to any Takeover Proposal (other than (x)&nbsp;an Acceptable
Confidentiality Agreement or (y)&nbsp;an agreement to reimburse the reasonable out of pocket
expenses of any Person (not to exceed $1,000,000, in the aggregate for all such Persons)
that submits a Takeover Proposal that the Company Board determines pursuant to this Section
6.4 constitutes or would reasonably be expected to lead to a Superior Proposal or that
submits a Takeover Proposal and thereafter, in response to such Takeover Proposal, Parent
revises any of the material terms of this Agreement, <U>provided</U> that such expense
reimbursement is only payable to such Person in the event the Company does not enter into a
Company Acquisition Agreement with respect to such Superior Proposal due to the fact that
the Company Board determines that pursuant to this Section&nbsp;6.4 the Takeover Proposal
submitted by such Person no longer constitutes a Superior Proposal or Parent revised the
terms of this Agreement and/or the Financing Commitment such that it caused such Superior
Proposal to no longer constitute a Superior Proposal (each, a &#147;<U>Company Acquisition
Agreement</U>&#148;) or (iii)&nbsp;take any action pursuant to Section&nbsp;8.1(e). Notwithstanding
anything to the contrary herein, prior to the time the Company Stockholder Approval is
obtained, but not after, if the Company is in receipt of a bona fide written Takeover
Proposal that the Company Board determines in good faith, after consultation with
independent financial advisors and outside legal counsel, constitutes a Superior Proposal,
after (in each case) giving effect to all of the adjustments to the terms of this Agreement
which may be offered by Parent (including pursuant to clause (iii)&nbsp;below) and after
consultation with outside legal counsel, the Company Board determines in good faith, that
the failure to take the action set forth in clauses (x)&nbsp;or (y)&nbsp;below would reasonably be
expected to result in a breach of its fiduciary duties under applicable Law, then the
Company Board may (x)&nbsp;make a Company Adverse Recommendation Change or (y)&nbsp;terminate this
Agreement and enter into a Company Acquisition Agreement with respect to such Superior
Proposal, <U>provided</U>, <U>however</U>, that the Company shall not terminate this
Agreement pursuant to the foregoing clause (y), and any purported termination pursuant to
the foregoing clause (y)&nbsp;shall be void and of no force or effect, unless in advance of or
concurrently with such termination the Company pays the Termination Fee and the Parent&#146;s
Expenses and otherwise complies with the provisions of Section&nbsp;8.1(e) and Section&nbsp;8.3; and
<U>provided</U> <U>further</U> that the Company Board may not withdraw, modify or amend
the Company Recommendation in a manner adverse to
Parent pursuant to the foregoing clause (x)&nbsp;or terminate this Agreement pursuant to the
foregoing clause (y)&nbsp;unless (A)&nbsp;the Company shall not have breached this Section&nbsp;6.4 and
(B):
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) such Superior Proposal has been made and has not been withdrawn and continues to be
a Superior Proposal;
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->43<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="justify" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii) the Company has given Parent at least two (2)&nbsp;Business Days&#146; prior written notice
of its intention to take such action (which notice shall specify the material terms and
conditions of any such Superior Proposal (including the identity of the party making such
Superior Proposal)) and has contemporaneously provided a copy of each of the relevant
proposed transaction agreements to be entered into by the Company with the party making such
Superior Proposal;
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii) prior to effecting such Company Adverse Recommendation Change or terminating this
Agreement to enter into a Company Acquisition Agreement with respect to such Superior
Proposal, the Company has negotiated, and has caused its Representatives to negotiate, in
good faith with Parent during such notice period to the extent Parent wishes to negotiate,
to enable Parent to revise the terms of this Agreement and/or the Financing Commitment such
that it would cause such Superior Proposal to no longer constitute a Superior Proposal; and
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iv) in the event of any material change to the terms of such Superior Proposal, the
Company shall, in each case, be required to deliver to Parent a new written notice (which
notice shall specify the change in the material terms and conditions of any such Superior
Proposal) and contemporaneously provide a copy of each of the relevant proposed transaction
agreements to be entered into by the Company with the party making such Superior Proposal,
the notice period shall have recommenced and the Company shall be required to comply with
its obligations under this Section&nbsp;6.4 with respect to such new written notice;
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%"><U>provided</U>, <U>however</U>, that if (A)&nbsp;the Company receives any Takeover Proposal
pursuant to which the stockholders of the Company would be entitled to receive 110% or more
of the Per Share Merger Consideration, and (B)&nbsp;the Board determines that such Takeover
Proposal constitutes a Superior Proposal, then the rights and obligations of the parties
pursuant to the immediately preceding Section&nbsp;6.4(e)(y)(B)(iii) and Section&nbsp;6.4(e)(y)(B)(iv)
shall not apply; provided, further, however, for purposes of determining whether or not a
Takeover Proposal shall have satisfied the provisions of clause (A)&nbsp;above, the Board must
either compare (1)&nbsp;the initial Takeover Proposal to the Per Share Merger Consideration
reflected in this Agreement, or (2)&nbsp;the then current Takeover Proposal to the then current
Per Share Merger Consideration proposed by the Parent, as applicable. For the avoidance of
doubt, nothing in this Section&nbsp;6.4(e) shall prevent or preclude Parent from proposing to
revise the terms of this Agreement or taking any actions relating thereto.
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f) Notwithstanding anything to the contrary herein, prior to the time the Company
Stockholder Approval is obtained, but not after, the Company may change, qualify, withhold, withdraw or modify, or publicly propose to change, qualify,
withhold, withdraw or modify, in a manner adverse to Parent, the Company Recommendation
(&#147;<U>Change of Recommendation</U>&#148;) in response to an Intervening Event if the Company
Board has determined in good faith, after consultation with outside legal counsel, that
failure to take such action would reasonably be expected to result in a breach of the
directors&#146; fiduciary duties under applicable Law; <U>provided</U>, <U>however</U>, that
prior to taking such action, (x)&nbsp;the Company Board has given Parent at least two (2)
Business Days&#146;
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->44<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="justify" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">prior written notice of its intention to take such action, (y)&nbsp;the Company
has negotiated, and has caused its Representatives to negotiate, in good faith with Parent
during such notice period to the extent Parent wishes to negotiate, to enable Parent to
revise the terms of this Agreement or the Financing Commitment in such a manner that would
obviate the need for taking such action and (z)&nbsp;following the end of such notice period,
the Company Board shall have considered in good faith any changes to this Agreement and the
Financing Commitment proposed in writing by Parent, and shall have determined in good
faith, after consultation with outside legal counsel, that failure to effect a Change of
Recommendation would reasonably be expected to result in a breach of the directors&#146;
fiduciary duties under applicable Law.
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(g) Nothing in this Section&nbsp;6.4 shall prohibit the Company Board from taking and
disclosing to the stockholders of the Company a position contemplated by Rule&nbsp;14e-2(a), Rule
14d-9 or Item 1012(a) of Regulation&nbsp;M-A promulgated under the Exchange Act, if failure to do
so would violate applicable Law; <U>provided</U> that the Company Board shall not recommend
that the Company stockholders tender their shares of Company Common Stock in connection with
a tender or exchange offer (or otherwise approve or recommend any Takeover Proposal) unless
such tender or exchange offer constitutes a Superior Proposal and the applicable
requirements of this Section&nbsp;6.4 shall have been satisfied.
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(h) As used in this Agreement, &#147;<U>Takeover Proposal</U>&#148; shall mean any inquiry,
proposal or offer from any Person (other than Parent and its Subsidiaries) or &#147;group&#148;,
within the meaning of Section 13(d) of the Exchange Act, relating to, in a single
transaction or series of related transactions, any (A)&nbsp;acquisition of assets of the Company
and its Subsidiaries equal to more than 20% of the Company&#146;s consolidated assets or to which
more than 20% of the Company&#146;s revenues or earnings on a consolidated basis are
attributable, (B)&nbsp;acquisition of more than 20% of the outstanding Company Common Stock, (C)
tender offer or exchange offer that if consummated would result in any Person beneficially
owning more than 20% of the outstanding Company Common Stock, (D)&nbsp;merger, consolidation,
share exchange, business combination, recapitalization, liquidation, dissolution or similar
transaction involving the Company or (E)&nbsp;combination of the foregoing types of transactions
if the sum of the percentage of consolidated assets, consolidated revenues or earnings and
Company Common Stock involved is more than 20%; in each case, other than the Transaction.
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) As used in this Agreement, &#147;<U>Superior Proposal</U>&#148; shall mean any bona fide
written Takeover Proposal that the Company Board has determined in its good faith judgment
is reasonably likely to be consummated in accordance with its terms, after taking into
account all legal, regulatory, timing, breakup fee and expense reimbursement
provisions of the proposal, the Person making the proposal and the likelihood of
consummation of such transaction on the terms set forth therein (as compared to the terms
herein), and that if consummated, would result in a transaction more favorable to the
Company&#146;s stockholders from a financial point of view than the transaction contemplated by
this Agreement (including any changes to the terms of this Agreement proposed by Parent in
response to such proposal or otherwise), <U>provided</U> that for purposes
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->45<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="justify" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">of the definition of &#147;Superior Proposal&#148;, the references to &#147;20%&#148; in the definition of Takeover
Proposal shall be deemed to be references to &#147;50%.&#148;
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(j) As used in this Agreement, &#147;<U>Excluded Party</U>&#148; shall mean any Person (other
than Parent and its Subsidiaries) or &#147;group&#148;, within the meaning of Section 13(d) of the
Exchange Act (so long as such Person and the other members of such group, if any, who were
members of such group immediately prior to the No-Shop Period Start Date constitute at least
50% of the equity financing of such group at all times following the No-Shop Period Start
Date and prior to the termination of this Agreement), from whom the Company has received a
Takeover Proposal after the execution of this Agreement and prior to the No-Shop Period
Start Date that, on or before the No-Shop Period Start Date, the Company Board determines in
good faith, after consultation with independent financial advisors and outside legal
counsel, constitutes or would reasonably be expected to result in a Superior Proposal, and
which Takeover Proposal has not been rejected or withdrawn as of the No-Shop Period Start
Date. Further, on the No-Shop Period Start Date, in addition to the information required to
be provided pursuant to this Section&nbsp;6.4, the Company shall identify for Parent which
Persons submitting Takeover Proposals have been determined by the Company Board to be an
Excluded Party and a summary of the reasons for such determination. Notwithstanding
anything contained in this Section&nbsp;6.4 to the contrary, any Excluded Party shall cease to be
an Excluded Party for all purposes under this Agreement upon the earlier of (x)&nbsp;twenty (20)
days after the No-Shop Period Start Date and (y)&nbsp;immediately at such time as such Takeover
Proposal made by such party is withdrawn, terminated, expires or no longer constitutes or
would reasonably be expected to result in a Superior Proposal; <U>provided</U>,
<U>however</U>, that a material change in or adjustment of a Takeover Proposal shall not be
considered a withdrawal or termination for the purposes of this Section&nbsp;6.4.
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(k) For purposes of this Section&nbsp;6.4, to the extent permitted by applicable Law, the
Company Board may act through the Special Committee, if the Special Committee is still in
existence.
</DIV>

<DIV align="justify" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.5 <U>Officers&#146; and Directors&#146; Indemnification</U>.
</DIV>



<DIV align="justify" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) In the event of any threatened or actual claim, action, suit, demand proceeding or
investigation, whether civil, criminal or administrative, including any such claim, action,
suit, proceeding or investigation in which any Person who is now, or has been at any time
prior to the date hereof, or who becomes prior to the Effective Time, a director or officer
of the Company or any of the Company Subsidiaries (each, together with such Person&#146;s heirs,
executors and administrators, an &#147;<U>Indemnified Party</U>&#148; and
collectively, the &#147;<U>Indemnified Parties&#148;</U>) is, or is threatened to be, made a
party based in whole or in part on, or arising in whole or in part out of, or pertaining to
(i)&nbsp;the fact that he or she is or was a director or officer of the Company or any of the
Company Subsidiaries, or is or was serving at the request of the Company or any of the
Company Subsidiaries as a director, officer, employee, fiduciary or agent of another
corporation, partnership, joint venture, trust or other enterprise, or (ii)&nbsp;the negotiation,
execution or performance of this Agreement, any agreement or document contemplated hereby or
delivered in connection herewith, or any of the transactions contemplated hereby or
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->46<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="justify" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">thereby, whether in any case asserted or arising at or before or after the Effective Time, the
parties hereto agree to cooperate and use their reasonable best efforts to defend against
and respond thereto. It is understood and agreed that the Company shall indemnify and hold
harmless and, from and after the Effective Time, the Surviving Corporation and Parent,
jointly and severally, shall indemnify and hold harmless, as and to the fullest extent
permitted by applicable Law, each Indemnified Party against any and all losses, claims,
damages, liabilities, costs, reasonable and documented expenses (including reasonable
attorneys&#146; fees and expenses), judgments, fines and amounts paid in settlement in connection
with any such threatened or actual claim, action, suit, demand, proceeding, inquiry or
investigation, and, in the event of any such threatened or actual claim, action, suit,
proceeding, inquiry or investigation (whether asserted or arising at or before or after the
Effective Time), (A)&nbsp;the Company and, after the Effective Time, the Surviving Corporation
and Parent shall promptly pay the reasonable and documented expenses in advance of the final
disposition of any such threatened or actual claim, action, suit, demand, proceeding,
inquiry or investigation to each Indemnified Party upon receipt of an undertaking by or on
behalf of such Indemnified Party if required by Law to repay such amount if it shall
ultimately be determined that he is not entitled to be indemnified therefor, (B)&nbsp;the
Indemnified Parties may retain one counsel satisfactory to them, and the Company and, after
the Effective Time, the Surviving Corporation and Parent shall pay all reasonable fees and
expenses of such counsel for the Indemnified Parties within twenty (20)&nbsp;days after
statements therefor are received, and (C)&nbsp;the Company and, after the Effective Time, the
Surviving Corporation and Parent will use their respective reasonable best efforts to assist
in the vigorous defense of any such matter; <U>provided</U>, <U>however</U>, that none of
the Company, the Surviving Corporation or Parent shall be liable for any settlement effected
without its prior written consent (which consent shall not be unreasonably withheld,
conditioned or delayed); and <U>provided</U> <U>further</U> that the Company, the
Surviving Corporation and Parent shall have no obligation hereunder to any Indemnified Party
when and if a court of competent jurisdiction shall ultimately determine, and such
determination shall have become final and non-appealable, that indemnification by such
entities of such Indemnified Party in the manner contemplated hereby is prohibited by
applicable Law. Any Indemnified Party wishing to claim indemnification under this Section
6.5, upon learning of any such threatened or actual claim, action, suit, demand, proceeding
or investigation, shall promptly notify the Company and, after the Effective Time, the
Surviving Corporation and Parent thereof; <U>provided</U> that the failure to so notify
shall not affect the obligations of the Company and the Surviving Corporation and Parent
except to the extent, if any, such failure to promptly notify materially prejudices such
party.
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) Parent and Merger Sub each agree that all rights to indemnification and advancement
of expenses existing in favor of, and all limitations on the personal liability of, each
Indemnified Party provided for in Section&nbsp;6.5(a) above or in the respective certificates of
incorporation or bylaws (or other applicable organizational documents) of the Company and
the Company Subsidiaries or otherwise in effect as of the date hereof (including through any
agreement or arrangement between the Company or any Company Subsidiary, on the one hand, and
any director, officer, employee or agent of the Company or any Company Subsidiary, on the
other hand) shall survive the Merger and continue in full force and effect for a period of
six (6)&nbsp;years from the Effective Time and,
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->47<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="justify" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">at the Effective Time, shall become the joint and
several obligations of the Surviving Corporation and any applicable Company Subsidiary;
<U>provided</U>, <U>however</U>, that all rights to indemnification, advancement of
expenses and limitations on personal liability in respect of any claims (each, a
&#147;<U>Claim</U>&#148;) asserted or made within such period shall continue until the final
disposition of such Claim. From and after the Effective Time, the Surviving Corporation and
each Company Subsidiary also agree to jointly and severally indemnify and hold harmless the
present and former officers and directors of the Company and the Company Subsidiaries in
respect of acts or omissions occurring prior to the Effective Time to the extent provided in
any written indemnification agreements between the Company and/or one or more Company
Subsidiaries and such officers and directors as listed in Section&nbsp;6.5(b) of the Company
Disclosure Schedule.
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) For a period of six (6)&nbsp;years after the Effective Time, the Parent and Surviving
Corporation shall, at no cost to the beneficiaries thereunder, cause to be maintained in
effect the current policies of directors&#146; and officers&#146; and fiduciary liability insurance
maintained by the Company (provided that the Surviving Corporation may substitute therefor
policies with reputable and financially sound carriers of at least the same coverage and
amounts containing terms and conditions which are no less advantageous) with respect to
claims arising from or related to facts or events which occurred at or before the Effective
Time; <U>provided</U>, <U>however</U>, that the Surviving Corporation shall not be
obligated to make annual premium payments for such insurance to the extent such premiums
exceed 200% of the annual premiums paid as of the date hereof by the Company for such
insurance (such 200% amount, the &#147;<U>Base Premium</U>&#148;); <U>provided</U>, <U>further</U>,
if such insurance coverage cannot be obtained at all, or can only be obtained at an annual
premium in excess of the Base Premium, the Surviving Corporation shall maintain the most
advantageous policies of directors&#146; and officers&#146; insurance obtainable for an annual premium
not in excess of the Base Premium; <U>provided</U>, <U>further</U>, if either the Company
or the Surviving Corporation, in each case, in its sole discretion elects, by giving written
notice to the other party at least ten (10)&nbsp;days prior to the Effective Time, then, in lieu
of the foregoing insurance, effective as of the Effective Time, the Company or the Surviving
Corporation, as applicable, shall purchase a directors&#146; and officers&#146; and fiduciary
liability insurance &#147;tail&#148; or &#147;runoff&#148; insurance program for a period of six (6)&nbsp;years after
the Effective Time with respect to wrongful acts and/or omissions committed or allegedly
committed at or prior to the Effective Time (such coverage shall have an aggregate coverage
limit over the term of such policy in an amount not to exceed the annual aggregate coverage
limit under the Company&#146;s existing directors and officers liability policy, and in all other
respects shall be comparable to such existing coverage), <U>provided</U> that the premium
for such &#147;tail&#148; or &#147;runoff&#148; coverage shall not exceed an amount equal to the Base Premium; <U>provided</U> that if the current
policies of directors&#146; and officers&#146; liability insurance maintained by the Company cannot be
maintained for the Base Premium and such &#147;tail&#148; or &#147;runoff&#148; coverage can only be obtained at
an annual premium in excess of the Base Premium, the Surviving Corporation shall maintain
the most advantageous &#147;tail&#148; or &#147;runoff&#148; coverage obtainable for an annual premium not in
excess of the Base Premium.
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) Notwithstanding anything in this Agreement to the contrary, the obligations under
this Section&nbsp;6.5 shall not be terminated or modified in such a manner as
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->48<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="justify" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">to adversely affect any indemnified party to whom this Section&nbsp;6.5 applies without the consent of each such
affected indemnified party. This Section&nbsp;6.5 is intended for the irrevocable benefit of,
and to grant third party beneficiary rights to, the Indemnified Parties and their respective
heirs and shall be binding on all successors of the Surviving Corporation. Each of the
Indemnified Parties and their respective heirs shall be entitled to enforce the provisions
of this Section&nbsp;6.5.
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e) In the event that, following the Effective Time, the Surviving Corporation or
Parent or any of their respective successors or assigns (i)&nbsp;consolidates with or merges
into any other Person and shall not be the continuing or surviving corporation or entity of
such consolidation or merger, (ii)&nbsp;transfers or conveys all or substantially all of its
properties and assets to any Person or (iii)&nbsp;commences a dissolution, liquidation,
assignment for the benefit of creditors or similar action, then, and in each such case, to
the extent necessary, proper provision shall be made so that the successors and assigns of
the Surviving Corporation or Parent, as the case may be, assume the obligations set forth in
this Section&nbsp;6.5.
</DIV>

<DIV align="justify" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.6 <U>Access to Information; Confidentiality</U>.
</DIV>



<DIV align="justify" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) Between the date hereof and the Effective Time, the Company shall, and shall cause
each of the Company Subsidiaries to, (i)&nbsp;furnish Parent with such financial and operating
data and other non-privileged information with respect to the business, properties and
personnel of the Company and the Company Subsidiaries as Parent may from time to time
reasonably request and (ii)&nbsp;use its reasonable best efforts to facilitate reasonable access
for Parent and its authorized representatives (including counsel, financial advisors and
auditors) during normal business hours, and upon reasonable advance notice, to the Company&#146;s
offices and properties; <U>provided</U> that all such access shall be coordinated through
the Financial Advisor, in accordance with such reasonable procedures as the Special
Committee may establish.
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) Prior to the Effective Time, Parent and Merger Sub shall hold in confidence all
such information on the terms and subject to the conditions contained in that certain
confidentiality agreement between Leonard Green &#038; Partners and the Company dated as of the
date of this Agreement (the &#147;<U>Confidentiality Agreement</U>&#148;). Notwithstanding anything
to the contrary contained herein, the Company, Parent and
Merger Sub hereby agree that in the event of a conflict between the Confidentiality
Agreement and this Agreement, the terms and provisions of this Agreement shall control.
</DIV>

<DIV align="justify" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.7 <U>Public Announcements</U>. The Company and Parent shall consult with each other before
issuing any press release or otherwise making any public statements with respect to this Agreement
or the Merger and shall not issue any such press release or make any such public statement without
the prior consent of the other party, which consent shall not be unreasonably withheld, conditioned
or delayed; <U>provided</U>, <U>however</U>, that a party may, without the prior consent of the
other party, issue such press release or make such public statement as may be required by Law or
the applicable rules of any stock exchange or quotation system if the party issuing such press
release or making such public statement has used its reasonable best efforts to consult with the
other party and to obtain such party&#146;s consent but has been unable to do so in a timely
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->49<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="justify" style="font-size: 10pt; margin-top: 6pt">manner. In this regard, the parties shall make a joint public announcement of this Agreement and the
Transaction contemplated hereby no later than the opening of trading on Nasdaq on the Business Day
following the date on which this Agreement is signed.
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.8 <U>Revolver Financing</U>. The Company agrees to use its commercially reasonable efforts
to provide such assistance as Parent may reasonably request in connection with any replacement,
refinancing or amendment of the Revolving Credit Agreement (such replacement or refinancing, the
&#147;<U>Replacement Revolver Financing</U>&#148;), including by (i)&nbsp;participating in customary rating
agency presentations, (ii)&nbsp;delivering to Parent and financing sources identified by Parent relevant
information with respect to the Company and its Subsidiaries (the &#147;<U>Company Information</U>&#148;)
and (iii)&nbsp;participating in the negotiation of revolving loan agreements, security agreements and
other customary agreements in connection with the Replacement Revolver Financing. In each case,
such cooperation shall be undertaken at Parent&#146;s cost and expense, and the Company shall be not be
required to provide any such assistance which would unreasonably interfere with its business
operations. Further, any such replacement, refinancing or amendment would be conditional upon
consummation of the Merger. In addition, at the request of Parent, in lieu of obtaining an
amendment to the Revolving Credit Agreement, immediately prior to consummation of the Merger (and
conditional upon consummation of the Merger), the Company shall voluntarily terminate all
outstanding commitments under the Revolving Credit Agreement and, to the extent the Company has
sufficient available cash, repay all amounts outstanding thereunder.
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.9 <U>Adoption by Parent</U>. Prior to the Effective Time, Parent shall take all requisite
action to adopt this Agreement in its capacity as the sole stockholder of Merger Sub.
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.10 <U>Notification of Certain Matters</U>. Prior to the Effective Time, Parent shall give
prompt notice to the Company, and the Company shall give prompt notice to Parent, of (a)&nbsp;the
occurrence, or failure to occur, of any event, which occurrence or failure to occur that, to
Parent&#146;s Knowledge or the Company&#146;s Knowledge, as applicable, is reasonably likely to cause any
representation or warranty of such party contained in this Agreement to be untrue or inaccurate in any respect that would
reasonably give rise to a failure of a condition to Closing in Section&nbsp;7.2(a) or Section&nbsp;7.3(a), as
applicable, in each case at any time from and after the date of this Agreement until the Effective
Time, (b)&nbsp;any material failure of Parent and Merger Sub or the Company, as the case may be, or of
any officer, director, employee or agent thereof, to comply with or satisfy any covenant, condition
or agreement that would reasonably give rise to a failure of a condition to Closing in Section
7.2(b) or Section&nbsp;7.3(b), as applicable, (c)&nbsp;any material notice or other communication received by
such party from any Governmental Entity in connection with the Transaction or from any Person
alleging that the consent of such Person is or may be required in connection with the Transaction,
if the subject matter of such communication or the failure of such party to obtain such consent
could be material to the Company, the Surviving Corporation or Parent and (d)&nbsp;any actions, suits,
claims, or proceedings commenced or, to the Company&#146;s Knowledge or Parent&#146;s Knowledge, as
applicable, threatened against, such party or its Affiliates which relate to the Transaction.
Notwithstanding the above, the delivery of any notice pursuant to this Section&nbsp;6.10 will not limit
or otherwise affect the remedies available hereunder to the party receiving such notice or the
conditions to such party&#146;s obligation to consummate the Merger.
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->50<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV align="justify" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.11 <U>Change in Control Offer</U>. Following the Merger, Parent shall cause the Company to
comply with Section&nbsp;3.10 (&#147;Change of Control&#148;) of the Note Indenture and Section&nbsp;4.1 (&#147;Merger and
Consolidation&#148;) of the Note Indenture.
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.12 <U>Backstop Commitment Letter</U>. On or prior to the Effective Time, the Guarantors
shall provide a backstop commitment letter to provide the funds required to comply with Section
3.10 (&#147;Change of Control&#148;) of the Note Indenture.
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.13 <U>Stock Option Agreements</U>. Prior to the Effective Time, the Company shall use its
commercially reasonable best efforts to obtain all agreements or
consents necessary for each Company Stock Option to be canceled at
the Effective Time
pursuant to, and as provided in, Section 2.1(d)(i).
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.14 <U>Warrant Amendments</U>. Prior to the Effective Time, the Company shall use its
commercially reasonable best efforts to obtain
all agreements or
modifications necessary for each Company Warrant to be canceled at the Effective Time
pursuant to, and as provided in, Section 2.1(e).
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.15 <U>Note Indenture</U>. The Company shall take, and shall cause each &#147;Subsidiary
Guarantor&#148; (as defined in the Note Indenture) to take, all necessary action prior to Closing to
consummate the Transaction in compliance with Section&nbsp;4.1 (&#147;Merger and Consolidation&#148;) of the Note
Indenture, including, by delivering, at the Closing, all necessary officers certificates, legal
opinions and supplemental indentures referenced in Section&nbsp;4.1 (&#147;Merger and Consolidation&#148;) of the
Note Indenture.
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.16 <U>Employee Benefits Matters</U>.
</DIV>



<DIV align="justify" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) On and after the Effective Time, Parent shall, and shall cause the Surviving
Corporation to, honor in accordance with their terms all employment agreements and all
bonus, retention and severance obligations, of the Company or any Subsidiary, all of which
are listed in Sections&nbsp;3.18 or 3.21 of the Company Disclosure Schedule, except as may
otherwise be agreed to by the parties thereto, and the Company or Parent shall pay at the
Effective Time to the applicable officers and employees listed in Section&nbsp;3.21 of the
Company Disclosure Schedule, any amounts with respect to such agreements and obligations
that are payable by their terms at the Effective Time or upon consummation of the Merger.
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) During the period commencing at the Effective Time and ending one (1)&nbsp;year
following the Effective Time, Parent shall cause the Surviving Corporation to provide the
employees of the Company and the Company Subsidiaries who remain employed by the Surviving
Corporation, Parent or their subsidiaries after the Effective Time with at least the types
and levels of employee benefits (including contribution levels but excluding any equity or
equity-based compensation arrangements) which are substantially similar in value to those
maintained by them from time to time for similarly-situated employees. Parent shall, and
shall cause the Surviving Corporation to, treat, and cause the applicable benefit plans to
treat, the service of such employees with the Company or the Company Subsidiaries
attributable to any period before the Effective Time as service rendered to Parent or the
Surviving Corporation or their subsidiaries for purposes of eligibility to participate,
vesting and for other appropriate benefits, including applicability of minimum waiting
periods for participation. Without limiting the
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->51<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="justify" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">foregoing, Parent shall not, and shall cause the Surviving Corporation to not, treat any such employees as a &#147;new&#148; employee for
purposes of any exclusions under any health or similar plan of Parent or the Surviving
Corporation for a pre-existing medical condition (except to the extent so treated under the
Company&#146;s corresponding plans), and any deductibles and co-pays paid under any of the
Company&#146;s or any of the Company Subsidiaries&#146; health plans for the year of the Effective
Time shall be credited towards deductibles and co-pays for the year of the Effective Time
under the health plans of Parent or the Surviving Corporation. Parent shall, and shall
cause the Surviving Corporation to, use commercially reasonable efforts to make appropriate
arrangements with its insurance carrier(s) to ensure such results.
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) After the Effective Time, Parent shall cause the Surviving Corporation to honor all
obligations which accrued prior to the Effective Time under the Programs in accordance with
the terms thereof.
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) Notwithstanding anything in this Agreement to the contrary, nothing contained
herein shall (i)&nbsp;be treated as an amendment of any particular Program, (ii)&nbsp;give any third
party, including any employee of the Company, any right to enforce the provisions of this
Agreement (including this Section&nbsp;6.15), (iii)&nbsp;obligate the Surviving Corporation, Parent or
any of their subsidiaries to (A)&nbsp;maintain any particular benefit plan, program, policy or
arrangement or (B)&nbsp;retain the employment of any particular employee or (iv)&nbsp;limit the
Surviving Corporation&#146;s, Parent&#146;s or any of their subsidiaries&#146; ability to amend any
particular benefit plan, program, policy or arrangement of the Surviving Corporation or
terminate an employee.
</DIV>

<DIV align="justify" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.17 <U>Rule&nbsp;16b-3</U>. Prior to the Effective Time, the Company shall take such steps as
may be required to cause dispositions of Company Common Stock, Company Stock Options and Company
Restricted Shares pursuant to the transactions contemplated by this Agreement by each individual
who is a director or officer of the Company to be exempt from Section 16(b) of the Exchange Act by
reason of Rule&nbsp;16b-3 under the Exchange Act.
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt">ARTICLE VII
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><U>Conditions to the Merger</U>
</DIV>

<DIV align="justify" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.1 <U>Conditions to the Obligations of Each Party to Effect the Merger</U>. The respective
obligations of each party to effect the Merger are subject to the satisfaction or waiver (to the
extent permitted by Law), at or prior to the Effective Time, of each of the following conditions:
</DIV>



<DIV align="justify" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) <U>Stockholder Approval</U>. The Company shall have obtained the Company
Stockholder Approval.
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) <U>Other Regulatory Approvals</U>. All material approvals, authorizations and
consents of any Governmental Entity required to consummate the Merger shall have been
obtained and remain in full force and effect, and all statutory waiting periods relating to
such approvals, authorizations and consents shall have expired or been terminated. Any
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->52<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="justify" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">waiting period under the HSR Act applicable to the Merger or the Transaction shall have
expired or early termination thereof shall have been granted.
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) <U>No Injunctions, Orders or Restraints; Illegality</U>. No preliminary or
permanent injunction or other order issued by a court or other Governmental Entity of
competent jurisdiction shall be in effect which would have the effect of (i)&nbsp;making the
consummation of the Merger illegal, or (ii)&nbsp;otherwise prohibiting the consummation of the
Merger; <U>provided</U>, <U>however</U>, that prior to a party asserting this condition
such party shall have used its commercially reasonable best efforts to prevent the entry of
any such injunction or other order and to appeal as promptly as possible any such injunction
or other order that may be entered.
</DIV>

<DIV align="justify" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.2 <U>Conditions to Obligations of Parent and Merger Sub</U>. The obligations of Parent and
Merger Sub to effect the Merger are further subject to the satisfaction of the following
conditions, any one or more of which may be waived by Parent at or prior to the Effective Time:
</DIV>



<DIV align="justify" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) <U>Representations and Warranties</U>. Each of the representations and warranties
of the Company contained in this Agreement shall be true and correct (determined without
regard to any materiality, Company Material Adverse Effect or similar qualification
contained in any representation or warranty) on and as of the
Closing Date, as if made on and as of such date (except to the extent a representation
or warranty is made as of a date other than the Closing Date, in which case such
representation or warranty shall be true and correct at and as of such date), except where
the failure of such representations and warranties to be so true and correct has not had and
would not reasonably be expected to have, individually or in the aggregate, a Company
Material Adverse Effect, except with respect to (i)&nbsp;the representations and warranties in
Sections&nbsp;3.1(a), 3.2, 3.3, 3.7(b) and 3.15, which shall be true and correct in all material
respects (determined without regard to any materiality or similar qualification contained in
any such representation or warranty) and (ii)&nbsp;the representations and warranties in (x)
Section&nbsp;3.6(b) and (y)&nbsp;Section&nbsp;3.9(a)(ii) relating to the absence of a Company Material
Adverse Effect, each of which shall be true and correct in all respects. Parent shall have
received a certificate signed on behalf of the Company, dated as of the Closing Date, to the
foregoing effect.
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) <U>Performance and Obligations of the Company</U>. The Company shall have
performed or complied in all material respects with all agreements and covenants required by
this Agreement to be performed or complied with by it on or prior to the Effective Time.
Parent shall have received a certificate signed on behalf of the Company, dated as of the
Closing Date, to the foregoing effect.
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) <U>Contribution Agreement</U>. The transactions contemplated by the Contribution
Agreement shall have been consummated.
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) <U>Company Material Adverse Effect</U>. Since the date of this Agreement, there
shall not have occurred any change, event, occurrence, development or circumstance which,
individually or in the aggregate, constitutes or could reasonably be expected to result in,
a Company Material Adverse Effect.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->53<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="justify" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e) <U>Certificate</U>. At the Effective Time, the Company shall furnish to Parent
and Merger Sub an affidavit stating, under penalty of perjury, that the Company is not and
has not been a United States real property holding corporation at any time during the
applicable period specified in Section&nbsp;897(c)(1)(A)(ii) of the Code.
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f) <U>Provider Numbers and Licenses</U>. Each of the Medicare provider numbers and
acute care hospital licenses of the Company and the Company Subsidiaries shall remain in
effect.
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(g) <U>No Notice of Termination</U>. No notice of termination under 42 C.F.R. &#167;
489.53(c) has been given by the Centers for Medicare &#038; Medicaid Services or the California
Department of Public Health with respect to Alta Los Angeles Hospitals, Inc. db/a as Norwalk
Community Hospital and Los Angeles Community Hospital.
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(h) <U>Stock Option Agreements</U>. The Company shall have obtained the Stock Option
Agreements.
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) <U>Warrant Amendments</U>. The Company shall have obtained the Warrant
Amendments.
</DIV>

<DIV align="justify" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.3 <U>Conditions to Obligations of the Company</U>. The obligation of the Company to effect
the Merger is further subject to the satisfaction of the following conditions, any one or more of
which may be waived by the Company at or prior to the Effective Time:
</DIV>



<DIV align="justify" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) <U>Representations and Warranties</U>. Each of the representations and warranties
of Parent and Merger Sub contained in this Agreement shall be true and correct (determined
without regard to any materiality or material adverse effect qualification contained in any
representation or warranty) at and as of the Closing Date, as if made at and as of such time
(except to the extent a representation or warranty is made as of a time other than the
Closing Date, in which case such representation or warranty shall be true and correct at and
as of such time), with only such exceptions as would not reasonably be expected to have,
individually or in the aggregate, a Parent Material Adverse Effect. The Company shall have
received a certificate signed on behalf of Parent and Merger Sub, dated the Closing Date, to
the foregoing effect.
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) <U>Performance of Obligations of Parent and Merger Sub</U>. Each of Parent and
Merger Sub shall have performed or complied in all material respects with all agreements and
covenants required by this Agreement to be performed or complied with by it on or prior to
the Effective Time, and the Company shall have received a certificate signed on behalf of
Parent and Merger Sub, dated as of the Closing Date, to the foregoing effect.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->54<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="center" style="font-size: 10pt; margin-top: 18pt">ARTICLE VIII
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><U>Termination, Amendment and Waiver</U>
</DIV>

<DIV align="justify" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8.1 <U>Termination</U>. This Agreement may be terminated and abandoned at any time prior to
the Effective Time, whether before or after the receipt of Company Stockholder Approval (except as
otherwise expressly noted):
</DIV>



<DIV align="justify" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) by the mutual written consent of Parent, Merger Sub and the Company;
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) by either of the Company, on the one hand, or Parent or Merger Sub, on the other
hand, by written notice to the other, if:
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) upon a vote taken thereon at a duly held meeting of holders of the Company Common
Stock (or at any adjournment or postponement thereof), held to obtain the Company
Stockholder Approval, the Company Stockholder Approval is not obtained; <U>provided</U>,
<U>however</U>, that the right to terminate this Agreement pursuant to this Section
8.1(b)(i) shall not be available to the Company if the failure to obtain the Company
Stockholder Approval was primarily due to the breach or failure of the Company to perform in
a material respect any of its obligations under this Agreement;
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii) any Governmental Entity of competent jurisdiction shall have issued an order,
decree, judgment, injunction or taken any other action which permanently restrains, enjoins
or otherwise prohibits or makes illegal the consummation of the Transaction, and such order,
decree, judgment, injunction or other action shall have become final and non-appealable; or
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii) the consummation of the Merger shall not have occurred on or before February&nbsp;15,
2011 (the &#147;<U>End Date</U>&#148;); <U>provided</U>, <U>however</U>, that the right to
terminate this Agreement under this Section&nbsp;8.1(b)(iii) shall not be available to a party if
the failure of the Merger to be consummated before the End Date was primarily due to the
breach or failure of such party to perform in a material respect any of its obligations
under this Agreement;
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) by written notice from Parent to the Company, if (A)&nbsp;at any time the
representations and warranties of the Company contained in this Agreement become untrue or
inaccurate or the Company breaches or fails to perform any of its agreements or covenants
contained in this Agreement, and which such inaccuracy, breach or failure to perform (i)
would give rise to the failure of a condition set forth in Section&nbsp;7.2 and (ii)&nbsp;cannot be
cured by the Company, or if capable of being cured, shall not have been fully cured within
twenty (20)&nbsp;days following receipt by the Company of written notice of such inaccuracy,
breach or failure to perform from Parent (or, if earlier, the End Date); <U>provided</U>
that such occurrence or circumstance shall not have resulted from or been caused by either
(x)&nbsp;the material breach or failure to perform of Parent or Merger Sub, in any material
respect, of any of their respective agreements or covenants contained in this Agreement, or
(y)&nbsp;the failure of any representation or warranty of Parent or Merger Sub contained in this
Agreement to be true and correct, in any material respect (without
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->55<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="justify" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">giving effect to any other limitation therein as to materiality, Company Material Adverse Effect or similar
qualification contained in any representation and warranty); or (B)&nbsp;the Company breaches or
fails to perform any of its obligations under Section&nbsp;6.4, which breach or failure to
perform, if curable by the Company, shall not have been fully cured by the Company within
five (5)&nbsp;days following receipt by the Company of written notice of such breach or failure
to perform from Parent;
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) by written notice from the Company to Parent if at any time the representations and
warranties of Parent or Merger Sub contained in this Agreement become untrue, inaccurate or
Parent or Merger Sub breaches or fails to perform any of their agreements or covenants
contained in this Agreement, and which such inaccuracy, breach or failure to perform (i)
would give rise to the failure of a condition set forth in Section&nbsp;7.3 and (ii)&nbsp;cannot be
cured by Parent or Merger Sub, or if capable of being cured, shall not have been fully cured
within twenty (20)&nbsp;days following receipt by Parent or Merger Sub of written notice of such
inaccuracy, breach or failure to perform from the Company (or, if earlier, the End Date);
<U>provided</U> that such occurrence or circumstance shall not have resulted from or been
caused by either (x)&nbsp;the material breach or failure to perform of the Company, in any
material respect, of any of its agreements or covenants contained in this Agreement, or (y)
the failure of any representation or warranty of the Company contained in this Agreement to
be true and correct, in any material respect
(without giving effect to any other limitation therein as to materiality, Company
Material Adverse Effect or similar qualification contained in any representation and
warranty);
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e) by written notice from the Company to Parent, prior to the receipt of the Company
Stockholder Approval, in order to concurrently enter into a Company Acquisition Agreement
with respect to a Superior Proposal if (i)&nbsp;the Company has complied in all respects with the
requirements of Section&nbsp;6.4 and (ii)&nbsp;prior to or concurrently with such termination, the
Company pays the Termination Fee and Parent&#146;s Expenses under Section&nbsp;8.3; or
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f) by written notice from Parent or Merger Sub to the Company, if (A)&nbsp;the Company
Board shall have failed to include the Company Recommendation in the Proxy Statement or
shall have effected a Company Adverse Recommendation Change; (B)&nbsp;the Company Board shall
have effected a Change of Recommendation; (C)&nbsp;the Company Board shall have failed to
recommend against any publicly announced Takeover Proposal and reaffirm the Company
Recommendation, in each case, within ten (10)&nbsp;Business Days following the public
announcement of such Takeover Proposal and in any event at least two (2)&nbsp;Business Days prior
to the Company Stockholders&#146; Meeting; (D)&nbsp;the Company enters into a Company Acquisition
Agreement; or (E)&nbsp;the Company or the Company Board shall have publicly announced its
intention to do any of the foregoing.
</DIV>
<DIV align="justify" style="font-size: 10pt; margin-top: 6pt">For purposes of this Section&nbsp;8.1, to the extent permitted by applicable Law, the Company Board may
act through the Special Committee, if the Special Committee is still in existence.
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8.2 <U>Effect of Termination</U>. In the event of the termination of this Agreement pursuant
to Section&nbsp;8.1, this Agreement shall forthwith become null and void and have no effect, without any
liability on the part of Parent, Merger Sub or the Company and their respective directors,
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->56<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="justify" style="font-size: 10pt; margin-top: 6pt">officers, employees, partners, members or stockholders and all rights and obligations of any party
hereto shall cease, <U>provided</U> that (i)&nbsp;the agreements contained in Sections&nbsp;6.6(b), 6.7,
8.2, 8.3 and Article&nbsp;IX of this Agreement, the Financing Commitment (in accordance with its terms)
and the Fund Guarantee (in accordance with its terms), shall survive any termination of this
Agreement and (ii)&nbsp;that nothing contained herein shall relieve any party from liabilities or
damages suffered by the other parties hereto arising out of any willful breach arising prior to
termination or fraud by such breaching party.
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8.3 <U>Fees and Expenses</U>.
</DIV>



<DIV align="justify" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) In the event that:
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 6pt; margin-left: 8%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) (A)&nbsp;a Takeover Proposal shall have been made, proposed or communicated
after the date hereof and not withdrawn prior to the Company Stockholders&#146; Meeting
or prior to the termination of this Agreement if there has been no Company
Stockholders&#146; Meeting, and (B)&nbsp;following the occurrence of an event described in the
preceding clause (A), this Agreement is terminated by the
Company or Parent pursuant to Section&nbsp;8.1(b)(i) or Section&nbsp;8.1(b)(iii) or by
Parent pursuant to Section&nbsp;8.1(c) and (C)&nbsp;within twelve (12)&nbsp;months of the date this
Agreement is terminated, the Company enters into a definitive agreement with respect
to any Takeover Proposal and such Takeover Proposal is consummated (in each case
whether or not the Takeover Proposal was the same Takeover Proposal referred to in
clause (A)); <U>provided</U> that for purposes of clause (C)&nbsp;of this Section
8.3(a)(i), the references to &#147;20%&#148; in the definition of Takeover Proposal shall be
deemed to be references to &#147;50%&#148;; or
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 6pt; margin-left: 8%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii) this Agreement is terminated by the Company pursuant to Section&nbsp;8.1(e); or
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 6pt; margin-left: 8%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii) this Agreement is terminated by Parent pursuant to Section&nbsp;8.1(f);
then, in any such event under clause (i), (ii)&nbsp;or (iii)&nbsp;of this Section&nbsp;8.3(a), the
Company shall pay to Parent all Parent&#146;s Expenses and the Termination Fee, in each
case, by wire transfer (instructions for which have been provided to the Company on
the date hereof) of same day funds (x)&nbsp;in the case of Section&nbsp;8.3(a)(iii), within
two (2)&nbsp;Business Days after such termination, (y)&nbsp;in the case of Section&nbsp;8.3(a)(ii),
prior to or concurrently with such termination or (z)&nbsp;in the case of Section
8.3(a)(i), two (2)&nbsp;Business Days after the consummation of a Takeover Proposal; it
being understood that in no event shall the Company be required to pay the
Termination Fee on more than one occasion. As used herein, &#147;<U>Termination
Fee</U>&#148; shall mean a cash amount equal to $6,200,000 (the &#147;<U>No-Shop Termination
Fee</U>&#148;); except in the event that this Agreement is terminated by the Company
pursuant to Section&nbsp;8.1(e) in order to enter into (I)&nbsp;prior to the No-Shop Period
Start Date, a definitive agreement with respect to a Takeover Proposal or (II)&nbsp;prior
to the Cut-off Date, a definitive agreement with respect to a Takeover Proposal with
an Excluded Party, which in either case, the Termination Fee shall mean a cash
amount equal to $3,600,000 (the &#147;<U>Go-Shop Termination Fee</U>&#148;). In
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->57<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="justify" style="font-size: 10pt; margin-top: 6pt; margin-left: 8%">the event that this Agreement is terminated pursuant to Section&nbsp;8.1(b)(i) or Section&nbsp;8.1(c)
all of the Parent&#146;s Expenses shall be paid by the Company to Parent by wire transfer
of same day funds within two (2)&nbsp;Business Days after such termination;
<U>provided</U>, that, the payment of the expense reimbursement pursuant to this
sentence shall not be deemed to relieve the Company of any subsequent obligation to
pay the Termination Fee pursuant to this Section&nbsp;8.3. The Company shall not be
required to pay more than an aggregate of $2,250,000 in Parent&#146;s Expenses pursuant
to this Section&nbsp;8.3(a).
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 6pt; margin-left: 8%">(b)&nbsp;Each of the parties hereto acknowledge that the agreements
contained in this Section&nbsp;8.3 are an integral part of the Transaction, and that
without these agreements, Parent and Merger Sub would not enter into this
Agreement; accordingly, if the Company fails to timely pay any amount due
pursuant to this Section&nbsp;8.3, and, in order to obtain the payment, Parent or
Merger Sub commences an Action which results in a judgment against the Company
for the payments set forth in this Section&nbsp;8.3, the Company shall pay Parent
its reasonable and documented costs and expenses (including reasonable and
documented attorneys&#146; fees) in connection with such suit, together with interest on
such amount at the prime rate as published in The Wall Street Journal in effect on
the date such payment was required to be made through the date such payment was
actually received. For the avoidance of doubt, any payments required to be made by
the Company to Parent pursuant to this Section&nbsp;8.3(b) shall not be subject to the
cap on Parent&#146;s Expenses set forth in Section&nbsp;8.3(a) above.
</DIV>

<DIV align="justify" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8.4 <U>Amendment</U>. This Agreement may be amended by the parties hereto by an instrument
in writing signed on behalf of each of the parties hereto at any time before or after the adoption
of this Agreement by holders of the Company Common Stock; <U>provided</U>, <U>however</U>, that
after any such adoption, no amendment shall be made which by Law requires further approval by such
stockholders without obtaining such approval.
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8.5 <U>Extension; Waiver</U>. At any time prior to the Effective Time, the parties hereto
may, to the extent legally allowed, (a)&nbsp;extend the time for the performance of any of the
obligations or other acts of the other parties hereto, (b)&nbsp;waive any inaccuracies in the
representations and warranties of the other parties contained herein or in any document delivered
pursuant hereto and (c)&nbsp;waive compliance by the other parties with any of the agreements or
conditions contained herein. Any agreement on the part of a party hereto to any such extension or
waiver shall be valid only if set forth in a written instrument signed on behalf of the party
against which such waiver or extension is to be enforced. The failure of a party to assert any of
its rights under this Agreement or otherwise shall not constitute a waiver of those rights. The
waiver by any party hereto of a breach of any provision hereunder shall not operate or be construed
as a waiver of any prior or subsequent breach of the same or any other provision hereunder.
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->58<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV align="center" style="font-size: 10pt; margin-top: 18pt">ARTICLE IX
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><U>General Provisions</U>
</DIV>

<DIV align="justify" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;9.1 <U>Notices</U>. All notices and other communications given or made pursuant hereto shall
be in writing and shall be deemed to have been duly given or made as of the date and time delivered
or sent if delivered personally or sent by facsimile (providing confirmation of transmission) or
sent by prepaid overnight carrier (providing proof of delivery) to the parties at the following
addresses or facsimile numbers (or at such other addresses or facsimile numbers as shall be
specified by the parties by like notice):
</DIV>

<DIV align="justify" style="font-size: 10pt; margin-left: 9%; margin-top: 6pt">(a) &nbsp;if to Parent or Merger Sub:
</DIV>

<DIV align="justify" style="font-size: 10pt; margin-left: 12%; margin-top: 6pt">c/o Leonard Green &#038; Partners, L.P.<BR>
11111 Santa Monica Blvd., #2000<BR>
Los Angeles, CA 90025<BR>
Attention: John Baumer<BR>
Facsimile: (310)&nbsp;954-0404
</DIV>

<DIV align="justify" style="font-size: 10pt; margin-left: 12%; margin-top: 6pt">with a copy to (which shall not constitute notice):
</DIV>

<DIV align="justify" style="font-size: 10pt; margin-left: 12%; margin-top: 6pt">Latham &#038; Watkins LLP<BR>
885 Third Avenue<BR>
New York, New York 10022<BR>
Attention: Howard Sobel<BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;John Giouroukakis<BR>
Facsimile: (212)&nbsp;751-4864
</DIV>

<DIV align="justify" style="font-size: 10pt; margin-left: 9%; margin-top: 6pt">(b) &nbsp;if to the Company:
</DIV>

<DIV align="justify" style="font-size: 10pt; margin-left: 12%; margin-top: 6pt">Prospect Medical Holdings, Inc<BR>
10780 Santa Monica Blvd., Suite&nbsp;400<BR>
Los Angeles, CA 90025<BR>
Attention: General Counsel<BR>
Facsimile: (310)&nbsp;943-4501
</DIV>

<DIV align="justify" style="font-size: 10pt; margin-left: 12%; margin-top: 6pt">with copies to (which shall not constitute notice):
</DIV>

<DIV align="justify" style="font-size: 10pt; margin-left: 12%; margin-top: 6pt">Troy &#038; Gould, P.C.<BR>
1801 Century Park East, Suite&nbsp;1600<BR>
Los Angeles, CA 90067<BR>
Attention: William Gould<BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Dale E. Short<BR>
Facsimile: (310)&nbsp;789-1459
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->59<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="justify" style="font-size: 10pt; margin-left: 12%; margin-top: 6pt">Locke Lord Bissell &#038; Liddell, LLP<BR>
300 South Grand Avenue, Suite&nbsp;2600<BR>
Los Angeles, CA 90071<BR>
Attention: Neal H. Brockmeyer<BR>
Facsimile: (213)&nbsp;341-6774
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;9.2 Certain Definitions. For purposes of this Agreement, the term:
</DIV>

<DIV align="justify" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<I>1998 Plan</I>&#148; means the
Prospect Medical Holdings, Inc. 1998 Stock Option Plan.
</DIV>

<DIV align="justify" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<I>Acceptable Confidentiality Agreement</I>&#148; means any confidentiality and standstill agreement that
contains provisions that are no less favorable to the Company than those contained in the
Confidentiality Agreement, it being understood that such confidentiality agreements need not
prohibit the submission of Takeover Proposals or amendments thereto to the Company.
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<I>Affiliate</I>&#148; of any Person means a Person that directly or indirectly, through one or more
intermediaries, controls, is controlled by, or is under common control with, the first-mentioned
Person.
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<I>Business Day&#148; </I>means the twenty four (24)&nbsp;hour period of any day other than (a)&nbsp;a Saturday or
Sunday or (b)&nbsp;a day on which the SEC or banks in the City of New York are authorized or required by
Law to be closed.
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<I>Company&#146;s Knowledge</I>&#148; means the actual (and not the constructive or imputed) knowledge of
those individuals identified in Section&nbsp;9.2 of the Company Disclosure Schedule.
</DIV>

<DIV align="justify" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<I>Company Equity Incentive Plans</I>&#148; means all employee equity incentive plans or arrangements of the Company.
</DIV>

<DIV align="justify" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<I>Company Material Adverse Effect</I>&#148; means, with respect to the Company, an effect, event,
occurrence, development or change, individually or in the aggregate with all other effects, events,
occurrences, developments and changes, which has a material adverse effect on the business, assets,
results of operations, or condition (financial or otherwise) of the Company and the Company
Subsidiaries taken as a whole, or would reasonably be expected to prevent or materially impair or
delay the consummation of the transactions contemplated by this Agreement, other than effects,
events, occurrences, developments or changes arising out of or resulting from (a)&nbsp;changes in
conditions in the U.S. or global economy or securities, capital or financial markets generally,
including changes in interest or exchange rates, (b)&nbsp;general changes or developments in political
or economic conditions within the industry or industries in which the Company and the Company
Subsidiaries operate, (c)&nbsp;changes in GAAP or the interpretation thereof after the date hereof, (d)
the negotiation, execution, announcement or performance of this Agreement or the consummation of
the transactions contemplated by this Agreement, including the impact thereof on relationships,
contractual or otherwise, with customers, lenders, partners or employees, (e)&nbsp;acts of God, acts of
war, sabotage or terrorism, or any escalation or worsening of any such acts of war, sabotage or
terrorism threatened or underway as of the date of this Agreement, (f)&nbsp;the implementation,
amendment or repeal of the Patient Protection and Affordable Care Act or any legal challenge or
judicial ruling related thereto, (g)&nbsp;changes in and of themselves in the credit ratings applicable
to the Company (it being understood and agreed that the facts and circumstances giving rise to such
changes in the credit ratings applicable to the Company may be taken into account when determining
whether there has been a Company Material Adverse Effect), (h)&nbsp;any decline in the market price, or
change in trading volume of the
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->60<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="justify" style="font-size: 10pt; margin-top: 6pt">Company Common Stock or any failure to meet internal or published projections, forecasts or revenue or earnings predictions (it being understood and agreed that the
facts and circumstances giving rise to such decline in the market price, change in trading volume
of the Company Common Stock or any failure to meet internal or published projections, forecasts or
revenue or earnings predictions may be taken into account when determining whether there has been a
Company Material Adverse Effect) or (i)&nbsp;the survey being conducted as of the date of this Agreement
by the California Department of Public Health on behalf of the Centers for Medicare &#038; Medicaid
Services with respect to Alta Los Angeles Hospitals, Inc. db/a as Norwalk Community Hospital and
Los Angeles Community Hospital (it being understood and agreed that the facts and circumstances
giving rise to such survey may be taken into account when determining whether there has been a
Company Material Adverse Effect), except, in the case of clauses (a), (b), (c)&nbsp;and (e)&nbsp;for any
effect, event, development or change that in a materially disproportionate way adversely affects
the Company and the Company Subsidiaries when compared to other Persons operating in the industry
or industries in which the Company and the Company Subsidiaries operate. Without limitation of clause (d)&nbsp;of the preceding sentence, for
purposes of determining whether a Company Material Adverse Effect has arisen from or been
contributed to by the termination, non-renewal or adverse modification of contracts, formations,
renewals and favorable modifications of contracts shall also be taken into account.
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<I>Company Party</I>&#148; means, with respect to the Company and any Company Subsidiary, any of their
respective former, current or future directors, officers, employees, agents, general or limited
partners, managers, members, stockholders, affiliates or assignees or any former, current or future
director, officer, employee, agent, general or limited partner, manager, member, stockholder,
affiliate or assignee of any of the foregoing.
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<I>Company Warrants&#148; </I>means all warrants to acquire shares of Company Common Stock.
</DIV>



<DIV align="justify" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<i>Company Stock Options</i>&#148; means all outstanding options to purchase shares of Company
Common Stock under any Company Equity Incentive Plan.

</div>


<DIV align="justify" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<I>Credit Facilities&#148; </I>means the (i)&nbsp;Note Indenture, (ii)&nbsp;Credit Agreement, dated April&nbsp;14, 2009,
between Brotman Medical Center, Inc. and Gemino Healthcare Finance, LLC, (iii)&nbsp;Loan Agreement,
dated July&nbsp;9, 2008, between Brotman Medical Center, Inc., as borrower, and JHA West 16, LLC, as
lender, as amended, and (iv)&nbsp;Loan Agreement, dated July&nbsp;9, 2008, between Brotman Medical Center,
Inc., as borrower, and JHA East 7, LLC, as lender, as amended.
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<I>Environment</I>&#148; means soil, sediment, surface or subsurface strata, surface water, ground water,
ambient air and any biota living in or on such media.
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<I>Environmental Laws</I>&#148; means any federal, state or local Law relating to the pollution,
protection, or restoration of the Environment, including those relating to the use, handling,
presence, transportation, treatment, storage, disposal, release or discharge of, or exposure to,
Hazardous Materials.
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<I>Equity Interest</I>&#148; means any share, capital stock, partnership, limited liability company,
membership, member or similar interest in any Person, and any option, warrant, right or security
(including debt securities) convertible into or exchangeable or exercisable therefor.
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<I>ERISA</I>&#148; means the Employee Retirement Income Security Act of 1974, as amended.
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->61<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV align="justify" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<I>ERISA Affiliate</I>&#148; means an Affiliate of the Company if it is considered a single employer with
the Company under ERISA Section 4001(b) or part of the same &#147;controlled group&#148; as the Company for
purposes of ERISA Section&nbsp;302(d)(8)(C).
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<I>Exchange Act</I>&#148; means the Securities Exchange Act of 1934, as amended, and the rules and
regulations promulgated thereunder.
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<I>Fund Guarantee</I>&#148; means that certain Guarantee executed by the Guarantors, dated as of the date
hereof, and attached as <U>Exhibit&nbsp;C</U> hereto.
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<I>GAAP</I>&#148; means generally accepted accounting principles as applied in the United States.
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<I>Guarantors</I>&#148; means Green Equity Investors V, L.P., a Delaware limited partnership and Green
Equity Investors Side V, L.P., a Delaware limited partnership.
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<I>Hazardous Materials</I>&#148; means any material, substance or waste that is listed, classified,
regulated, characterized or otherwise defined as &#147;hazardous,&#148; &#147;toxic,&#148; &#147;radioactive,&#148; a
&#147;pollutant,&#148; or a &#147;contaminant&#148; (or words of similar intent or meaning) under applicable
Environmental Law, including but not limited to petroleum, petroleum by-products, asbestos or
asbestos-containing material, urea formaldehyde insulation, toxic mold, polychlorinated biphenyls,
flammable or explosive substances, or pesticides.
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<I>HSR Act</I>&#148; means the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, and the
rules and regulations thereunder.
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<I>Indebtedness</I>&#148; means, with respect to any Person, without duplication, (A)&nbsp;all indebtedness of
such Person for borrowed money, whether secured or unsecured, (B)&nbsp;all obligations of such Person
under conditional sale or other title retention agreements relating to property purchased by such
Person, (C)&nbsp;all capitalized lease obligations of such Person, (D)&nbsp;all obligations of such Person
under interest rate or currency hedging transactions (valued at the termination value thereof) and
(E)&nbsp;all guarantees of such Person of any such Indebtedness of any other Person.
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<I>Intervening Event</I>&#148; means a material event or circumstance relating to the business, results
of operations, assets or financial condition of the Company and the Company Subsidiaries taken as a
whole that was not known to the Company Board on the date of this Agreement (or if known, the
consequences of which were not known to or reasonably foreseeable by the Company Board as of the
date hereof), which event or circumstance, or any material consequences thereof, becomes known to
the Company Board prior to the time at which the Company receives the Company Stockholder Approval;
<U>provided</U>, <U>however</U>, that in no event shall the receipt, existence or terms of a
Takeover Proposal or any matter relating thereto or consequence thereof constitute an Intervening
Event.
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<I>IRS</I>&#148; means the United States Internal Revenue Service.
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<I>Law</I>&#148; or &#147;<I>Laws</I>&#148; means any federal, state, local or foreign law, statute, ordinance, rule,
regulation, judgment, order, injunction, decree or agency requirement of any United States
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->62<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="justify" style="font-size: 10pt; margin-top: 6pt">federal, state or local or foreign governmental or regulatory agency, commission, court, body, entity or
authority.
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<I>Material Contract</I>&#148; means any contact, agreement, commitment, arrangements, leases, and other
instruments to which the Company or any Company Subsidiary is a party or by which the Company, any
Company Subsidiary or any of their respective properties or assets is bound that:
</DIV>



<DIV align="justify" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(A) was filed or required to be filed by the Company as a &#147;material contract&#148; since
September&nbsp;30, 2009, as part of the Filed SEC Documents pursuant to Item&nbsp;601(b)(10) of
Regulation&nbsp;S-K under the Securities Act or disclosed by the Company on a Current Report on
Form 8-K and that are to be performed in whole or in part at or after the date of this
Agreement;
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(B) except for ordinary course service contracts consistent with past practices,
contains covenants of the Company or any Company Subsidiaries that limit in
any material respect the ability of the Company or any of its Subsidiaries (or which,
following the consummation of the Merger, could restrict the ability of the Surviving
Corporation or any of its Affiliates outside of the ordinary course of business) to compete
in any line of business, any type of product or service, in any channel of distribution or
field of commercial endeavor, in any geographic area, or to sell, supply or distribute any
service or product;
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(C) is a joint venture, partnership, limited liability or other similar agreements or
arrangements relating to the formation, creation, operation, management or control of any
partnership or joint venture that is material to the business of the Company and its
Subsidiaries, taken as a whole;
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(D) individually or in the aggregate with other contracts, that would accelerate
payment obligations, performance deadlines, or modify or accelerate any other material
obligation due to the Merger or the Transaction in excess of $250,000 in the aggregate;
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(E) is a collective bargaining agreement or similar agreement;
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(F) pursuant to which the Company or any Company Subsidiary has Indebtedness
outstanding (or commitments in respect of Indebtedness) in an amount in excess of $2,500,000
outstanding (other than intercompany indebtedness);
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(G) involves contract licensing or otherwise specifically concerning intellectual
property (except for non-exclusive, commercially available, off-the-shelf software programs
for which the Company and the Company Subsidiaries, taken as a whole, pay an annual fee of
less than $250,000) that is material to the business of the Company and the Company
Subsidiaries, taken as a whole;
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(H) accounted for aggregate revenue to the Company or any Company Subsidiary of more
than $5,000,000 during the Company&#146;s 2009 fiscal year;
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->63<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="justify" style="font-size: 10pt; margin-top: 6pt;margin-left:4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(I)&nbsp;was entered into after September&nbsp;30, 2009 or is not yet consummated involving the
acquisition or disposition, directly or indirectly (by merger or otherwise), of assets or
capital stock or other equity interests of another person (other than acquisitions or
dispositions of supplies and inventory in the ordinary course of business consistent with
past practice) for aggregate consideration under such contract in excess of $500,000
excluding indemnification, &#147;earn-out&#148; or other contingent obligations;
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 6pt;margin-left:4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(J)&nbsp;with respect to any acquisition, divesture, merger or similar transaction that
contains &#147;earn-out&#148; or other contingent purchase price obligations that are expected to
result in payments in excess of $500,000;
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 6pt;margin-left:4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(K)&nbsp;that involves any agency or department of the United States federal government for
the purchase of goods and/or services from the Company or any Company Subsidiary which would
reasonably be expected to result in payments to the Company or any Company Subsidiary; or
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 6pt;margin-left:4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(L)&nbsp;that prohibit the payment of dividends or distributions in respect of the common
stock of the Company or any Company Subsidiary, prohibit the pledging of the common stock of
the Company or any Company Subsidiary or prohibit the issuance of guarantees by any wholly
owned Company Subsidiary.
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<I>Nasdaq</I>&#148; means the Nasdaq Global Market or the Nasdaq Stock Market LLC, as appropriate.
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>&#147;Note Indenture&#148; </I>shall mean that certain Indenture, dated as of July&nbsp;29, 2009, among the
Company, certain Company Subsidiaries and U.S. Bank National Association, and the 12&#190;% Senior
Secured Notes due 2014 issued thereunder.
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<I>Parent Material Adverse Effect</I>&#148; means, with respect to Parent or Merger Sub, an effect,
event, occurrence, development or change which materially adversely affects the ability of Parent
or Merger Sub to perform their obligations hereunder or to consummate the Merger and the other
transactions contemplated hereby.
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<I>Parent Party</I>&#148; means, collectively, with respect to Parent and Merger Sub, their respective
former, current or future directors, officers, employees, agents, general or limited partners,
managers, members, stockholders, affiliates or assignees or any former, current or future director,
officer, employee, agent, general or limited partner, manager, member, stockholder, affiliate or
assignee of any of the foregoing.
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>&#147;Parent&#146;s Expenses&#148; </I>means all reasonable documented third-party out-of-pocket fees and
expenses incurred by Parent and its Affiliates at any time after March&nbsp;1, 2010 and prior to the
termination of this Agreement in connection with the Transaction and the preparation and
negotiation of this Agreement, including all reasonable fees and expenses of counsel, investment
banking firms, financial advisors, accountants, experts and consultants to Parent and its
Affiliates.
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->64<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV align="justify" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<I>Parent&#146;s Knowledge</I>&#148; shall mean the actual (and not the constructive or imputed) knowledge of
John Baumer and Alyse Wagner.
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<I>Permits</I>&#148; means all licenses, permits, registrations, accreditations, provider numbers,
certificates, consents, orders, approvals and other authorizations from, all federal, state, local
and other governmental authorities, all self-regulatory organizations and all courts and other
tribunals, presently required or necessary to own or lease, as the case may be, and to operate each
of Company and the Company Subsidiaries respective properties and to carry on each of Company and
the Company Subsidiaries respective businesses.
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<I>Permitted Liens&#148; </I>means: (A)&nbsp;zoning or other restrictions, easements, rights-of-way, title
exceptions, defects, liens, imperfections of title, restrictive covenants and other matters of
record affecting the Owned Real Property (provided that they were incurred prior to the date hereof
and do not, individually or in the aggregate, materially interfere with the use of such Owned Real
Property or the Company&#146;s or the Company Subsidiaries&#146; operation of their respective businesses as
currently operated); (B)&nbsp;pledges or deposits by the Company or any of the Company Subsidiaries
under workmen&#146;s compensation Laws, unemployment insurance Laws or similar legislation, or good
faith deposits in connection with bids, tenders, contracts (other than for the
payment of Indebtedness) or leases to which such entity is a party, or deposits to secure
public or statutory obligations of such entity or to secure surety or appeal bonds to which such
entity is a party, or deposits as security for contested Taxes, in each case incurred or made in
the ordinary course of business consistent with past practice; (C)&nbsp;liens imposed by Law, including
carriers&#146;, warehousemen&#146;s, landlords&#146; and mechanics&#146; liens, in each case incurred in the ordinary
course of business consistent with past practice for sums not yet due or being contested in good
faith by appropriate proceedings; (D)&nbsp;statutory liens for Taxes, assessments or other governmental
charges not yet due and payable or which are being contested in good faith by appropriate
proceedings; (E)&nbsp;with respect to real property subject to Leases, statutory liens of lessors and
liens provided in leases so long as the payment of rent or the performance of obligations under
such Leases is not delinquent; (F)&nbsp;liens that have been placed by third parties on the fee title of
real property under Leases or on easements affecting Owned Real Property (provided that they were
incurred prior to the date hereof and do not, individually or in the aggregate, materially
interfere with the use of such real property or the Company&#146;s or the Company Subsidiaries&#146;
operation of their respective businesses as currently operated) and (G)&nbsp;liens, pledges and security
interests granted under the Credit Facilities and Revolving Credit Agreement.
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<I>Person</I>&#148; means an individual, corporation, limited liability company, partnership,
association, trust, unincorporated organization, other entity or group (as defined in Section 13(d)
of the Exchange Act).
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>&#147;Revolving Credit Agreement&#148; </I>means that certain Credit Agreement, dated as of July&nbsp;29, 2009
among the Company, as borrower, the Royal Bank of Canada, as administrative agent, and the other
financial institutions and lenders a party thereto, as amended.
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<I>SEC</I>&#148; means the Securities and Exchange Commission.
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<I>Securities Act</I>&#148; means the Securities Act of 1933, as amended, and the rules and regulations
promulgated thereunder.
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<I>Stock Option Agreements</i>&#148; means the agreement or consent of at least eighty percent (80%) of all of the holders of Company
 Stock Options under the 1998 Plan who hold, in the aggregate, not less than ninety percent (90%) of the total number
of Company Stock Options under the 1998 Plan, to cancel, at the Effective Time pursuant to, and as
 provided in, Section 2.1(d)(i),
all of such holders&#146; Company Stock Options under the 1998 Plan.
</div>



<P align="center" style="font-size: 10pt"><!-- Folio -->65<!-- /Folio -->
</DIV>



<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV align="justify" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<I>Subsidiary</I>&#148; means (i)&nbsp;any corporation, partnership, limited liability company, joint venture
or other business entity of which a majority of the securities or other interests having ordinary
voting power (or in the case of a partnership, more than a majority of the general partnership
interests) is beneficially owned directly, or indirectly through one or more intermediaries, or
both, by Parent or the Company, as the case may be, and (ii)&nbsp;in the case of the Company, any
corporation, partnership, limited liability company, joint venture or other business entity of
which the management is otherwise controlled or the right to designate the individual or
individuals who own a majority of the securities or other interests is controlled, directly, or
indirectly through one or more intermediaries, or both, by the Company.
</DIV>

<DIV align="justify" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<I>Tax Returns</I>&#148; means all reports, returns, declarations, statements or other information
required to be supplied to a Taxing authority or any other Person in connection with Taxes,
including all attachments thereto and amendments thereof.
</DIV>

<DIV align="justify" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<I>Taxes</I>&#148; means (i)&nbsp;any and all taxes, levies, imposts, fees, duties, assessments and similar
charges of any kind (together with any and all interest, penalties, additions to tax and additional
amounts imposed with respect thereto) imposed by any government or taxing authority, including:
taxes or other charges on or with respect to income, franchises, windfall or other profits, gross
receipts, property, sales, use, capital stock, payroll, employment, social security, net worth,
excise, withholding, ad valorem, stamp, transfer, value added or gains taxes and similar charges
and (ii)&nbsp;any liability for amounts described in clause (i)&nbsp;under Treasury Regulation&nbsp;Section
1.1502-6, as a result of transferee liability, as a result of being a member of an affiliated,
combined, consolidated or unitary group or as a result of any agreement, implied or express, to
indemnify any Person for amounts described in clause (i).
</DIV>

<DIV align="justify" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<I>Warrant Amendments</I>&#148; means all amendments or
modifications necessary for each Company Warrant listed in Item 1 of Section 3.3(f) of the Company Disclosure Schedule
to be canceled at the Effective Time pursuant to, and as provided in, Section&nbsp;2.1(e).
</DIV>

<DIV align="justify" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;9.3 <U>Terms Defined Elsewhere</U>. The following terms are defined elsewhere in this
Agreement, as indicated below:
</DIV>
<DIV align="right">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="96%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="40%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="55%">&nbsp;</TD>
</TR>
<TR></TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><B><I>&#147;5330 Filing&#148;</I></B>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Section&nbsp;3.13(b)</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><B><I>&#147;Action&#148;</I></B>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Section&nbsp;3.8</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><B><I>&#147;Agreement&#148;</I></B>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Preamble</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><B><I>&#147;Appraisal Rights&#148;</I></B>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Section&nbsp;2.4</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><B><I>&#147;Base Premium&#148;</I></B>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Section&nbsp;6.5(c)</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><B><I>&#147;Book-Entry Shares&#148;</I></B>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Section&nbsp;2.1(c)</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><B><I>&#147;Certificate&#148;</I></B>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Section&nbsp;2.1(c)</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><B><I>&#147;Certificate of Merger&#148;</I></B>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Section&nbsp;1.2</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->66<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="right">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="96%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="40%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="55%">&nbsp;</TD>
</TR>
<TR></TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><B><I>&#147;Change of Recommendation&#148;</I></B>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Section&nbsp;6.4(f)</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><B><I>&#147;Claim&#148;</I></B>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Section&nbsp;6.5(b)</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><B><I>&#147;Closing&#148;</I></B>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Section&nbsp;1.3</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><B><I>&#147;Closing Date&#148;</I></B>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Section&nbsp;1.3</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><B><I>&#147;Code&#148;</I></B>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Section&nbsp;2.3</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><B><I>&#147;Company&#148;</I></B>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Preamble</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><B><I>&#147;Company Acquisition Agreement&#148;</I></B>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Section&nbsp;6.4(e)</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><B><I>&#147;Company Adverse Recommendation Change&#148;</I></B>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Section&nbsp;6.4(e)</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><B><I>&#147;Company Balance Sheet&#148;</I></B>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Section&nbsp;3.7(b)</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><B><I>&#147;Company Board&#148;</I></B>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Recitals</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><B><I>&#147;Company Common Stock&#148;</I></B>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Recitals</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><B><I>&#147;Company Disclosure Schedule&#148;</I></B>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Article&nbsp;III</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><B><I>&#147;Company Equity Incentive Plans&#148;</I></B>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Section&nbsp;2.1(d)(i)</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><B><I>&#147;Company Information&#148;</I></B>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Section&nbsp;6.8</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><B><I>&#147;Company Preferred Stock&#148;</I></B>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Section&nbsp;3.3(a)</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><B><I>&#147;Company Recommendation&#148;</I></B>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Section&nbsp;6.4(e)</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><B><I>&#147;Company Restricted Shares&#148;</I></B>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Section&nbsp;2.1(d)(ii)</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><B><I>&#147;Company SEC Reports&#148;</I></B>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Section&nbsp;3.7(a)</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><B><I>&#147;Company Stockholder Agreement&#148;</I></B>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Recitals</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><B><I>&#147;Company Stockholder Approval&#148;</I></B>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Section&nbsp;3.17</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><B><I>&#147;Company Stockholders&#146; Meeting&#148;</I></B>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Section&nbsp;6.1(c)</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><B><I>&#147;Company Stock Options&#148;</I></B>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Section&nbsp;2.1(d)(i)</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><B><I>&#147;Company Subsidiaries&#148;</I></B>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Section&nbsp;3.1(c)</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><B><I>&#147;Confidentiality Agreement&#148;</I></B>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Section&nbsp;6.6(b)</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><B><I>&#147;Contribution Agreement&#148;</I></B>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Recitals</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><B><I>&#147;Contributing Stockholders&#148;</I></B>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Recitals</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><B><I>&#147;Cut-off Date&#148;</I></B>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Section&nbsp;6.4(b)</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><B><I>&#147;DGCL&#148;</I></B>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Recitals</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><B><I>&#147;DOL&#148;</I></B>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Section&nbsp;3.13(c)</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><B><I>&#147;Dissenting Shares&#148;</I></B>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Section&nbsp;2.4</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><B><I>&#147;Effective Time&#148;</I></B>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Section&nbsp;1.2</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><B><I>&#147;Employee Programs&#148;</I></B>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Section&nbsp;3.13(a)</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><B><I>&#147;Encumbrances&#148;</I></B>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Section&nbsp;3.4</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><B><I>&#147;End Date&#148;</I></B>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Section&nbsp;8.1(b)(iii)</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><B><I>&#147;Excluded Party&#148;</I></B>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Section&nbsp;6.4(j)</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->67<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="right">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="96%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="40%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="55%">&nbsp;</TD>
</TR>
<TR></TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><B><I>&#147;Excluded Shares&#148;</I></B>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Section&nbsp;2.1(b)</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><B><I>&#147;Filed SEC Documents&#148;</I></B>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Article&nbsp;III</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><B><I>&#147;Financial Advisor&#148;</I></B>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Section&nbsp;3.15</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><B><I>&#147;Financing&#148;</I></B>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Section&nbsp;4.6</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><B><I>&#147;Financing Commitment&#148;</I></B>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Section&nbsp;4.6</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><B><I>&#147;Governmental Entity&#148;</I></B>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Section&nbsp;3.6</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><B><I>&#147;Go-Shop Termination Fee&#148;</I></B>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Section&nbsp;8.3(a)</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><B><I>&#147;Grant Date&#148;</I></B>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Section&nbsp;3.3(c)</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><B><I>&#147;Indemnified Parties&#148;</I></B>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Section&nbsp;6.5(a)</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><B><I>&#147;Indemnified Party&#148;</I></B>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Section&nbsp;6.5(a)</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><B><I>&#147;Health Care Law&#148;</I></B>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Section&nbsp;3.26(a)</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><B><I>&#147;HIPAA&#148;</I></B>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Section&nbsp;3.26(a)</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><B><I>&#147;Leases&#148;</I></B>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Section&nbsp;3.11(b)</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><B><I>&#147;Merger&#148;</I></B>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Recitals</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><B><I>&#147;Merger Consideration&#148;</I></B>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Section&nbsp;2.2(a)</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><B><I>&#147;Merger Sub&#148;</I></B>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Preamble</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><B><I>&#147;No-Shop Period Start Date&#148;</I></B>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Section&nbsp;6.4(a)</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><B><I>&#147;No-Shop Termination Fee&#148;</I></B>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Section&nbsp;8.3(a)</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><B><I>&#147;Option Merger Consideration&#148;</I></B>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Section&nbsp;2.1(d)(i)</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><B><I>&#147;Other Filings&#148;</I></B>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Section&nbsp;6.2</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><B><I>&#147;Owned Real Properties&#148;</I></B>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Section&nbsp;3.11(a)</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><B><I>&#147;Parent&#148;</I></B>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Preamble</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><B><I>&#147;Paying Agent&#148;</I></B>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Section&nbsp;2.2(a)</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><B><I>&#147;Paying Agent Agreement&#148;</I></B>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Section&nbsp;2.2(a)</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><B><I>&#147;Payment Fund&#148;</I></B>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Section&nbsp;2.2(a)</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><B><I>&#147;PBGC&#148;</I></B>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Section&nbsp;3.13(c)</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><B><I>&#147;Per Share Merger Consideration&#148;</I></B>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Recitals</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><B><I>&#147;Programs&#148;</I></B>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Section&nbsp;3.26(c)</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><B><I>&#147;Proxy Statement&#148;</I></B>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Section&nbsp;6.1(a)</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><B><I>&#147;Privacy and Security Rules&#148;</I></B>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Section&nbsp;3.26(g)</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><B><I>&#147;Registered Intellectual Property&#148;</I></B>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Section&nbsp;3.22(a)</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><B><I>&#147;Replacement Revolver Financing&#148;</I></B>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Section&nbsp;6.8</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><B><I>&#147;Representatives&#148;</I></B>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Section&nbsp;6.4(a)</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><B><I>&#147;Sarbanes-Oxley Act&#148;</I></B>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Section&nbsp;3.7(d)</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><B><I>&#147;Schedule&nbsp;13E-3&#148;</I></B>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Section&nbsp;6.1(a)</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->68<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="right">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="96%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="40%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="55%">&nbsp;</TD>
</TR>
<TR></TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><B><I>&#147;Securities Laws&#148;</I></B>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Section&nbsp;3.7(a)</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><B><I>&#147;Special Committee&#148;</I></B>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Recitals</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><B><I>&#147;Superior Proposal&#148;</I></B>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Section&nbsp;6.4(i)</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><B><I>&#147;Surviving Corporation&#148;</I></B>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Section&nbsp;1.1(a)</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><B><I>&#147;Takeover Laws&#148;</I></B>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Section&nbsp;3.2(a)</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><B><I>&#147;Takeover Proposal&#148;</I></B>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Section&nbsp;6.4(h)</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><B><I>&#147;Termination Fee&#148;</I></B>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Section&nbsp;8.3(a)</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><B><I>&#147;Transaction&#148;</I></B>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Recitals</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><B><I>&#147;Transactions Rule&#148;</I></B>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Section&nbsp;3.26(g)</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><B><I>&#147;VCP Filing&#148;</I></B>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Section&nbsp;3.13(b)</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><B><I>&#147;WARN Act&#148;</I></B>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Section&nbsp;3.14(b)</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><B><I>&#147;Warrant Merger Consideration&#148;</I></B>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Section&nbsp;2.1(e)</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;9.4 <U>Interpretation</U>. The headings contained in this Agreement are for reference
purposes only and shall not affect in any way the meaning or interpretation of this Agreement.
Whenever the words &#147;include&#148;, &#147;includes&#148; or &#147;including&#148; are used in this Agreement, they shall be
deemed to be followed by the words &#147;without limitation&#148;. The words &#147;hereof&#148;, &#147;herein&#148; and
&#147;hereunder&#148; and words of similar import when used in this Agreement shall refer to this Agreement
as a whole and not to any particular provision of this Agreement. All terms defined in this
Agreement shall have the defined meanings when used in any document made or delivered pursuant
hereto unless otherwise defined therein. The definitions contained in this Agreement are
applicable to the singular as well as the plural forms of such terms and to the masculine as well
as to the feminine and neuter genders of such term. Any agreement, instrument or statute defined
or referred to herein or in any agreement or instrument that is referred to herein means such
agreement, instrument or statute as from time to time amended, modified or supplemented, including
(in the case of agreements or instruments) by waiver or consent and (in the case of statutes) by
succession of comparable successor statutes and references to all attachments thereto and
instruments incorporated therein. References to a Person are also to its permitted assigns and
successors.
</DIV>

<DIV align="justify" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;9.5 <U>Non-Survival of Representations, Warranties, Covenants and Agreements</U>. Except for
Articles I, II and Article&nbsp;IX, Section&nbsp;6.5 and any covenant or agreement of the parties which by
its terms contemplates performance after the Effective Time, (a)&nbsp;none of the representations,
warranties, covenants and agreements contained in this Agreement or in any instrument delivered
pursuant to this Agreement shall survive the Effective Time and (b)&nbsp;thereafter no party shall have
any rights against another party with respect thereto.
</DIV>

<DIV align="justify" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;9.6
<U>Entire Agreement; Specific Performance</U>.
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) This Agreement (i)&nbsp;constitutes, together with the Confidentiality Agreement, the
Fund Guarantee, the Financing Commitment and the Company Disclosure Letter, the entire
agreement and supersedes all of the prior agreements and
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->69<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="justify" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">understandings, both written and
oral, among the parties, or any of them, with respect to the subject matter hereof, and (ii)
shall be binding upon and inure to the benefit of the parties hereto and their respective
successors and permitted assigns.
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) The parties hereto agree that irreparable damage would occur in the event that any
provision of this Agreement were not performed in accordance with the terms hereof, and that
the parties shall be entitled to an injunction, specific performance and other equitable
relief to prevent breaches of this Agreement and to enforce specifically the terms and
provisions hereof, this being in addition to any other remedy to which they are entitled at
law or in equity. Without limitation of the foregoing, the Company shall be entitled to an
injunction, specific performance and other equitable relief to enforce the Guarantors&#146;
obligations under the Fund Guarantee and the Financing Commitment. Each of the parties
agrees that it will not oppose the granting of an injunction, specific performance and other
equitable relief on the basis that the other parties have an adequate remedy at law or an
award of specific performance is not an appropriate remedy for any reason at law or equity.
Any party seeking an injunction or injunctions to prevent breaches of this Agreement and to
enforce specifically the terms and provisions of this Agreement shall not be required to
provide any bond or other security in connection with any such order or injunction.
</DIV>

<DIV align="justify" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;9.7 <U>Assignment; Benefit</U>. Except as expressly permitted by the terms hereof, neither this
Agreement nor any of the rights, interests or obligations hereunder shall be assigned by any of the
parties hereto without the prior written consent of the other parties. Nothing in this Agreement,
express or implied, is intended, or shall be deemed, to confer on any Person other than the parties
hereto or their respective successors and permitted assigns any rights, remedies, obligations or
liabilities under or by reason of this Agreement, except for (i)&nbsp;the rights of the Indemnified
Parties under the provisions of Section&nbsp;6.5 (which is intended to be for the benefit of the persons
covered thereby and may be enforced by such persons) and (ii)&nbsp;after the Effective Time, the rights
of holders of Company Common Stock to receive the Per Share Merger Consideration and the rights of
holders of Company Stock Options, Company Restricted Shares and Company Warrants to receive the
amounts specified in Section&nbsp;2.1(d) and (e).
</DIV>

<DIV align="justify" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;9.8 <U>Severability</U>. If any provision of this Agreement, or the application thereof to
any Person or circumstance is held invalid or unenforceable, the remainder of this Agreement, and
the application of such provision to other Persons or circumstances, shall not be affected thereby,
and to such end, the provisions of this Agreement are agreed to be severable.
</DIV>

<DIV align="justify" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;9.9 <U>Choice of Law; Consent to Jurisdiction</U>.
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) This Agreement and all disputes, claims or controversies arising out of or relating
to this Agreement, or the negotiation, validity or performance of this Agreement, or the
transactions contemplated hereby, shall be governed by and construed and enforced in
accordance with the laws of the State of Delaware without regard to its rules of conflict of
laws.
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) Each of the Company, Parent and Merger Sub hereby irrevocably and unconditionally
(i)&nbsp;consents to submit to the sole and exclusive jurisdiction of the Court
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->70<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="justify" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">of Chancery of
the State of Delaware or, if under applicable law exclusive jurisdiction over the matter is
vested in the federal courts, any court of the United States located in the State of
Delaware, for any litigation arising out of or relating to this Agreement, or the
negotiation, validity or performance of this Agreement, or the transactions contemplated
hereby, (ii)&nbsp;agrees not to commence any litigation relating thereto except in such courts,
(iii)&nbsp;waives any objection to the laying of venue of any such litigation in such courts and
(iv)&nbsp;agrees not to plead or claim in such courts that such litigation brought therein has
been brought in any inconvenient forum. Each of the parties hereto agrees, (x)&nbsp;to the
extent such party is not otherwise subject to service of process in the State of Delaware,
to appoint and maintain an agent in the State of Delaware as such party&#146;s agent for
acceptance of legal process, and (y)&nbsp;that service of process may also be made on such party
by prepaid certified mail with a proof of mailing receipt validated by the United States
Postal Service constituting evidence of valid service. Service made pursuant to (x)&nbsp;or (y)
above shall have the same legal force and effect as if served upon such party personally
within the State of Delaware. For purposes of implementing the parties&#146; agreement to
appoint and maintain an agent for service of process in the State of Delaware, each of
Parent and Merger Sub does hereby appoint The Corporation Trust Company, Corporation Trust
Center, 1209 Orange Street, Wilmington, DE 19081 as such agent.
</DIV>

<DIV align="justify" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;9.10 <U>Expenses</U>. Except as set forth in Section&nbsp;8.3, whether or not the Merger is
consummated, all costs and expenses incurred in connection with the Merger, this Agreement or the
transactions contemplated hereby shall be paid by the party incurring or required to incur such
expenses.
</DIV>

<DIV align="justify" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;9.11 <U>Counterparts</U>. This Agreement may be executed in counterparts, all of which shall
be considered one and the same agreement and shall become effective when one or more counterparts
have been signed by each of the parties and delivered to the other party. Facsimile or other
electronic transmission of any signed original document shall be deemed the same as delivery of an
original. At the request of any party, the parties will confirm facsimile or other electronic
transmission by signing a duplicate original document.
</DIV>

<DIV align="justify" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;9.12 <U>No Personal Liability of Directors, Officers, Owners, Etc.</U>
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) Without limiting the rights of the Parent or Merger Sub under this Agreement,
Parent and Merger Sub acknowledge and agree that each of them has no right of recovery
against, and no personal liability shall attach to, in each case with respect to damages of
the Parent or its Affiliates, any of the Company Parties (other than the Company to the
extent provided in this Agreement), through the Company or otherwise, whether by or through
attempted piercing of the corporate veil, by or through a claim by or on behalf of the
Company against any Company Party, by the enforcement of any assessment or by any legal or
equitable proceeding, by virtue of any statute, regulation or applicable Law, or otherwise.
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) Except as expressly provided in the Fund Guarantee and the Financing Commitment and
without limiting the rights of the Company under this Agreement, the Company acknowledges
and agrees that it has no right of recovery against, and no
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->71<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="justify" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">personal liability shall attach
to, in each case with respect to damages of the Company, any of the Parent Parties (other
than Parent and Merger Sub to the extent provided in this Agreement), through either Parent
or otherwise, whether by or through attempted piercing of the corporate, limited partnership
or limited liability company veil, by or through a claim by or on behalf of either Parent or
any other Parent Party, by the enforcement of any assessment or by any legal or equitable
proceeding, by virtue of any statute, regulation or applicable Law, or otherwise.
</DIV>

<DIV align="justify" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;9.13 <U>Company Disclosure Schedule</U>. Any fact or combination of facts that has been
disclosed in any Section of the Company Disclosure Schedule shall be deemed to be disclosed with
respect to any other Section of this Agreement to the extent that it is reasonably apparent that
such disclosure is applicable to such other Section. The inclusion of any information in the
Company Disclosure Schedule shall not be deemed to be an admission or acknowledgement, in and of
itself, that such information is required by the terms hereof to be disclosed, is material, has
resulted or is reasonably expected to result in a Company Material Adverse Effect or is outside the
ordinary course of business or that it would otherwise be appropriate to include any such
information.
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><I>&#091;Remainder of page intentionally left blank&#093;</I>
</DIV>



<P align="center" style="font-size: 10pt"><!-- Folio -->72<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV align="justify" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;IN WITNESS WHEREOF, Parent, Merger Sub and the Company have caused this Agreement to be
executed as of the date first written above by their respective officers thereunto duly authorized.
</DIV>
<Div align="right">
<TABLE width="95%" border="0" cellspacing="0" cellpadding="0" style="font-size: 10pt">
<TR>

    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="48%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
</TR>
<TR>
    <TD colspan="3" align="left">IVY HOLDINGS INC.<BR>
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD valign="top">By:&nbsp;&nbsp;</TD>
    <TD colspan="2" style="border-bottom: 1px solid #000000" align="left">/s/ John M. Baumer&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD>&nbsp;</TD>
    <TD valign="top">Name:&nbsp;&nbsp;</TD>
    <TD align="left">John Baumer&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD>&nbsp;</TD>
    <TD valign="top">Title:&nbsp;&nbsp;</TD>
    <TD align="left">President&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR>
    <TD colspan="5">&nbsp;</TD>
</TR>
<TR>
    <TD colspan="3" align="left">IVY MERGER SUB CORP.<BR>
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD valign="top">By:&nbsp;&nbsp;</TD>
    <TD colspan="2" style="border-bottom: 1px solid #000000" align="left">/s/ John M. Baumer&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD>&nbsp;</TD>
    <TD valign="top">Name:&nbsp;&nbsp;</TD>
    <TD align="left">John Baumer&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
   <TD>&nbsp;</TD>
    <TD valign="top">Title:&nbsp;&nbsp;</TD>
    <TD align="left">President&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR>
    <TD colspan="5">&nbsp;</TD>
</TR>
<TR>
    <TD colspan="3" align="left">PROSPECT MEDICAL HOLDINGS, INC.<BR>
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>

    <TD valign="top">By:&nbsp;&nbsp;</TD>
    <TD colspan="2" style="border-bottom: 1px solid #000000" align="left">/s/ Samuel S. Lee&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD>&nbsp;</TD>
    <TD valign="top">Name:&nbsp;&nbsp;</TD>
    <TD align="left"> Samuel S. Lee&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD>&nbsp;</TD>
    <TD valign="top">Title:&nbsp;&nbsp;</TD>
    <TD align="left">Chief Exective Officer&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>

</TABLE>
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
